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DEVELOPMENT OF QUANTITATIVE LC-MS/MS METHODS FOR 
THE PHARMACOLOGICAL STUDIES OF ANTI-CANCER DRUGS 
LAN LI 
ABSTRACT 
In the development of anti-cancer drugs, it is essential to study the 
pharmacological profiles of the drugs. Among the analytical tools utilized in the 
pharmacological studies, LC-MS/MS has gained increased popularity due to its 
unequivocal sensitivity and specificity, as well as the ability of handling a wide variety of 
compounds with relatively simple sample preparation procedures.  
In this work, a brief review on the method rational, instrumentations, analytical 
method validation, and work flow of the method development was included. The 
processes of LC-MS/MS method development for the pharmacological studies of three 
anti-cancer drugs (i.e., methoxyamine, fludarabine, and 6-benzylthioinosine) were 
illustrated. To be more specific, a tetra-enzyme cocktail utilized for DNA adducts release 
was introduced. LC-MS/MS methods for the analysis of methoxyamine modified DNA 
abasic sites and fludarabine incorporated in DNA were developed toward the DNA 
adducts released from DNA with the enzyme cocktail. The methods were applied to the 
drug effect and drug mechanism studies. Another two LC-MS/MS method was developed 
for the quantification of 2-fluoroadenine released from the fludarabine incorporated DNA 
and free 6-benzylthioinosine drug molecule in mouse and human plasma. The first 
method helped to provide direct evidence to a newly proposed drug resistance mechanism 
 iv
toward fludarabine through DNA base excision repair; while the second method realized 
the pharmacokinetic studies of the drug. 
The results in this work not only demonstrated the capability of LC-MS/MS in 
solving sophisticated pharmacological puzzles, but will provide useful information 
guiding the preclinical studies and clinical therapy development of the anti-cancer drugs 
listed above.  
 v
TABLE OF CONTENTS 
 
ABSTRACT ................................................................................................................ iii 
LIST OF TABLES ..................................................................................................... xii 
LIST OF FIGURES .................................................................................................. xiii 
 
CHAPTER I. INTRODUCTION TO PHARMACOLOGICAL STUDY OF DRUGS 
AND ANALYTICAL METHOD DEVELOPMENT .................................................. 1 
1.1. Pharmacological studies of anti-cancer drugs ................................................ 1 
1.1.1. General introduction ...................................................................................... 1 
1.1.2. Three anti-cancer drugs .................................................................................. 3 
1.1.3. LC-MS/MS and pharmacological studies ...................................................... 7 
1.2. Quantitative LC-MS/MS method development ............................................. 8 
1.2.1. Liquid chromatography .................................................................................. 9 
1.2.2. Biological sample extraction ........................................................................ 14 
1.2.3. Mass spectrometry ....................................................................................... 21 
1.2.4. Method validation ........................................................................................ 31 
1.2.5. A general work flow of quantitative LC-MS/MS method development ...... 36 
1.3. Conclusion ................................................................................................... 39 
1.4. References .................................................................................................... 39 
  
 vi
CHAPTER II. ENZYMATIC RELEASE OF DNA ADDUCTS FROM DNA 
BACKBONE.............................................................................................................. 44 
2.1. Introduction .................................................................................................. 44 
2.2. Material and methods ................................................................................... 48 
2.2.1. Chemicals and solutions .............................................................................. 48 
2.2.2. MX-AP DNA preparation ............................................................................ 49 
2.2.3. Enzymatic hydrolysis condition optimization ............................................. 50 
2.2.4. Digestion efficiency determination .............................................................. 52 
2.3. Results and discussions ................................................................................ 53 
2.3.1. Comparison between sequential digestion and enzyme cocktail ................. 53 
2.3.2. Significance of DNase I, NP1, and PDE I in the digestion .......................... 53 
2.3.3. Enzyme kinetics ........................................................................................... 55 
2.3.4. DNA concentration determination through the released dNs ...................... 57 
2.4. Conclusion ................................................................................................... 61 
2.5. References .................................................................................................... 61 
CHAPTER III. MEASUREMENT OF METHOXYAMINE (MX) ON ITS 
THERAPEUTIC TARGET, MX MODIFIED DNA ABASIC SITES (MX-AP), 
WITH LC-MS/MS ..................................................................................................... 66 
3.1. Introduction .................................................................................................. 66 
3.2. Material and methods ................................................................................... 71 
3.2.1. Chemicals and solutions .............................................................................. 71 
 vii
3.2.2. Synthesis of MX-dR and MX-R .................................................................. 72 
3.2.3. LC-MS/MS and LC-MS instrumentations ................................................... 72 
3.2.4. Sample extraction......................................................................................... 75 
3.2.5. Synthesis and purification of DNA oligomer with known amount of MX-AP 
sites ...................................................................................................................... 76 
3.2.6. Preparation of MX-AP DNA calibrators ...................................................... 78 
3.2.7. Enzymatic release of MX-AP ...................................................................... 79 
3.2.8. Cell culture and treatment ............................................................................ 79 
3.2.9. Lymphocytes separation............................................................................... 80 
3.2.10. DNA extraction ............................................................................................ 81 
3.2.11. MX-AP concentration normalization ........................................................... 83 
3.3. Results and discussions ................................................................................ 84 
3.3.1. Characterization of MX-dR and the IS with mass spectrometry ................. 84 
3.3.2. Digested DNA sample extraction ................................................................. 88 
3.3.3. LC separation of the analyte from the matrix interferences ........................ 89 
3.3.4. MX-AP DNA standard preparation .............................................................. 93 
3.3.5. Method performance .................................................................................... 96 
3.3.6. Analysis of TMZ plus MX treated T98G cells ............................................ 99 
3.3.7. Analysis DNA samples from TMZ plus MX treated patient ..................... 100 
3.4. Conclusion ................................................................................................. 104 
3.5. References .................................................................................................. 104 
 viii
CHAPTER IV. DRUG EFFECT ANALYSIS OF FLUDARABINE (F-ARA-A) BY 
MEASURING THE DRUG INCORPORATION IN DNA WITH LC-MS/MS ..... 108 
4.1. Introduction ................................................................................................ 108 
4.2. Material and methods ..................................................................................110 
4.2.1. Chemicals and solutions .............................................................................110 
4.2.2. Preparation of F-ara-A ................................................................................ 111 
4.2.3. LC-MS/MS instrumentation ....................................................................... 111 
4.2.4. Cell culture and treatment ...........................................................................112 
4.2.5. Cellular DNA extraction .............................................................................113 
4.2.6. Enzymatic hydrolysis of DNA ....................................................................115 
4.3. Results .........................................................................................................115 
4.3.1. MS characterization of F-ara-A ..................................................................115 
4.3.2. LC method development .............................................................................116 
4.3.3. Drug effect analysis of F-ara-A on HL60 cells ...........................................119 
4.4. Conclusion ................................................................................................. 121 
4.5. References .................................................................................................. 121 
CHAPTER V. DETERMINATION OF 2-FLUOROADENINE REMOVED FROM 
FLUDARABINE (F-ARA-A) INCORPORATED IN DNA WITH LC-MS/MS .... 123 
5.1. Introduction ................................................................................................ 123 
5.2. Material and methods ................................................................................. 127 
5.2.1. Chemicals and solutions ............................................................................ 127 
 ix
5.2.2. LC-MS/MS instrumentation ...................................................................... 128 
5.2.3. Synthesis of F-ara-A incorporated DNA 40-mer ....................................... 130 
5.2.4. Removal of F-Ade from F-ara-A incorporated DNA 40-mer by UDG ..... 131 
5.2.5. Cell isolation and culture ........................................................................... 132 
5.2.6. Cell treatment ............................................................................................. 133 
5.2.7. Preparation of F-Ade calibrators and QCs ................................................. 134 
5.2.8. SPE of cell lysates and UDG-digested DNA ............................................. 135 
5.2.9. Construction of calibration curves ............................................................. 135 
5.2.10. Matrix effect and recovery ......................................................................... 136 
5.2.11. Stability ...................................................................................................... 137 
5.3. Results ........................................................................................................ 138 
5.3.1. Synthesis of F-ara-A incorporated DNA 40-mer ....................................... 138 
5.3.2. LC-MS/MS method for the measurement of F-Ade .................................. 141 
5.3.3. Analytical method validation ..................................................................... 145 
5.3.4. Determination of F-Ade in F-ara-A incorporated DNA 40-mer and cells 
treated with F-ara-A ................................................................................................. 151 
5.4. Discussion .................................................................................................. 153 
5.4.1. F-ara-A incorporated DNA is a target for BER pathways ......................... 153 
5.4.2. UDG is a DNA glycosylase having activity on F-ara-A:T mismatches .... 154 
5.4.3. LC-MS/MS method provides unequivocal identification and quantification 
of F-Ade ................................................................................................................... 155 
 x
5.4.4. F-Ade concentrations in cells treated with F-ara-A correlate with dose and 
time .................................................................................................................... 156 
5.4.5. Identification of an unknown substance existing in the same MRM channel 
with F-Ade, yet with different retention time .......................................................... 157 
5.5. Conclusion ................................................................................................. 158 
5.6. References .................................................................................................. 161 
CHAPTER VI. QUANTITATIVE DETERMINATION OF 6BT WITH LC-MS/MS, 
A PHARMACOKINETIC STUDY IN MICE, AND AN IN VITRO DRUG 
MECHANISM STUDY ........................................................................................... 165 
6.1. Introduction ................................................................................................ 165 
6.2. Material and methods ................................................................................. 168 
6.2.1. Chemicals and solutions ............................................................................ 168 
6.2.2. LC-MS/MS instrumentation ...................................................................... 170 
6.2.3. Standard solutions, plasma calibrators and controls, and mouse plasma 
samples .................................................................................................................... 171 
6.2.4. LLE of 6BT ................................................................................................ 172 
6.2.5. Matrix effect and recovery studies ............................................................. 172 
6.2.6. Stability studies .......................................................................................... 173 
6.2.7. Preliminary PK study of 6BT in mice ........................................................ 174 
6.3. Results and discussions .............................................................................. 175 
6.3.1. Method development ................................................................................. 175 
 xi
6.3.2. Method validation ...................................................................................... 182 
6.3.3. Method application in a preliminary PK study in mice ............................. 191 
6.3.4. Enhanced 6BT uptake in leukemia cell lines ............................................. 194 
6.3.5. On-line SPE extraction of 6BT with a boronic acid cartridge ................... 197 
6.4. Conclusions ................................................................................................ 201 
6.5. References .................................................................................................. 201 
 
  
 xii
LIST OF TABLES 
 
Table 3.1: Calibration equation of MX-AP ...................................................................... 97 
Table 3.2: Accuracy, intra- and inter-assay precision ....................................................... 98 
Table 5.1: Recovery and matrix effect data .................................................................... 146 
Table 5.2: Calibration equations of F-Ade ..................................................................... 147 
Table 5.3: Accuracy, intra- and inter-assay precision of F-Ade in HL60 cell lysate. .... 149 
Table 5.4: Stability of F-Ade in HL60 cell lysate under various test conditions ............ 150 
Table 5.5: F-Ade concentrations measured from QCs and the real samples .................. 152 
Table 6.1: Matrix effect and recovery ............................................................................. 184 
Table 6.2: Calibration equations of 6BT in mouse and human plasma .......................... 187 
Table 6.3: Accuracy, intra- and inter-assay precisions of 6BT ....................................... 188 
Table 6.4: Stability data of 6BT under various test conditions....................................... 190 
Table 6.5: 6BT uptake in different cell lines .................................................................. 196 
 
  
 xiii
LIST OF FIGURES 
 
Figure 1.1: Methoxyamine, fludarabine, and 6-benzylthioinosine ..................................... 6 
Figure 1.2: Illustration of liquid chromatography ............................................................. 11 
Figure 1.3: Illustration of off-line SPE ............................................................................. 18 
Figure 1.4: Illustration of on-line SPE .............................................................................. 20 
Figure 1.5: Illustration of ESI ........................................................................................... 23 
Figure 1.6: Illustration of QqQ mass analyzer .................................................................. 27 
Figure 1.7: Illustration of electron multiplier ................................................................... 30 
Figure 1.8: Workflow of bioanalytical LC-MS/MS method development ....................... 38 
Figure 2.1: Enzyme digestion efficiency comparison....................................................... 56 
Figure 2.2: LC-MS/MS of dNs released after enzyme digestion ...................................... 60 
Figure 3.1: Normal AP site recognition by APE and invalidated BER through AP site 
blockage with MX ........................................................................................................... 69 
Figure 3.2: Enzymatic release of MX-AP from the DNA backbone as MX-dR .............. 86 
Figure 3.3: Mass spectra of MX-dR and MX-R ............................................................... 87 
Figure 3.4: Representative MRM chromatograms of MX-dR, MX-R (IS), and other 
matrix interference ............................................................................................................ 92 
Figure 3.5: MX-oligo synthesis ........................................................................................ 95 
Figure 3.6: MX drug effect studies ................................................................................. 103 
Figure 4.1: Mass spectra of F-ara-A ............................................................................... 117 
 xiv
Figure 4.2: Representative MRM chromatograms of F-ara-A and other matrix 
interferences .................................................................................................................... 118 
Figure 4.3: A dose-effect profile of F-ara-AMP on HL60 cells ..................................... 120 
Figure 5.1: The chemical structures of 2-fluoroadenine, fludarabine phosphate, and the IS, 
2-chloroadenine ............................................................................................................... 126 
Figure 5.2: Synthesis of F-ara-A incorporated DNA 40-mer ......................................... 140 
Figure 5.3: The mass spectra of F-Ade and Cl-Ade (IS) ................................................ 142 
Figure 5.4: Representative MRM chromatograms of F-Ade and IS ............................... 143 
Figure 5.5: Identification of the shifted peak .................................................................. 160 
Figure 6.1: The mass spectra of 6BT and the internal standard ...................................... 177 
Figure 6.2: The proposed major fragments of 6BT and the IS ....................................... 178 
Figure 6.3: Representative MRM chromatograms of analytes in human plasma ........... 181 
Figure 6.4: Representative MRM chromatograms of mouse plasma samples................ 192 
Figure 6.5: Plasma concentration-time profile of 6BT ................................................... 193 
Figure 6.6: Reaction between the phenyl boronic acid and a molecule carrying 
cis-hydroxyl groups ........................................................................................................ 199 
Figure 6.7: Representative MRM chromatogram for the on-line SPE of 6BT ............... 200 
 
  
1 
 
 
 
 
 
 
CHAPTER I 
 
 
INTRODUCTION TO PHARMACOLOGICAL STUDY OF DRUGS AND 
ANALYTICAL METHOD DEVELOPMENT 
 
 
1.1. Pharmacological studies of anti-cancer drugs 
 
1.1.1. General introduction 
 
 Cancer has become one of the biggest threats to human health and life. In 2010, 
there were over 1.5 million new cancer cases diagnosed in United States, and the number 
of deaths from cancer were estimated at over 0.5 million [1]. Among all of the anti-
cancer treatments available to date, chemotherapy, along with surgery and radiotherapy 
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are the most common approaches. The key of establishing effective chemotherapy 
strategies lies in the development of anti-cancer drugs. In National Cancer Institute along, 
during the past two decades, more than 80,000 compounds were screened as anti-cancer 
drug candidates, and there are over 1,500 clinical trials undergoing [2]. As the majority of 
the anti-cancer drugs are extremely heterogeneous chemical entities, in the drug 
discovery and therapy development, it is essential to understand the pharmacological 
properties of the drugs [3]. 
 The pharmacological study of the drugs consists of two major components, 
pharmacokinetic studies and pharmacodynamic studies. 
 Pharmacokinetic (PK) study includes liberation, adsorption, distribution, 
metabolism, and excretion of the pharmaceutical substance administered to the living 
organism. Among these studies, liberation study discovers the process of drug releasing 
from specific formulations; absorption and distribution studies illustrate the process of 
the drug entering the circulation of the living organisms and the dissemination of the drug 
in the living organisms, respectively; metabolism study focus on the irreversible chemical 
transformations from the drug to its metabolites; excretion studies elucidates the process 
in which the drug and/or its metabolites are eliminated from the living organism. This 
study scheme is often referred as LADME [4].  
 Differing from PK studies that discovers “what the body does to the drug”, 
pharmacodynamic (PD) studies aims “what the drug does to the body” [5]. To be more 
3 
 
specific, PD studies evaluate the physiological impacts of the pharmaceutical substance 
to the living organisms. It has a focus of understanding the functioning mechanisms of 
the drug and usually involves three major objects: receptor binding, postreceptor effects, 
and chemical interactions [6]. The major goal of PD study is to establish the dose-
response profile, thus PD study is often carried out together with the PK study. 
 
1.1.2. Three anti-cancer drugs 
 
 In this work, in order to facilitate the pharmacokinetics and/or pharmacodynamics 
of three anti-cancer drugs, methoxyamine (MX), fludarabine (F-ara-A), and 6-
benzylthioinosine (6BT), LC-MS/MS methods were developed and applied to the studies. 
The major aims in LC-MS/MS facilitated pharmacological studies of these drugs can be 
described as the following: 
 MX (figure 1.1 A) is a small molecule that is reactive to DNA 
apurinic/apyrimidinic (AP) sites. The blockage of the AP sites by MX is able to 
invalidate the enzymatic recognition and repair of the AP sites through DNA base 
excision repair (BER), and thus reverse the BER related drug resistance to some 
methylating agents and anti-metabolites [7, 8]. MX is currently under phase I clinical 
studies and the PK profile of the drug is analyzed with an LC-MS/MS method developed 
by our group [9].  In the drug effect analysis of MX, a part of PD studies of the drug, the 
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blocking efficiency of MX toward the AP sites must be evaluated. In another word, 
methods are needed in quantification of MX modified AP (MX-AP) sites and free AP 
sites. The significance of the drug effect study lies in its ability of providing better 
understand on the drug functioning mechanisms and potential in guiding the clinical trials. 
 F-ara-A (figure 1.1 B) is a purine analogue effective in the treatment of 
hematological malignancies [10]. The monophosphate form of the drug has been 
approved by United States Food and Drug Administration (FDA) to treat refractory B-
cell chronic lymphocytic leukemia (CLL), and the pharmacological properties of the drug 
have been intensively studied [11]. As F-ara-A inhibits multiple enzymes involved in 
DNA synthesis, it was generally accepted as a DNA chain terminator [12, 13]. However, 
recent studies indicated that F-ara-A may also be incorporated in the middle of a DNA 
strand, and BER can be one of the mechanisms contributing to the drug resistance [8]. To 
have a better understand of the drug functioning and resistance mechanisms, methods 
have to be developed to quantify the drug incorporation in DNA and to analyze the drug 
moiety released during BER (i.e., the 2-fluoroadenine or F-Ade). The former study can 
be considered as a part of the PD study; while the later, as a metabolism study, belongs to 
the category of PK studies. 
 6BT (figure 1.1 C) is another purine analogue that has shown great potential in 
the treatment of acute myeloid leukemia (AML). As it induces differentiation or highly 
specific cytotoxicity to the malignant cells from multiple subtypes of AML, it may 
provide cure to the cancers without introducing serious side effects. Although the 
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mechanisms of differentiation inducement remain unclear, the specific cytotoxicity of 
6BT to the AML cells may be attributed to its specific entry into the malignant cells. To 
better understand the functioning mechanisms and PK profile of the drug, methods must 
be developed to analyze the free drug from biological matrices. The results will, for sure, 
benefit both the preclinical and clinical studies of the drug.  
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Figure 1.1, Three anti-cancer drugs: methoxyamine (A), fludarabine (B), and 6-
benzylthioinosine (C).  
NH 2
O
C H 3
Methoxyamine (MX) 
M.W. = 47 
A 
N
O
OH
OH
N
NN
NH2
F
OH
Fludarabine (F-ara-A) 
M.W. = 285 
B 
N
O
OH
OH
N
NN
S
OH
6-Benzylthioinosine (6BT)
M.W. = 374 
C 
7 
 
1.1.3. LC-MS/MS and pharmacological studies 
 
 Among the wide variety of tools utilized in the pharmacological studies, LC-
MS/MS has gained more and more popularity due to its high sensitivity and specificity. 
In this work, LC-MS/MS has demonstrated its problem solving abilities in all the 
research projects proposed in the above section: 
 In the evaluation of the blocking efficiency of MX to the AP sites, the MX-AP 
adducts were quantified with an LC-MS/MS method. In this method, the DNA was first 
hydrolyzed enzymatically, so that the MX-AP adducts could be released from DNA 
backbone as free small molecules, MX-deoxyribose (MX-dR). Then, LC-MS/MS method 
was developed toward the released small molecule, and the quantification of MX-AP 
adducts was realized. By applying the developed method into the drug effect studies, 
dose- and time- effect profiles were obtained from an in vitro cell study; while another 
time-effect profile was obtained from an in vivo study carried out on a patient enrolled in 
the phase I clinical studies. With the LC-MS/MS evaluation of the free AP sites already 
achieved by Roberts et al. [14], future combination of the methods will provide a even 
better view to the blocking efficiency of MX to the AP sites. 
 Similar strategies have been applied into the incorporation analysis of F-ara-A: 
the incorporated drug was first release with enzymatic hydrolysis, and then analyzed with 
LC-MS/MS. The method has been utilized in a dose-effect study of F-ara-A on a 
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leukemia cell line, HL60. Quantitative evaluation of the drug incorporation with 
validated methods may also provide insight in drug functioning mechanism elucidation. 
 In the assessment of the drug resistance effects on the incorporated F-ara-A 
through uracil DNA glycosylase (UDG), an LC-MS/MS method was developed for the 
analysis of F-Ade, a molecule released by UDG from the incorporated drug. The positive 
results shown in the detection of F-Ade from in vitro UDG digestion on F-ara-A 
incorporated DNA 40-mer and cellular DNA provided direct evidences to the effect of 
BER on the incorporated drug. Measurement of F-Ade from the cell lysates obtained 
from F-ara-A treated cells also served as in vivo support for the mechanism. 
 Quantification of 6BT from mouse and human plasma with LC-MS/MS method 
we developed enabled the PK study of the drug. In fact, a preliminary PK study has 
already been performed on mice, and the PK parameters were calculated after PK 
modeling. Meanwhile, the semi-quantitative analysis of 6BT from different types of cells 
also illustrated the enhanced entry of 6BT into leukemia cell lines. The results explain the 
specific cytotoxicity of 6BT to the leukemia cells. 
 
1.2. Quantitative LC-MS/MS method development 
 
 In order to provide accurate and reliable data for the PK and PD studies, a 
quantitative LC-MS/MS method usually includes four elements: liquid chromatography 
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(LC) separation of the analyte(s) from other interferences compounds, biological sample 
extraction in order to exclude matrix effects, mass spectrometry detection of the 
analyte(s), and analytical method validation or method performance evaluation. All four 
elements are described in more details in the flowing sections. 
 
1.2.1. Liquid chromatography 
 
 Although the high detection specificity of mass spectrometers allows effective 
analyte detection from relative complicated sample matrix, too much interference, 
however, will attenuate the detection sensitivity. The interference compounds can 
compete with the analyte during the ionization process, decreasing the ionization 
efficiency of the analyte, and thus hurt the detection sensitivity. To avoid this situation, 
liquid chromatography (LC) is often needed to separate the analyte from the sample 
matrix.  
 The principle of LC can be simply described as the following: first, carried by the 
mobile phase, the sample (i.e., a mixture of analyte, matrix substances, and solvents) is 
introduced to the column; as the mobile phase keeps flowing, all of the compounds are 
also moved forward by the mobile phase; however, the compounds that have stronger 
interactions with the stationary phase move slower, and tend to stay longer on the column; 
by this means, the compounds in the mixture can be separated based on their different 
10 
 
affinities to the stationary phase, and finally eluted out from the column in an order of 
time (figure 1.2). 
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Figure 1.2, Illustration of liquid chromatography.  
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 Currently, the most typical separation mechanisms utilized in LC-MS/MS include: 
normal phase/ reverse phase, ion-pairing, and ion-exchange LC [15].  
  Normal phase LC utilizes the polarity of the compounds in the separation. 
Normal phase LC is realized through a polar stationary phase, typically silica or polar 
organic functional groups (e.g., cyano and amino), and a non-polar mobile phase (e.g., 
hexane and heptanes). Based on the principle of like-dissolves-like, polar compounds will 
have stronger interactions with the stationary phase and be eluted out later than those 
relatively non-polar compounds. Slightly polar solvent, such as isopropanol, ethyl acetate, 
and chloroform are often mixed with the non-polar mobile phase to increase the elution 
power toward the extremely polar compounds [15].  
 Reverse phase LC, opposite to the normal phase LC, utilizes non-polar stationary 
phase, typically alkyl hydrocarbons (e.g., octadecyl, octyl, and butyl), combined with 
polar water miscible organic solvents (e.g., methanol, acetonitrile, and tetrahydrofuran) 
as the mobile phase. Reverse phase LC retains non-polar compounds on the columns 
longer than the polar ones. Strong elusion power in reverse phase LC can be achieved by 
increase the percentage of organic solvents in the mobile phases [15]. Comparing to the 
normal phase LC, reverse phase LC is more commonly used in LC-MS/MS analysis.  
 Aqueous normal-phase LC, a newly developed LC mechanism, has started to 
get popular in the separation of polar compounds. It utilizes the reverse phase columns 
with polar surface modification as the stationary phase. The mobile phase is usually 
composed of high percentage of relatively polar organic solvent (e.g., methanol and 
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acetonitrile) with the addition of a small portion of water. As the polarity of the stationary 
phase is still higher than the mobile phase, polar compounds can be retained on the 
column, yet non-polar compounds and inorganic salts are eluted out with no or little 
retention [15]. 
  Ion-pairing LC can be performed on both normal and reverse phase column, yet 
it is more commonly carried out on a reverse phase column. When the analyte is 
relatively polar and hard to be retained on the reverse phase column, a “counter-ion”, 
namely the ion-pairing agent, of opposite charge to the analyte is added into the mobile 
phase. This ion-pairing agent often possesses a relative non-polar moiety that can have 
stronger interaction with the stationary phase. After the column is fully equilibrated with 
the mobile phase, the stationary phase is kinetically coated with the ion-pairing agent. As 
the ion-pairing agent is able to interact with the analyte ions through electrostatic 
attraction, the analyte can also be retained on the column temporarily. When the ion-
pairing agent is eluted out, the analyte is eluted out with it. Examples of the most 
commonly used ion-pairing agents that are compatible with MS detection are 
trifluoroacetic acid (TFA) (anionic), pentafluoroproprionic acid (PFPA) (anionic), 
heptafluorobutyric acid (HFBA) (anionic), and triethylamine (cationic) [15,  16]. 
  Ion-exchange LC utilizes stationary phases presenting ionizable groups that 
attract ions with opposite charge. To retain the analyte, the pH of the mobile phase must 
be adjusted to a specific value, under which the analyte can be attracted by the stationary 
phase through electrostatic interaction. During the elusion process, the pH of the mobile 
14 
 
phase can be changed to a value that prevent or minimize the interaction between the 
analyte and the stationary phase. Comparing to the reverse phase LC and ion-pairing LC, 
ion-exchange LC is less commonly used in LC-MS/MS because of the large amount of 
buffer salts it introduces often suppresses the ionization [15]. 
 
1.2.2. Biological sample extraction 
 
 As the analysis of anti-cancer drugs often involves complicated biological 
samples (e.g., plasma, tissue, urine, in vitro enzymatic reaction products, etc.), 
interferences (e.g., proteins, lipids, fatty acids, organic salts, glycerol, etc.) in these 
samples are often hard to be completely eliminated by LC along. If not removed before 
the LC-MS/MS analysis, they can easily contaminate the LC column and invalid the 
analysis. To insure the successful of the analysis, and make the methods robust for 
repeating analysis, certain sample extraction procedures must be carried out to clean up 
the sample matrix before the LC-MS/MS analysis. 
 Three major sample extraction strategies are commonly utilized for biological 
samples: protein precipitation, liquid-liquid extraction, and solid-phase extraction. 
 Protein precipitation Protein is one of the most common matrix interference 
often exists in large amount in some biological samples (e.g., plasma and tissue). If not 
being eliminated before LC, it may precipitate when encountered the organic solvents in 
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the LC process and clog the LC system. The best way to avoid this situation is to 
precipitate it out before the LC-MS/MS analysis. The structure of a protein is held by 
three major kinds of weak interactions: hydrophobic interactions, hydrogen bonds, and 
electrostatic interactions. Thus disturbing one or more of these interactions is the most 
effective way to precipitate the protein. Addition of organic solvents, such as methanol 
and acetonitrile, is able to interrupt the hydrophobic interaction; while introducing 
extremes of pH disrupts the electrostatic interactions [17]. As a result, the protein 
precipitation is often realized by mixing the biological samples together with organic 
solvents and volatile acids or bases. After a short vortex, the mixture can be centrifuged 
and the supernatant is taken out. This supernatant can either be dried and then 
reconstituted before analysis, or directly injected into the LC-MS/MS system. 
 Protein precipitation is the simplest and fastest strategy in biological sample 
extraction. However, it is not effective in removing other interferences, such as lipids and 
salts. When there are needs for cleaner samples, other extraction strategies must be 
considered. 
 Liquid-liquid extraction (LLE) utilizes the distribution ratio of a certain 
compound in two immiscible solvents to extract the compound [18]. To be more specific, 
after mixing the two immiscible solvents completely, any compound dissolved in these 
two phases will reaches an equilibration. At this moment, the ratio of the concentrations 
of this compound in the two solvents, [compound]solvent 1 / [compound]solvent 2, becomes a 
constant. Given the volumes of the two solvents are the same, the one in which the 
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compound has higher solubility tends to retain more mass of the compound. In another 
word, the solvent that dissolves the compound more easily, namely the extraction solvent, 
is able to “absorb” the compound from the other solvent. In real extraction procedure, the 
extraction solvent is often utilized in a larger volume to ensure high recovery. 
 As most of the biological samples are already in aqueous solution, organic 
solvents are often applied to extract the compounds from the aqueous phase. Based on the 
polarity of the analyte, extraction solvents ranged from different polarities can be chosen 
for the best extraction efficiency. Extremely hydrophobic analyte can be extract more 
efficiently with non-polar solvents, such as hexane and carbon tetrachloride. For polar 
analytes, polar solvents, such as chloroform and ethyl acetate, can be the effective 
extraction solvents. When extracting extremely polar compounds, adjusting pH, mixing 
the extraction solvent with small portion of water miscible solvents (e.g., isopropanol), 
and/or salting out can also be applied to increase extraction efficiency [18]. 
 Besides polarity, another rule of extraction solvents selection is the boiling points. 
Solvents with low boiling points are often preferred, as they can be dried by evaporation 
easily during the sample concentration process [18]. 
 Comparing to protein precipitation, LLE is more complicated and harder to be 
optimized. Nevertheless, it is more effective in removing salts from biological samples 
comparing to protein precipitation. Meanwhile, due to the introducing of organic solvents, 
LLE can also precipitate and remove proteins efficiently. 
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 Solid-phase extraction (SPE) is the most complicated extraction method in the 
three, yet it is also the one that provides the cleanest sample after extraction. Unlike the 
LLE utilizing liquid as the extraction material, SPE use solid sorbent as the extraction 
material. The extraction mechanisms are very similar to those of LC. Normal/reverse 
phase, ion-pairing, and ion-exchange are, again, the major extraction mechanisms. 
However, instead of pumping mobile phase continuously through the solid phase and 
eluting the analyte gradually from the sorbent with a gradient or isocratic method, the 
extraction can be clearly divided into a loading stage and an elusion stage. 
 Generally speaking, the SPE can be achieved through the following process. First, 
the solid sorbent is equilibrated with a buffered solution called loading buffer. This 
loading buffer usually provides weaker interaction to the analyte comparing the sorbent. 
Then, the sample dissolved in or diluted with the loading buffer is added onto the sorbent. 
Because the analyte has stronger interaction with the sorbent than it has with the loading 
buffer, the analyte can be temporarily retained by the sorbent. Other interference 
compounds that do not interact with the sorbent will pass through the sorbent, and 
sometimes, be further cleaned up by a wash step. Finally, another buffered solution that 
dissolves the analyte better than the sorbent, namely the elusion buffer, is applied to wash 
off the analyte from the sorbent. At this moment, the analyte will be dissociated from the 
sorbent, while the interferences that interact with the sorbent more strongly may still stay 
on the sorbent. By this means, the analyte can be effectively purified from the biological 
samples (figure 1.3) [19]. 
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Figure 1.3, Illustration of off-line SPE. 
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 In fact, SPE can happen either off-line or on-line. In an off-line SPE, the 
cartridges packed with specific sorbent are equilibrated, loaded with samples, washed, 
and striped with elusion buffer in separated steps. In an on-line SPE, however, the 
cartridge is connected into an LC system, and pre-equilibrated with a continuous flow of 
loading solution. After the sample has been injected onto the cartridge, the mobile phase 
can be switched to the elusion buffer that flows to the opposite direction (figure 1.4). 
When the elusion buffer reaches to the cartridge, it is able to dissociate the analyte from 
the sorbent in a narrow the elusion band. 
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Figure 1.4, Illustration of on-line SPE.  
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1.2.3. Mass spectrometry 
 
 Mass spectrometry is a technique that identifies the molecules through their mass 
to charge (m/z) ratio. The basic working procedure of a mass spectrometer includes 
several steps. First, the sample containing the analyte is vaporized in the ion source. Then, 
the vaporized analyte particles together with the vaporized particles of other species in 
the sample are ionized in the gas phase through a certain ionization mechanism. 
Afterward, these ions enter into an electromagnetic field, the mass analyzer, and get 
separated based on their m/z ratios. Finally, the separated ions can be amplified by the 
detector, and the collection of ion signals composes the mass spectrum [20]. To increase 
the specificity of the analysis, the ionized analyte is often picked out by adjusting the 
electromagnetic field. Then the selected analyte ion will be further broken down to a 
batch of specific fragments. By picking a proper fragment of the analyte ion for the 
analyte monitoring and analysis, the analyte can be identified and measured with both 
high specificity and sensitivity. 
 To achieve this procedure, the mass spectrometer must possess several elements: 
the ion source, the mass analyzer, and the detector. 
 Ion Sources The most commonly used ionization methods coupled with liquid 
chromatography are electrospray ionization (ESI), atmospheric pressure chemical 
ionization (APCI), and atmospheric pressure photoionization (APPI) [21]. 
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 In ESI, the sample solution is passed through a capillary tube. With the help of a 
high electric potential, either positive or negative, added at the end of the capillary tubing, 
the solution can be sprayed into a jet of charged droplets. Meanwhile, a flow of nebulizer 
gas along the same direction with the spray helps disperse the droplets and increases the 
spray efficiency. The small dimensions of the droplets significantly increase their surface 
areas, and enable the solvent to evaporate quickly. At the same moment, a heated drying 
gas is applied to these droplets to avoid condensation and accelerate evaporation. During 
the process of evaporation, the decreased dimension of the droplet keeps increasing the 
charge density on its surface. Eventually, the repulsion between the like charges breaks 
up the droplets and releases single ions and neutral molecules (figure 1.5). ESI is a gentle 
ionization technique that especially efficient for polar compounds that is already ionized 
in solution through protonation or deprotonation. It is especially valuable in the 
ionization of large molecules, such as proteins and oligonucleotides, as it reduces the 
chances of fragmentation during ionization [22]. 
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Figure 1.5, Illustration of ESI.  
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 APCI is a form of chemical ionization, and is often realized on a modified ESI 
source. However, unlike ESI that the majority of the ionization happens in solution, in 
APCI, the ionization takes place after the solution is fully gasified. To be more specific, 
after the sample solution is sprayed through a capillary tube with the help of the nebulizer 
gas, the liquid droplets are evaporated in the source and form neutral aerosol cloud. Once 
the aerosol cloud is formed, nitrogen or oxygen ionized by the corona discharge is able to 
pass their charges to the solvent molecules, and then the solutes. The advantage of APCI 
comparing to ESI lies in its ability to ionize less polar compounds. Yet it is not as gentle 
as ESI, and tends to generate more fragments during ionization [23]. 
 APPI Unlike ESI and APCI that depend on compound polarity during ionization, 
APPI ionizes molecules according to their ionization energy. In APPI, after the aerosol 
cloud is formed by the spray, the photons generated by the Krypton discharge lamp can 
interact with the molecules in the gas phase and pass their energy to the molecules. Then 
the neutral molecules utilize this energy as the ionization energy and get ionized. 
Nowadays, to improve the ionization efficiency, a dopant is often added to the ionization 
chamber. In this case, the photos generated by the Krypton discharge lamp first ionize the 
dopant. Then, the dopant passes the charges to the compounds of interest. This kind of 
ionization mechanism is also named as dopant-assisted APPI (DA-APPI). The advantage 
of this technique lies in its ability of ionizing extremely non-polar compounds. 
Nevertheless, as this technique requires heating the sample solution up to 250-350 Ԩ, its 
application is only limited to compounds with good thermal stability [21, 24]. 
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 As all compounds studied in this work were polar compounds, ESI was utilized 
throughout this work. 
 Mass analyzers Currently, the most commonly used mass analyzers in LC-
MS/MS are triple-quadruple (QqQ), ion-trap (IT-MS), and quadruple-time-of-flight (Q-
TOF) mass spectrometers. 
 QqQ This type of mass spectrometer consists two quadrupole mass filters (Q1 and 
Q3) in series and a non mass-resolving quadruple (Q2) in between. Thus QqQ works as a 
tandem mass spectrometer (MS/MS) that is able to give two dimensions of mass 
separation. Each quadrupole consists of four parallel metal electrodes. For Q1 and Q3, 
among the four electrodes, each pair of electrodes opposite to each other are connected 
and applied with the same radio frequency voltage. By applying another direct current 
onto the radio frequency voltages, a specific electromagnetic field is formed between the 
electrodes. This magnetic field only allows ions with certain m/z to have stable 
trajectories. And thus only these specific ions can pass through the field without hitting 
the electrodes; while all the other undesired ions are filtered out. Unlike Q1 and Q3, Q2 is 
the collision center that accommodates the collision-induced dissociation (CID). In this 
chamber, neutral gas molecules, such as helium, nitrogen, and argon, are accelerated. 
When these molecules collide with the ions traveled through Q1, the high kinetic energy 
carried by these molecules can be passed to the ions and break these ions into fragments. 
Although Q2 does not have mass-resolving power, the quadruple design is able to focus 
the fragments and pass them to Q3 (figure 1.6). Because LC-MS/MS realized through 
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QqQ is able to provide a wide linear calibration range for the compounds, it is most 
commonly utilized in the quantitative analysis of pharmaceutical compounds and their 
metabolites [25, 26]. In this work, all LC-MS/MS was performed exclusively with this 
type of mass spectrometers. 
 IT-MS Similar to the quadrupoles in QqQ, IT-MS is also composed of four 
electrodes added with radio frequency voltages, and generates a specific electromagnetic 
field. However, instead of letting the ions passing through, IT-MS traps the ions of 
interest first, and then exports these ions for detection. When MS/MS applies, IT-MS first 
traps the molecular ions with m/z of interest. Then, in the same trap chamber, the trapped 
ions are broken down with CID. Finally, IT-MS exports the fragments to the detector and 
generates a spectrum of the fragments. The advantage of IT-MS lies in its high sensitivity 
in the full scan mode. Besides, by its intrinsic design, IT-MS is able to handle more than 
one degree of fragmentation. After the first CID, the trap is able to pick out a specific 
fragment of the analyte, namely the daughter ion, and carry out another CID toward this 
daughter ion to obtain granddaughter ion. This property is especially useful in unknown 
specie identification. However, as the linear calibration range of compounds on IT-MS is 
usually much narrower comparing to QqQ, it only has very limited application in the 
quantification works [27]. 
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Figure 1.6, Illustration of QqQ mass analyzer. 
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 Q-TOF With the only difference of Q3 substituted by a time-of-flight (TOF) mass 
analyzer, Q-TOF has very similar configuration as QqQ. The basic working mechanism 
of TOF can be explained as the following: all the ions are accelerated by a certain electric 
field to gain kinetic energy. The higher the charge, the more kinetic energy the ion will 
gain. For the ions with the same charge, the kinetic energy they gained would be the same. 
Then these ions are exported to a high vacuum space free of electromagnetic field, so that 
they can fly freely toward the detector. As when the kinetic energy is the same, the ions 
weight less fly faster, ions with different m/z will reach the detector at different time and 
get resolved.  In this instrumentation, Q1 can serve as a pre-filter for the molecular ions, 
and Q2 remains to be the collision center. The fragments generated by CID can then be 
further resolved and analyzed by the TOF. Under some occasions, when intact molecules 
are the objects of the analysis, TOF can be operated along. In another word, all the ions 
entered into the mass spectrometer can bypass the Q1 and Q2, and directly enter TOF for 
analysis. The advantages of Q-TOF lie in its high mass resolution and the wide m/z 
analysis range. Thus, it is often utilized in unknown compound identification and large 
molecule (e.g., peptides, proteins, oligonucleotides, etc.) analysis. [28, 29]. 
 Detector When the ions finally travel to the detector of the mass spectrometer, the 
detector amplifies and records either the charges or the currents produced by these ions. 
The signals are then passed to the data analysis system and get presented as certain 
spectrum. Although there are multiple types of detectors (e.g., Microchannel plate 
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detector, Faraday cup, ion-to-photon detector, etc.), electron multiplier is the most 
typically used detector for the previously mentioned instrumentations. 
 During the working cycle of the electron multiplier, the ions reach to the detector 
can be amplified by secondary emission. To be more specific, the single electron can be 
accelerated by an electric field and then collide with the secondary emissive material 
coated on the surface of the electron multiplier tube. This kind of collision induces the 
emission of another 1-3 electrons. When the secondary emission is repeated for several 
cycles, the one electron reached the detector can be amplified to a beam of electrons 
(figure 1.7). Finally, this beam of electron is collected by a metal anode and demonstrated 
as a detectable pulse [30]. 
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Figure 1.7, Illustration of electron multiplier.  
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1.2.4. Method validation 
 
 Once an LC-MS/MS method (including the proper sample extraction method) has 
been developed, it is necessary to evaluate the performance of the method, especially 
when the developed method will be utilized for quantitative purposes. 
 Although there are many different standards for method validation, the most 
commonly accepted one in the pharmaceutical industry in United States is the “Guidance 
for Industry Bioanalytical Method Validation” proposed by FDA [31]. According to FDA, 
several factors about the method and the analyte have to be considered when validating a 
bioanalytical method. These factors include selectivity, recovery, calibration curve, 
accuracy, precision, and stability. Besides, as the matrix of the biological samples, even 
the matrix of the post-extract samples, may affect the signal of the analyte, evaluation of 
matrix effect has also become a must in the method validation. 
 Selectivity studies how specific the bioanalytical method is toward the analyte. 
The interferences coming from same type of blank biological samples, yet from at least 
six different sources have to be tested. The signal of the interference caused by non-
specific responses should be evaluated at the level of lower limit of quantification 
(LLOQ). In another word, the non-specific response of the detector should not affect the 
accurate quantification of the LLOQ. 
 Recovery is an evaluation of the effectiveness of the extraction methods. It can be 
obtained by comparing the signals of the analyte in the extracted sample and in the pure 
32 
 
authentic analyte solution spiked in the post-extraction blank matrix. To determine the 
recovery of the extraction method accurately, at least three concentration levels (i.e., a 
low, a medium, and a high) throughout the calibration range should be evaluated. At each 
concentration level, three replicates of the samples should be prepared. The mean value 
and the standard deviation of the measurements should be recorded and reported.  
 Matrix effect is an evaluation of the effectiveness of both the extraction methods 
and LC methods, because if the extraction method or LC failed to provide enough 
separation between the analyte and the interferences, the signal of the analyte may be 
significantly suppressed or, sometimes, enhanced. Matrix effect is usually calculated by 
comparing the signals of the analyte in the pure authentic solution spiked in the post-
extraction blank matrix with that in the pure authentic solution along. Like the 
determination of recovery, at least three concentration levels are needed, and three 
replicates are required for each concentration level. The mean and standard deviation of 
the measurements should be recorded and reported. 
 Calibration curve The calibrators must be prepared in the same biological matrix 
as the real samples. Usually, the calibrators should be prepared by spiking know amount 
of analyte into the biological matrix. For a linear calibration curve, at least six non-zero 
calibrators should be included in the curve. A double-blank sample with no addition of 
analyte or the internal standard (IS) should be included. Besides, a zero sample, with no 
addition of analyte, yet containing same concentration of IS as all the non-zero calibrators, 
should also be included. The accuracy and precision of each calibrator should be 
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evaluated. The accuracy of each calibrator is determined by the percent error of the 
calculated concentration (equation 1.1).  
ܣܿܿݑݎܽܿݕ ൌ   ሺܣ݈݊ܽݕݐ݁ሻ௠௘௔௦. െ ሺܣ݈݊ܽݕݐ݁ሻ௡௢௠௜.ሺܣ݈݊ܽݕݐ݁ሻ௡௢௠௜.  ൈ 100% 
   (1.1) 
Here (Analyte)meas. represents the measured concentration of the analyte from the 
calibration curve. (Analyte)nomi. indicates the nominal concentration of the analyte. 
 The inter-assay precision of each calibrator is determined by the coefficient of 
variation (CV%) from several measurements toward the same calibrator (equation 1.2).  
ܥܸ% ൌ ܵݐܽ݊݀ܽݎ݀ ܦ݁ݒ݅ܽݐ݅݋݊ܣݒ݁ݎܽ݃݁  ൈ 100% 
  (1.2) 
 Sometimes, the same calibration curve is repeated for several times on different 
days, so that the inter-assay precision of the calibrators can be determined. By dividing 
the standard deviation of the calculated values with the average of the calculated values, 
the inter-assay precision can be obtained. 
 For any point on the calibration curve, except the LLOQ, the accuracy and 
precision should be within ±15%. For LLOQ, the values should not exceed ±20%. 
 Accuracy and Precision The calculations of the accuracy and precision are the 
same with those described above. However, to evaluate the accuracy and precision of a 
method, a set of quality control (QC) samples are needed. These QC samples usually 
include at least three concentration levels (low, medium, and high). For each 
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concentration level, five parallel replicates should be prepared. Since the accuracy and 
precision at the LLOQ should also be evaluated, if the low concentration QC samples 
(LQCs) are not the same with the LLOQ, another five replicates of LLOQ should be 
prepared. 
 During real sample analysis, there is possibility that some of the real samples 
possess concentrations either higher or lower than the upper or lower limit of 
quantification. In these occasions, diluted or concentrated quality control samples are also 
need for the accuracy and precision studies. 
 The acceptable criteria of accuracy and precision for the QC samples are, again, 
within ±15%, except at LLOQ as ±20%. 
 Stability The stability studies provide important information on sample handling 
and storage. The most common stability studies include the following categories: short-
term stability, long-term stability, freeze and thaw stability, post-preparative stability, and 
stock solution stability. The short-term, long-term, and freeze and thaw stabilities 
illustrate the stability of the analyte in the biological matrix. The post-preparative 
stability analyzes the stability of the analyte in the post-extraction sample matrix. The 
stock solution stability measures the stability of the analyte in high concentration pure 
stock solutions. For each stability study, at least two concentration levels, a low and a 
high, are needed. At each concentration level, three parallel replicates should be prepared. 
The signals of the analyte in the samples after incubation will be compared with those 
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freshly made samples. The degradation of the analyte can then be clearly indicated by the 
signal loss. 
 Short-term stability studies are usually carried out under room temperature. The 
biological matrix spiked with known concentrations of analyte will be left on bench top 
or in a place that away from direct light exposure. The samples are usually kept under 
this condition for 4 to 24 h. However, the study time can be adjusted accordingly based 
on the actual need in the real sample analysis.  
 Long-term stability In this type of studies, the spiked samples should be kept in a 
desired storage place, such as a refrigerator (4 Ԩ) or in a freezer (-20 or -80 Ԩ). The total 
study time should be longer than the time span between the collection time of the first 
sample and the analysis time of the last sample. The most common time span is from 1 to 
6 months. 
 Freeze and thaw stability At least three freeze and thaw cycles should be carried 
out for this type of studies. For each cycle, the samples should be frozen in the desired 
storage temperature (e.g., -20 or -80 Ԩ) for 12-24 h. Then, the samples should be thawed 
under room temperature without assistance. 
 Post-preparative stability After the samples are processed, they usually will be 
kept in an autosampler, waiting for analysis. Therefore, the stability of the analyte and the 
internal standard in the processed samples should also be evaluated. The study time 
should not be shorter than the total running time of a whole batch of sample. 
36 
 
 Stock solution stability For the stock solutions, at least two kinds of stabilities 
must be studied: short-term stability at room temperature, as well as freeze and thaw 
stability. At least 6 hours storage at room temperature should be included in the short-
term stability studies; at least three freeze-and-thaw cycles should be carried out in the 
freeze and thaw stability studies. 
 
1.2.5. A general work flow of quantitative LC-MS/MS method development 
 
 A quantitative LC-MS/MS method can be developed in the following work flow 
(figure 1.8): 
 First, the analyte is infused into the mass spectrometer for mass identification and 
characterization. In this step, the mass spectrum of the analyte is obtained, so that the 
molecule ion(s) can be identified. Under most of the occasions, to further improve the 
detection specificity, CID is also introduced, fragmenting the selected molecular ion into 
a batch of specific product ions. By scanning these product ions, the predominant product 
ion is often picked out for analyte identification and quantification. Then the mass 
spectrometer can monitor the analyte through specific mass transition channel. 
Meanwhile, a suitable internal standard (IS) is also selected to increase the accuracy and 
precision of the analysis. Mass identification and characterization will be carried out to 
this IS as well. 
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 Then, an LC method will be developed toward the analyte and the IS. The LC 
method must be able to provide sufficient separation between the analyte and the possible 
interferences existing in the sample matrix. For accurate peak integration, the analyte 
signal peak eluted from the column must be symmetrical, and the retention time must be 
repeatable. 
 Afterward, an effective extraction method can be developed to further eliminate 
the interferences in the sample matrix. A preliminary recovery and matrix effect study 
can be carried out to evaluate the effectiveness of the extraction method. 
 Then, repeat injections toward a post-extraction biological sample can be carried 
out on the LC-MS/MS system with the developed LC-MS/MS method. If the signal does 
not vary significantly (i.e., CV% less than 15%) between each injection and the signal of 
the analyte or the IS does not decrease significantly with the repeated analysis, both the 
extraction and the LC method can be kept. 
 Next, the ESI and MS/MS parameters can be fine tuned to provide the maximum 
detection sensitivity. 
 Finally, the whole method can be validated with the FDA guidance. When all of 
the validation criteria are met, the method becomes an analytical method, and can be 
applied to real pharmacological studies. 
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Figure 1.8, Workflow of bioanalytical LC-MS/MS method development.  
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1.3. Conclusion 
  
 In this chapter, a brief discussion has been made on the importance of 
pharmacological studies, including pharmacokinetics and pharmacodynamics studies, in 
the process of anti-cancer drug development. Then three anti-cancer drugs with different 
unsolved problems in their pharmacological studies were introduced; LC-MS/MS 
methodologies on how to solve these problems were proposed. To emphasize the 
problem solving ability of LC-MS/MS in the pharmacological studies of the anti-cancer 
drugs, the mechanisms and techniques of LC, biological sample extraction, mass 
spectrometry, and bioanalytical method validation has been reviewed briefly. A general 
workflow of bioanalytical LC-MS/MS method development has also been laid out at the 
end of the chapter. By following the workflow, pharmacological studies involving similar 
problems can be achieved with LC-MS/MS methods. 
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CHAPTER II 
 
 
ENZYMATIC RELEASE OF DNA ADDUCTS FROM DNA BACKBONE 
 
 
2.1. Introduction 
 
 When DNA is under the stress of certain anti-cancer drugs or some cancerogenic 
agents, abnormities will be introduced into DNA bases, or even the entire nucleotide 
residue [1-4]. To evaluate the effects of these anti-cancer drugs or cancerogenic agents on 
DNA, the resulted DNA adducts are often quantified. DNA adducts with strong and 
unique fluorescent or UV absorption can be directly measured with a fluorescent or UV 
spectrometer. However, for most of the adducts that do not give strong and specific 
signals on fluorescent or UV detectors, mass spectrometry remains one of the most 
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effective tools for DNA adduct quantification. Meanwhile, to facilitate the DNA adduct 
quantification with mass spectrometry, the adducts are often released from the DNA 
backbone with enzymatic hydrolysis procedures. The typical end products of this type of 
hydrolysis are mononucleotide monophosphates or nucleosides, and the released adducts. 
 The most commonly utilized enzymes include bovine pancreatic 
deoxyribonuclease I (DNase I), micrococcal nuclease (MN) from Staphylococcus aureus, 
nuclease P1 (NP1) from Penicillium citrinum, phosphodiesterase I (PDE I) from snake 
venom, phosphodiesterase II (PDE II) from spleen, and calf intestinal or shrimp alkaline 
phosphatase (ALP).  
 Deoxyribonuclease I is an endonuclease splitting phosphodiester bonds 
preferentially adjacent to pyrimidine nucleotides and typically yields tetranucleotides 
with a free 3’-end hydroxyl group and a free 5’-end phosphate group [5]. DNase I is able 
to take both single and double strand DNA as digestion substrates. However, the activity 
of DNase I can be inhibited by histones when digesting chromatin [6]. The optimized pH 
for DNase I is 7.8. To achieve best digestion efficiency, DNase I can be activated with 
bivalent metal ions, such as Mg2+ and Ca2+. In another word, chelating agents such as 
EDTA can deactivate the enzyme by depleting the metal ions needed for the enzyme 
activity [7]. The activity of DNase I can also be inhibited by detergent, such as sodium 
dodecyl sulfate (SDS) [8]. 
 Micrococcal nuclease is an endo-exonuclease that can hydrolyze both DNA and 
RNA. Although it is relatively non-specific, it does have a preference of cleaving at sites 
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rich in adenylate, deoxyadenylate or thymidylate. The typical products of MN digestion 
are mono- or di- nucleotides [9]. Yet unlike DNase I that generates 5’-phophonucleotides, 
MN releases 3’-phosphonucleotides. MN functions better under slightly basic pH (i.e., 
pH 7.0-10.0), with the optimized pH of 9.2. Again, Ca2+ is important for the activation of 
the enzyme; while the enzyme can be inhibited by chelating agents or nucleoside 5’-
phosphates or deoxyribonucleoside 5’-phosphates [9, 10].  
 Nuclease P1 is a 5’ to 3’ exonuclease. The common substrate for this enzyme is 
RNA and single strand DNA. The completely hydrolyzed product is single nucleotides 
with a phosphate group on the 5’ position [11]. Double strand DNA is not an effective 
substrate of NP1 especially under the existence of high concentrations (i.e., higher than 
400 mM) of NaCl. NP1 has higher specificity to the nucleotides located on the 5’ end of 
the phosphodiester bonds comparing to those located on the 3’ end of the phosphodiester 
bonds [12]. The best pH for NP1 functioning is 5.4, and the optimized digestion 
temperature is 70 Ԩ. The enzyme can be activated by a variety of metal ions, such as 
Cu2+, Co2+, Mn2+, Fe2+, Ba2+, and Zn2+. The enzyme’s activity can be significantly 
suppressed (c.a. 50%) with the existence of 0.1-0.2% SDS (w/v) [11]. 
 Phosphodiesterase I is a 3’ to 5’ exonuclease. It can successively hydrolyze 
DNA or RNA from 5’ end to 3’ end to single nucleotide level. Same to NP1, PDE I 
releases single nucleotides with 5’-phosphate as the typical digestion product [13]. It is 
even more non-specific comparing to nuclease P1, and it is only sensitive to the 
configuration of the phosphate in the phosphodiester bond [14]. Optimized digestion 
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efficiency of PDE I can be achieved by adjusting the pH to 8.9 under the existence of 
Mg2+ [15]. EDTA as well as reducing agents, such as glutathione, cysteine, and ascorbic 
acids, are effective inhibitors for PDE I. The enzyme can also be partially inhibited by 
ATP, ADP, and AMP [15]. 
 Phosphodiesterase II is a 5’ to 3’ exonuclease. The action of PDE II on DNA 
requires prior removal of the 5’-end phosphate group and the generation of a free 
hydroxyl group. Then it successively hydrolyzes DNA or RNA and releases single 
nucleotides with 3’-phosphate. The enzyme acts the most efficiently at pH 5.5 in a 
succinate or phosphate buffer. Similar enzyme activity can also be achieved in acetate 
buffer between pH 6.0 and 7.0 [16]. 
 Alkaline phosphatase is a hydrolase removes phosphate groups from a wide 
variety of molecules, such as protein and nucleotides. As its name suggested, ALP 
hydrolyzes the phosphate groups most efficiently under alkaline conditions. For example, 
the optimized pH for bovine intestinal ALP is pH 9.8 [17, 18]. 
 When a DNA adduct needs to be released from the DNA backbone, either one of 
two enzyme combinations are the most commonly selected: DNase plus NP1 and/or PDE 
I [19-23], or MN plus PDE II [24-26]. Both enzyme combinations are sufficient to 
completely hydrolyze DNA into single nucleotide level, and thus release the DNA adduct 
as free small molecule. However, ALP is also added into the digestion system sometimes, 
because the removal of the phosphate group can, sometimes, simplify the LC method 
development. In our study, we mixed together DNase I, NP1, PDE I, and ALP as an 
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enzyme cocktail. By utilizing MX-AP DNA as a model, the components and digestion 
time of the enzyme cocktail have been optimized. However, for different DNA adduct, 
the digestion efficiency of each enzyme may vary. To achieve best digestion effect for a 
specific DNA adduct, the enzyme system will need to be optimized individually. 
 
2.2. Material and methods 
 
2.2.1. Chemicals and solutions 
 
 MX·HCl, BisTris, Calf Thymus DNA, O-(4-Nitrobenzyl) hydroxylamine, ethanol, 
sodium citrate, DNase I, NP1, and ALP (bovine intestinal) were obtained from Sigma-
Aldrich (St. Louis, MO). NaH2PO4, NaCl, and ZnCl2 were purchased from Fisher 
Scientific (Fair Lawn, NJ). Tris base was from Bio-Rad Laboratories (Hercules, CA). 
Hydrochloric acid was from EMD Chemicals (Gibbstown, NJ). PDE I was obtained from 
Worthington Biochemical Corporation (Lakewood, NJ). Deionized water was prepared 
by the Barnstead NANOpure® water purification system (Thermo Scientific, Waltham, 
MA, USA). 
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2.2.2. MX-AP DNA preparation 
 
 To obtain the MX-AP DNA, AP-DNA was first prepared following a procedure 
modified from an existing method [27]. To be more specific, 5.0 mg of lyophilized calf 
thymus DNA was resuspended in 4.0 mL of 10 mM Tris-HCl (pH 7.0). Then, the pre-
existing AP sites on the CT-DNA were blocked by mixing the DNA solution with 1 mL 
of 10 mM O-(4-Nitrobenzyl) hydroxylamine (NBHA, dissolved in 10 mM Tris-HCl and 
adjusted to pH 7.0 with HCl). After incubation at 37 Ԩ for 2 h, the pre-existing AP sites 
were considered as been blocked completely. Then, the DNA solution was transferred 
into clean 1.5 mL centrifuge tubes as 250 µL per aliquot. In each tube, DNA was 
precipitated with 1.0 mL of pre-chilled (-20 Ԩ) ethanol and was left at -20 Ԩ for 30 min. 
DNA pellets were recovered by centrifugation at 4 Ԩ, 10000 × g for 15 min. Then the 
pellet in each tube was washed with pre-cold (4 Ԩ) 70% ethanol for 3 times. For each 
wash, the DNA pellet was mixed with 1 mL of 70% ethanol by 1 min vortex, followed by 
centrifugation at 10000 × g for 5 min. After washing, the DNA pellets were dried by 
leaving the centrifuge tubes uncapped in a fume hood for 30 min at room temperature. 
The dried DNA pellet in each centrifuge tube was resuspended in 250 µL of 10 mM 
sodium citrate buffer (containing 10 mM sodium citrate, 10 mM NaH2PO4, and 10 mM 
NaCl, adjusted to pH 5.0 with HCl). AP sites were generated by heating the DNA 
solution at 70 Ԩ on a heat block (VWR International, Radnor, PA) for 30 min, and the 
reaction was stopped by chilling the DNA samples on ice immediately after heating. 
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Then, DNA was precipitated out, washed, and dried again with the methods described 
above. By resuspending the DNA pellets in 10 mM Tris-HCl (pH 7.0), the pellets in the 
1.5 mL centrifuge tubes were combined and the concentration of DNA was adjusted to 2 
mg/mL by its UV absorption at 260 nm (i.e., 1 OD is equivalent to 50 µg/mL DNA). At 
this step, AP-DNA is obtained. 
 For each 2.5 mL of AP-DNA solution, after addition of 2.5 mL of 20 mM MX 
(dissolved in 30 mM of BisTris, pH 7.0) the mixture was incubated in 37 Ԩ for 2 h. Next, 
the DNA was precipitated out, washed for three times according to the methods described 
above, and then dried with the same method yet for 1 h. Finally, the dried DNA pellet 
was resuspended in 5 mM BisTris (pH 7.0) to a concentration of 1 mg/mL (based on UV 
absorption at 260 nm). 
 
2.2.3. Enzymatic hydrolysis condition optimization 
 
 Several different digestion methods were tried for the optimized digestion 
condition. MX-AP DNA (1 mg/mL in 5 mM BisTris, pH 7.0) prepared in section 2.7 was 
utilized in the tests. Digestion samples were prepared as triplets for each digestion 
method. The enzyme working solutions were prepared as the following: DNase I was 
dissolved with 0.9% NaCl to 10 mg/mL (ca. 20000 unit/mL); NP1 was dissolved with 1 
mM ZnCl2 to 1 mg/mL (ca. 200 unit/mL); PDE I was dissolved with deionized water to 
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100 unit/mL. Each 0.5 µL (12.5 units) of ALP was mixed with 40 µL of PDE right before 
the addition of PDE I. 
 Method 1: each 40 µL of MX-AP DNA was incubated with 0.4 µL of DNase I at 
37 Ԩ for 1.5 h. Then, 0.6 µL of NP1 was added and incubated with the DNA at 37 Ԩ for 
another 3 h. Finally, a 1.6 µL of PDE I and ALP mixture was added and incubated with 
the DNA at 37 Ԩ for 12.5 h. 
 Method 2: An enzyme cocktail was prepared by mixing 10 µL DNase I, 15 µL 
NP1, 40 µL PDE I, and 0.5 µL of ALP. For each 40 µL of MX-AP DNA, 2.6 µL of the 
enzyme cocktail was added and mixed well with the DNA sample. The incubation was 
then kept at 37 Ԩ for 17 h. 
 Method 3: An enzyme cocktail was prepared by mixing 10 µL 0.9% NaCl, 15 µL 
NP1, 40 µL PDE I, and 0.5 µL of ALP. For each 40 µL of MX-AP DNA, 2.6 µL of the 
enzyme cocktail was added and mixed well with the DNA sample. The incubation was 
then kept at 37 Ԩ for 17 h. 
 Method 4: An enzyme cocktail was prepared by mixing 10 µL DNase I, 15 µL 1 
mM ZnCl2, 40 µL PDE I, and 0.5 µL of ALP. For each 40 µL of MX-AP DNA, 2.6 µL of 
the enzyme cocktail was added and mixed well with the DNA sample. The incubation 
was then kept at 37 Ԩ for 17 h. 
 Method 5: An enzyme cocktail was prepared by mixing 10 µL DNase I, 15 µL 
NP1, 40 µL deionized water, and 0.5 µL of ALP. For each 40 µL of MX-AP DNA, 2.6 
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µL of the enzyme cocktail was added and mixed well with the DNA sample. The 
incubation was then kept at 37 Ԩ for 17 h. 
 Method 6-10: An enzyme cocktail was prepared by mixing 10 µL DNase I, 15 µL 
NP1, 40 µL PDE I, and 0.5 µL of ALP. For each 40 µL of MX-AP DNA, 2.6 µL of the 
enzyme cocktail was added and mixed well with the DNA sample. The incubation was 
then kept at 37 Ԩ for 5, 10, 15, 20, and 25 h, respectively. 
  
2.2.4. Digestion efficiency determination 
 
 The mean peak area of the triplicate samples digested with the same method was 
obtained and compared with that of the triplicate samples digested with the other methods. 
In the same set of experiments (method 1-5, or method 6-10), the highest mean peak area 
obtained from a certain digestion method was arbitrarily assigned as 100%. The 
percentiles of the mean peak areas of the other samples in the set were calculated with 
equation 2.1. The digestion efficiencies of different methods were compared through 
these percentiles. 
ܲ݁ݎܿ݁݊ݐ݈݅݁ ൌ ̅ܣܣ௠௔௫തതതതതതത ൈ 100% 
     (2.1) 
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2.3. Results and discussions 
 
2.3.1. Comparison between sequential digestion and enzyme cocktail 
 
 By referring to the work of Yamazoe et al. and Lin et al., the quaternary enzyme 
system consisting of DNase I, NP1, PDE I, and ALP was chosen [28, 29]. In this system, 
DNase I is thought to increase the digestion speed of NP1 and PDE I by generating free 
ends on the DNA. In addition, the oligonucleotide generated by DNase I weakens the 
hydrogen bonds between the double strand, and releases single strand DNA, a better 
substrate for NP1 [11]. When the first three enzymes work together to hydrolyze the 
DNA, single strand or double strand, into deoxyribonucleotides (dNMPs), ALP works at 
the same time to remove the phosphate groups from the dNMPs, resulting 
deoxyribonucleosides (dNs). Although the four enzymes work in a sequential mechanism, 
according to some previous work in DNA adduct release [19-23], DNaseI, NP1 or PDE I, 
and ALP are often mixed together as an enzyme cocktail, and the digestion can be 
achieved in one step instead of through a multi-step sequential digestion process. As 
comparing to the one-step cocktail digestion, when there is no automatic liquid handling 
system available, the procedure is much more complicated. Besides, when the sample 
size is small, handling of small volume (less than 0.5 µL) of enzyme solution is also 
involved. Without automation techniques, the accuracy and reproducibility of this kind of 
sample handling can be relatively low. Diluting the enzyme solution into larger volumes 
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may reduce the errors caused by pipetting, but the large sample size may introduce more 
complicity and waste of solvent in sample extraction. Based on these considerations, the 
releasing efficiencies of the tetra-enzyme system on MX-AP adducts through sequential 
digestion and through cocktail digestion were compared. In the digestion method 1 and 2, 
the amount of each enzyme and the total digestion time were controlled to be the same. 
The digestion efficiency was measured with the method described in section 2.2.4. 
 Figure 2.1 A (column 1 and 2) indicated that although the cocktail digestion 
released slightly lower amount of MX-dR comparing to the sequential digestion, the 
difference is not significant (p < 0.05). When taking the advantages it can bring about, the 
cocktail digestion will have more value in practice.  
 
2.3.2. Significance of DNase I, NP1, and PDE I in the digestion 
 
 After the cocktail digestion has been chosen as the preferred digestion strategy, 
the significances of each enzyme in the release of MX-AP were evaluated. Although ALP 
is not necessary in enzymatic release of MX-AP from the DNA backbone, it is the only 
enzyme that removes the phosphate group. It has to be included in the system as long as 
the non-phosphorylated digestion products are preferred. In this work, developing LC 
method for the non-phosphorylated products is relatively straightforward comparing to 
the phosphorylated products, thus ALP was kept in the enzyme cocktail. For the other 
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three enzymes, three different enzyme combinations (digestion method 3 to 5), each with 
one enzyme missing, were experimented. The amounts of all the other enzymes and the 
digestion time were kept the same in each experiment.  
 According to column 3 to 5 in figure 2.1 A, elimination of any one of the enzymes 
(DNase I, NP1, or PDE I) led to digestion efficiency losses at different extents. However, 
DNase I seemed to play the least important role in the digestion process. This result is 
also consistent with the digestion mechanism of DNase I, as it is an enzyme that only 
increases the efficiency of the other two enzymes. The data also indicated that NP1 was 
the key enzyme in the release of MX-AP; while the maximum digestion efficiency, 
however, was only achieved with the synergy of PDE I.  
 
2.3.3. Enzyme kinetics 
 
 After the optimization of digestion process and enzyme cocktail composition, the 
best digestion time was experimented. By digesting the MX-AP DNA with the enzyme 
cocktail for 5, 10, 15, 20, and 25 h, a kinetic curve was obtained (figure 2.1 B). From the 
curve, the optimized digestion time was between 15 and 20 h. As a result, a total 
digestion time of 17 h was adopted due to its best fit to an 8 h working schedule. 
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A 
 
B 
 
Figure 2.1, Enzyme digestion efficiency comparison. (A) The MX-AP DNA was digested 
with 5 different methods (the number below each column represent the number of the 
digestion method); and (B) the kinetics profile of the enzyme cocktail from 5 h to 25 h.
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2.3.4. DNA concentration determination through the released dNs 
 
 Although DNA concentration is most frequently determined by the UV absorption 
of the DNA samples at 260 nm (OD260), with the interferences caused by impurities, such 
as protein and RNA, the accuracy of the measurement can be seriously affected. 
Evaluation of OD260/OD280 or OD260/OD230 may provide some idea on the purity of the 
DNA samples, but the results are still qualitative instead of quantitative.  
 During the enzymatic release of DNA adducts, however, all the normal DNA 
units are released as dNs (or dNMPs when ALP is not added). The released dNs can 
serve as perfect indicators for DNA quantification without introducing complicated 
procedures. Another advantage of utilizing dNs released from enzyme digestion as the 
standard for DNA quantification lies in that it can, at same time, reflect the digestion 
efficiency of the enzymes on a specific DNA sample. During the DNA extraction, some 
of the impurities introduced during the extraction process, such as SDS and protease K, 
may hurt the efficiency of the enzymes and lead to lower DNA adduct release. In another 
word, even when two samples contain exactly the same concentrations of DNA, 
impurities in one sample may lead to much less DNA adduct release for the sample 
contaminated with SDS or protease K comparing to the sample with higher purity. DNA 
concentration determination with dNs can also normalize the digestion efficiency and 
make the results more reliable.  
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 In this work, commercially available calf-thymus DNA (CT-DNA) was utilized as 
pure DNA standard. We assume that the concentration of the CT-DNA standards can be 
accurately determined by its OD260 due to its high purity. The concentrations of the CT-
DNA standard and the real samples were first roughly normalized to 1 mg/mL according 
to their OD260. Then, both the standard and the real samples were digested with the 
method 2 described in section 2.2.3. After enzyme digestion and IS addition, yet prior to 
the sample extraction, 1 µL of the digestion product was taken out from each real sample 
and the standard, and diluted with deionized water for 1000 times. Next, the diluted 
digestion samples were injected into an LC-MS/MS system and analyzed with a newly 
developed LC-MS/MS method (figure 2.2). The peak areas of the dNs of the real samples 
were integrated, and compared with the CT-DNA standard. The peak area of each type of 
dN (i.e., dA, dC, dG, or dT) of the standard was assigned as 100%. The percentile of a 
specific dN in a real sample was determined with equation 2.2: 
݀ܰ% ൌ ܣேܣே,ௌ௧ௗ ൈ 100% 
    (2.2) 
Here AN indicates the peak area of a specific dN in the real sample; while AN,Std indicates 
the peak area of a specific dN in the digested CT-DNA standard. N can be substituted 
with A, C, G, or T. 
 Then the concentration of a certain DNA sample can be calculated more 
accurately with equation 2.3. 
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ሾܦܰܣሿ௠௘௔௦. ൌ ሾܦܰܣሿௌ௧ௗ ൈ ݀ܣ%൅ ݀ܥ%൅ ݀ܩ%൅ ݀ܶ%4  
   (2.3) 
Here [DNA]meas. means the measured DNA concentration of a real sample; while 
[DNA]Std. indicates the DNA concentration  of the CT-DNA standard (i.e., 1 mg/mL in 
this work). In this equation, dA%, dC%, dG%, and dT% are the percentiles of dA, dC, 
dG, and dT, respectively. 
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Figure 2.2, LC-MS/MS of dNs released after enzyme digestion. Column: Waters (Milford, 
MA) YMC-AQ® column (2.0mm×50mm, 5 µm); mobile phase: isocratic elution with 0.1% 
formic acid, 5% methanol, and 94.9% water (v/v/v), ambient temperature (23 Ԩ), at 0.3 
mL/min; ESI mode: positive; MRM channels: m/z 252 > 136 for dA (red), m/z 228 > 112 
for dC (green), m/z 268 > 152 for dG (orange), and m/z 243 > 127 for dT (blue); source-
dependent parameters: 30 for CUR, 5000 for IS, 300 for TEM, 40 for G1, 40 for G2; 
compound-dependent parameters: 50 for DP, 8 for EP; MRM settings: medium for CAD, 
25.0 for CE, 15.0 for CXP, 100 ms for Dewell Time.  
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2.4. Conclusion 
 
 In this section, a one-step enzymatic digestion protocol with a tetra-enzyme 
cocktail has been optimized for the release of MX-AP from DNA backbone. Comparing 
to the sequential digestion, this protocol possesses similar digestion efficiency, yet is 
much more accurate and easy to handle. The significance of each enzyme in the cocktail 
was evaluated, and a kinetics profile of the enzyme cocktail was obtained. Besides 
optimizing the digestion system, a more accurate way to calculate DNA concentrations in 
real samples was developed. This new method is more reliable in the concentration 
determination for less pure DNA samples, yet does not introduce much complication in 
sample processing and analysis. Our methods will not only benefit the analysis of MX-
AP adducts, but also useful in the analysis of other DNA adducts with further 
optimizations. 
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CHAPTER III 
 
 
MEASUREMENT OF METHOXYAMINE (MX) ON ITS THERAPEUTIC 
TARGET, MX MODIFIED DNA ABASIC SITES (MX-AP), WITH LC-MS/MS 
 
 
3.1. Introduction 
 
 In chemotherapy of cancers, methylating agents and anti-metabolites are often 
utilized because of their abilities of introducing DNA base abnormal, and thus the 
replication and/or repair of the cancer cell DNA can be disrupted [1, 2]. Some of the 
methylated bases or base analogues can be recognized and hydrolysed from DNA strand 
by specific DNA glycosylases [3, 4]. This enzymatic hydrolyzation process initiates an 
important DNA repair mechanism, BER pathways. After the removal of the abnormal 
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bases, AP sites are generated on the DNA strand. The non-coding, highly mutagenic AP 
site lesions can be recognized by AP endonuclease (APE), and then be further repaired 
through later steps in BER [5] (figure 3.1A). Upon complete repair, the cytotoxicity of 
the anti-cancer agent can be removed, and thus the drug effects will be significantly 
attenuated [6]. An example of BER induced drug resistance has been observed during the 
clinical practice with TMZ.  
 TMZ has been approved in glioblastoma multiforme (GBM) treatments by FDA 
since 2005 [7]. After been administered orally, it can be hydrolyzed spontaneously under 
physiological pH to its activated form, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide 
(MTIC), and eventually releases an active methyldiazonium cation that methylates 
adenine and guanine into N3-methyladenine (N3mA), N7-methylguanine (N7mG), and 
O6-methylguanine (O6mG) [8]. The high mutagenicity and cytotoxicity of these 
methylated bases contribute to the anti-cancer activity of the drug [9, 10]. However, the 
therapeutic effect of TMZ is often attenuated by drug resistance resulted from several 
cellular defense mechanisms: N3mA and N7mG (share over 80% of the total methylated 
species) can be repaired through BER [8, 10]; while O6mG (around 5%) is often repaired 
by O6-alkylguanine-DNA alkyltransferase (AGT) and DNA mis-match repair (MMR) [11, 
12]. As a result, blocking drug resistance through BER can be an effective way in drug 
resistant reversing [6]. MX was introduced as an anti-cancer agent under this 
circumstance. 
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 Being reactive to the ring-open form of the AP sites, MX was originally utilized 
as AP site quantification agent, and was considered as a tool in the studies of BER 
pathways [13]. By forming stable adducts with the AP sites, however, MX is also able to 
invalidate the recognition of APE toward the AP sites, and thus results a halt in the repair 
process [14, 15] (figure 3.1B). Since MX blocks the activity of APE by modifying AP 
sites chemically, instead of introducing inhibition to APE itself, it is the first drug of its 
kind [16]. Studies have shown that MX is able to potentiate the drug effects of at least 
two methylating agents [i.e., TMZ and 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)] 
and one anti-metabolite (i.e., fludarabine), both in vitro and in vivo [16, 14, 4]. The 
combined therapy of MX plus TMZ on patients with advanced solid tumors has entered 
into phase I clinical trial [17]. 
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Figure 3.1, Normal AP site recognition by APE (A) and invalidated BER through AP site 
blockage with MX (B).  
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 Although a LC-MS/MS method for the quantification of free MX from plasma 
samples has been developed by our group and has been applied to the pharmacokinetic 
studies of the drug [18], to evaluate the drug effect of MX, an analytical method must be 
developed for the analysis of MX-AP as it is the end point of drug action. In this work, 
we utilized a tetra-enzyme cocktail to release the MX-AP from the DNA backbone as 
MX-dR. The enzymatic digestion product was simply processed by protein precipitation 
and analyzed by a newly developed LC-MS/MS method. By utilizing MX-R as the IS, 
and a set of calibrators prepared by spiking DNA 11-mer with known amount of MX-AP 
adduct into blank CT-DNA, a calibration curve for MX-AP was established, and the 
method accuracy and precision were evaluated through a set of quality control calibrators. 
The method developed was then applied to the MX-AP analysis on cellular DNA of 
T98G cells treated with TMZ combined with MX. A dose-effect and a time-effect profile 
were obtained after the analysis. DNA was also extracted from the lymphocytes of a 
patient with solid tumor enrolled in the Phase I clinical study of TMZ plus MX drug 
combination. Analysis of the MX-AP sites with the method we developed illustrated a 
clear time-effect relationship in the patient. This method has already demonstrated its 
significance in the drug effect studies of MX, and may provide dosimetric guidelines to 
the future clinical trials. 
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3.2. Material and methods 
 
3.2.1. Chemicals and solutions 
  
 MX·HCl, 2’-deoxyribose, ribose, ammonium formate, formic acid, isopropanol, 
acetonitrile, BisTris, CT-DNA, O-(4-Nitrobenzyl) hydroxylamine, ethanol, sodium citrate, 
DNase I from bovine pancreas, NP1 from Penicillium citrinum, bovine intestinal ALP, 
and Tris EDTA buffer were obtained from Sigma-Aldrich (St. Louis, MO). Triethylamine, 
NaH2PO4, NaCl, ZnCl2, PBS, water saturated phenol, and chloroform were purchased 
from Fisher Scientific (Fair Lawn, NJ). Tris base and 10% SDS were from Bio-Rad 
Laboratories (Hercules, CA). DMEM medium and L-glutamine were from Mediatech 
(Manassas, VA). RNase and protease K were from Invitrogen (Carlsbad, CA). DNA 11-
mers 5’-GCCGT-U-AGGTA-3’ and 5’-AGGTAGCCGT-U-3’ were synthesized by 
Integrated DNA Technologies (Coralville, IA). Methanol was purchased from Pharmco-
AAPER (Brookfield, CT). 1,1,1,3,3,3-Hexafluoro-2-propanol was obtained from 
Oakwood Products (West Columbia, SC). Uracil DNA glycosylase (with 10× enzyme 
buffer) was from New England Biolabs (Ipswich, MA). Acetic acid was from 
Mallinckrodt Baker (Phillipsburg, NJ). Hydrochloric acid was from EMD Chemicals 
(Gibbstown, NJ). Snake venom PDE I was obtained from Worthington Biochemical 
Corporation (Lakewood, NJ). Fetal bovine serum was purchased from Hyclone 
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Laboratories (Logan, UT). TMZ was from Ochem (Des Plaines, IL). Deionized water 
was prepared by the Barnstead NANOpure® water purification system (Thermo 
Scientific, Waltham, MA, USA). 
  
3.2.2. Synthesis of MX-dR and MX-R 
 
 MX·HCl powder was dissolved in deionized water to a concentration of 1.0 M. 
2’-Deoxyribose and ribose powders were dissolved in deionized to make 1.0 M solutions, 
respectively. Then each concentrated solution was diluted with deionized water to a 
concentration of 10 mM.  To synthesize MX-dR, 10 µL of MX·HCl solution (1.0 M), 10 
µL of deoxyribose solution (10 mM) and 80 µL of deionized water were pipetted together 
into a 0.5 mL microcentrifuge tube. Then the tube was kept in 70 Ԩ for 2 h. For the 
synthesis of MX-R, the IS, the 1 M MX·HCl solution was diluted with deionized water to 
10 mM. Then, 10 µL of MX·HCl solution (10 mM), 10 µL of ribose solution (1.0 M) and 
80 µL of deionized water were pipetted together into a 0.5 mL microcentrifuge tube. 
Then the tube was kept in 70 Ԩ again for 2 h. Both reactions were stopped by 100 × 
dilution with deionized water. Then, the reaction products were kept in -4 Ԩ till use. 
 
3.2.3. LC-MS/MS and LC-MS instrumentations 
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 The instrument system included a Shimadzu HPLC system (Kyoto, Japan) 
composed of a solvent reservoir, a degasser (DGU-20A3), a binary pump (LC-20AD), a 
flow controller (CBM-20A), and an autosampler (SIL-20ACHT), together with an AB 
SCIEX 5500 QTRAP® 5500 mass spectrometer (Foster City, CA) controlled by Analyst 
software (version 1.5.1). 
 
 LC-MS/MS of MX-dR and the IS 
 Chromatographic separation was carried out on a Thermo (West Palm Beach, FL) 
HypercarbTM column (2.1×50 mm, 5 µM) at ambient temperature (23 Ԩ) with a flow rate 
of 0.4 mL/min. A two-solvent gradient, 5 mM ammonium formate (NH4Fc, pH 3.5) (A) 
and 5 mM NH4Fc (pH 3.5) in 67% methanol and 33% isopropanol (v/v) (B), was utilized 
for complete separation of MX-dR from the matrix interferences. At the beginning of the 
LC, 100% A was held for 1.0 min. Then the content of A was dropped quickly from 100% 
to 40% within 1.0 to 1.1 min. Next, the mobile phase was held at 40% A till 5.9 min, 
followed by returning to 100% A at 6.0 min. Before each run, there was an equilibration 
set as 5 min. The column eluent was diverted to the waste before 2.49 min, and then to 
the mass spectrometer between 2.50 min and 3.10 min. At 3.11 min the flow was diverted 
to the waste again till the end of the run. 
 The mass spectrometer was operated at the positive-electrospray-ionization (ESI+) 
mode. It was tuned by flow injection of a mixture of MX-dR (100 ng/mL) and MX-R 
(100 ng/mL) in the mobile phase (60% B) at a flow rate of 0.4 mL/min. The source-
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dependent parameters were as follows: curtain gasTM (CUR), 20; ionspray voltage (IS), 
5500; temperature (TEM), 300; gas 1 (G1), 60.0; gas 2 (G2), 60.0. The compound-
dependent parameters were as follows: Declustering Potential (DP), 50.0; Entrance 
Potential (EP), 8.00. Detection of MX-dR and MX-R was based on MRM with the 
conditions set as follows: Collision Gas (CAD), low; Collision Energy (CE), 10.0; 
Collision Cell Exit Potential (CXP), 11.0; Dewell Time, 100 ms. Two MRM channels: 
m/z 164 > 117, and m/z 180 > 102 were utilized to monitor MX-dR and MX-R, 
respectively. 
 
 LC-MS of the oligonucleotides 
 The chromatography separation of the oligonucleotides was carried out on an 
Xterra MSC18® column (2.0×50 mm, 3.5 µm, Waters, Milford, MA) by adjusting an 
existing method [19]. Isocratic separation was performed at ambient temperature (23 Ԩ) 
at a flow rate of 0.2 mL/min with a mobile phase containing 86% 200 mM 1,1,1,3,3,3-
Hexafluoro-2-propanol [HFIP, adjusted to pH 7.0 with N,N,N-Triethylamine (TEA)] and 
14% methanol (v/v). The column eluent was diverted to the waste before 2.00 min, and 
then to the mass spectrometer at 2.00 min. 
 Negative-electrospray-ionization (ESI-) mode MS was operated with the source-
dependent parameters as the following: CUR, 20; IS, -4500; TEM, 400; G1, 40; G2, 40. 
The compound-dependent parameters were as follows: DP, -100; EP, -10. DNA 11-mers 
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5’-GCCGT-U-AGGTA-3’ and 5’-AGGTAGCCGT-U-3’, 5’-GCCGT-AP-AGGTA-3’, as 
well as 5’-GCCGT-(MX-AP)-AGGTA-3’ were monitored with the Q1 M1 scan mode 
(selected reaction monitoring or SIR) in channel m/z 670.5 (M-5H), m/z 651.8 (M-5H), 
and m/z 657.5 (M-5H), respectively. The Dewell Time was set as 100 ms for each 
channel. 
 The DNA 11-mers were diluted with deionized water to 1 µg/mL. For each 
analysis, 2 µL of sample was injected onto the column. 
 
3.2.4. Sample extraction 
 
 Briefly speaking, the samples were mixed with excessive amount of acetonitrile 
(20 × volumes), and vortexed for 2 min. Then, the mixtures were centrifuged at 15,000 × 
g at 4 Ԩ for 10 min. Same volume of the supernatant as the acetonitrile added in was 
taken out from each sample and evaporated to dryness at 20 Ԩ  for 60 min in a 
TurboVap® LV Evaporator (Zymark, Hopkinton, MA) under a pressurized stream of 
nitrogen gas (10 psi). Then, the residues were reconstituted in deionized water right 
before LC-MS/MS analysis. 
 For the calibrators except for the double blank, 46.6 µL of IS spiked digestion 
product [including 40 µL of DNA, 2.6 µL of enzyme cocktail, and 4 µL of the IS solution 
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(1.00×104 times diluted with deionized water from the reaction product mentioned in 
section 3.2.2)], 932 µL of acetonitrile was added. After vortex and centrifugation, 932 µL 
of the supernatant was taken out and evaporated to dryness. Each residual was finally 
reconstituted in 39.8 µL of deionized water. 
 For the double blank, 45.6 µL of the digestion product [40 µL of DNA, 2.6 µL of 
enzyme cocktail, and 4 µL of deionized water were mixed together completely; 1 µL of 
the mixture was then taken out for DNA concentration normalization (section 2.3.4)], 912 
µL of acetonitrile was added. After vortex and centrifugation, 912 µL of the supernatant 
was taken out and evaporated to dryness. The residual was finally reconstituted in 37.3 
µL of deionized water. 
 For all the real samples, 16.5 µL of the IS spiked digestion product [15 µL of 
DNA, 0.98 µL of enzyme cocktail, and 1.5 µL IS solution (1.00×104 times diluted with 
deionized water from the reaction product mentioned in section 3.2.2) were mixed 
together completely; 1 µL of the mixture was then taken out for DNA concentration 
normalization (section 2.3.4)], 330 µL of acetonitrile was added. After vortex and 
centrifugation, 330 µL of the supernatant was taken out and evaporated to dryness. Each 
residual was reconstituted in 13.5 µL of deionized water before. 
 
3.2.5. Synthesis and purification of DNA oligomer with known amount of MX-AP sites 
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 To synthesize the DNA oligomer containing known amount of MX-AP sites, 200 
µg of DNA 11-mer (with a uracil incorporated at the 6th position on each oligomer 
molecule) was dissolved in 92.9 µL of uracil DNA glycosylase (UDG) buffer (1 ×, pH 
8.0, containing 20 mM Tris-HCl, 1 mM DTT and 0.1 mM EDTA). Then, 7.1 µL of UDG 
solution [5000 unit/mL enzyme in a pH 7.4 buffer solution containing 10 mM Tris-HCl, 
50 mM KCl, 1 mM DTT, 0.1 mM EDTA, and 50% glycerol (v/v)] was added to remove 
the uracil (1.7 nmol oligomer per unit enzyme), and generate DNA 11-mer with an AP 
site at the 6th position (AP-oligo). The digestion system was kept in 37 Ԩ water bath for 1 
h with slight agitation for complete the enzymatic reaction. After the incubation, 100 µL 
of the resulted AP-oligo (1.00 mg/mL) was reacted with equal volume of 60 mM MX 
solution (dissolved in 90 mM of BisTris, pH 7.0). In order to complete the reaction 
between AP sites and MX, and to obtain DNA 11-mer with one MX-AP adduct at the 6th 
position (MX-oligo), the system was kept in 37 Ԩ water bath for 2 h. The resulted MX-
oligo (1.00 mg/mL) was kept at 4 Ԩ before purification. 
 The MX-oligo obtained was purified with a solid phase extraction (SPE) 
procedure. Oasis® HLB cartridge (3 cc, 60 mg, Waters, Milford, MA, USA) was 
activated with 3 mL of acetonitrile, and then balanced with 3 mL of 0.1 M 
triethylammonium acetate buffer (TEAAc), pH 7.0. 100 µL of MX-oligo (1.00 mg/mL) 
was diluted with 900 µL of deionized water, and was added onto the SPE cartridge. After 
the sample had passed through, the cartridge was washed with 3 mL of 0.1 M TEAAC 
(pH 7.0). Finally, the MX-oligo was eluted with 2 mL of 0.1 M TEAAC (pH 11.0) in 10% 
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acetonitrile and 90% water (v/v) [20]. The cartridge eluent was dried on the TurboVap® 
LV evaporator under a pressurized stream of nitrogen gas (10 psi) at 25 Ԩ for 4 h. The 
residue was reconstituted in 100 µL of deionized water and kept in -20 Ԩ till use. 
 Another DNA 11-mer with a uracil incorporated at the 11th position (5’-
AGGTAGCCGT-U-3’) was processed exactly the same way (incubated with UDG, 
reacted with MX, purified with SPE, and reconstituted in deionized water to 1 mg/mL) to 
serve as a negative control (U-end-oligo). 
 
3.2.6. Preparation of MX-AP DNA calibrators 
 
 MX-oligo after purification (1.00 mg/mL) was diluted with 1.00 mg/mL blank 
CT-DNA solution (in 5 mM BisTris, pH 7.0) for 4.00×103, 8.00×103, 1.60×104, 3.20×104, 
6.40×104, 1.28×105, and 2.56×105 times. The resulted MX-AP DNA calibrators were 
22.7, 11.4, 5.70, 2.85, 1.43, 0.715, and 0.358 MX-AP adducts/106 bases, respectively. 
Two blank samples, a single blank (1.00 mg/mL U-end-oligo diluted with 1.00 mg/mL 
CT-DNA for 4.00×103 times, with the addition of the IS solution after enzyme digestion) 
and a double blank (1.00 mg/mL U-end-oligo diluted with 1.00 mg/mL CT-DNA for 
4.00×103 times, without the addition of the IS solution after enzyme digestion), were 
prepared at the same time. For the accuracy and precision studies, three concentrations of 
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MX-AP calibrators (i.e., 22.7, 2.85, and 0.358 adducts/106 bases) were prepared in 
quintuplicate. The IS solution was added after the DNA hydrolysis. 
 
3.2.7. Enzymatic release of MX-AP 
 
 An enzyme cocktail was prepared by mixing 10 µL DNase I, 15 µL NP1, 40 µL 
PDE I, and 0.5 µL of ALP. For each 40 µL of MX-AP DNA, 2.6 µL of the enzyme 
cocktail was added and mixed well with the DNA sample. The incubation was then kept 
at 37 Ԩ for 17 h. The amount of the enzyme cocktail was adjusted proportionally to the 
amounts of DNA in the real samples. 
 
3.2.8. Cell culture and treatment 
 
 T98G (a human brain fibroblast cell line) cells obtained from American Type 
Culture Collection (ATCC, Rockville, MD, USA) were cultured in DMEM medium 
supplemented with 10% (v/v) fetal bovine serum and 2 mM of L-glutamine at 37 Ԩ in a 
humidified 5% CO2 incubator. 
 In the dose-response study, each 5 × 106 cells, the dosages of TMZ were chosen 
as 0.750, 1.13, and 1.50 mM. At each dosage of TMZ, the concentration of MX varied as 
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5.00, 10.0, 15.0, 20.0, and 25.0 mM. The treatment was kept at 37 Ԩ in a humidified 5% 
CO2 incubator for 24 h. In the time-response study, each 5 × 106 cells were treated with 
0.750 mM of TMZ plus 25.0 mM MX for 6, 12, 24, 48, and 72 h at 37 Ԩ  in the 
humidified 5% CO2 incubator. The pre-treatment control was obtained by incubating 5 × 
106 cells in the same incubator for 24 h without drug administration. The treatment was 
stopped by removal of culture media, and the cells were washed three times with 5 mL 
PBS (1×, pH 7.4). After washing, another 5 mL of PBS (1×, pH 7.4) solution was added 
into each culture dish. The cells were lifted by a cell scraper (Costar, Corning, NY) and 
transferred to a clean 15 mL centrifuge tube. Then, the cells were recovered from the 
suspension by centrifugation (350 × g at 4 Ԩ for 10 min). After centrifugation, the cell 
pellets collected were stored in -20 Ԩ till DNA extraction. 
 
3.2.9. Lymphocytes separation 
 
 Peripheral blood samples were collected into heparinized Vacutainer® tubes (BD, 
Franklin Lakes, NJ) from the patient who had signed written informed consent at the 
University Hospital Case Medical Center (Cleveland, OH).  At the time of blood drawing, 
the patient was administered with 350 mg TMZ plus 35 mg of MX. Blood was drawn at 0, 
2, 4, and 24 h; and the blood samples were fractioned by Ficoll-Paque method [21]. 
Briefly, 10 mL heparinized blood was layered on the top of 12 mL Ficoll-Paque Plus 
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reagent (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) in a 50 mL sterile 
polypropylene centrifuge tube (RNase/DNase free); then the tube was centrifuged at 4 Ԩ 
and 300 × g for 30 min. Cells at the interface were collected and transferred into a clean 
15 mL centrifuge tube, and washed twice with 10 mL PBS (1×, pH 7.4). For each wash 
step, the cells were gently vortexed with the PBS for 1 min, and then centrifuged down at 
4 Ԩ and 300 × g for 10 min. After wash, the cell pellets were frozen at -20 Ԩ till DNA 
extraction. The time between blood sample collection and DNA extraction was within 1 
month. 
 
3.2.10. DNA extraction 
 
 For each 15 mL centrifuge tube containing the T98G cell pellet or the 
lymphocytes from the patient, 2 mL of TE buffer (containing 10 mM Tris and 1 mM 
EDTA, pH 8.0) was added. A short vortex was performed to ensure homogenous 
suspension. Next, 0.24 mL of 10% SDS solution was added and mixed with the cell 
suspension gently by inverting the centrifuge tubes slowly for several times. After 
complete mixing, 20 µL of RNase (20 mg/mL dissolved in deionized water) was added 
and was incubated with the sample at 37 Ԩ for 1 h. Then, 25 µL of protease K (20 
mg/mL dissolved in deionized water) was added and was incubated with the sample at 37 
Ԩ for another 1 h. Then, the samples were extracted twice with phenol followed by two 
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times extraction with chloroform. For the extraction with phenol, 2 mL of water saturated 
phenol was added into each tube and vortexed with the sample for 1 min. The samples 
were then centrifuged at 1500 × g and 4 Ԩ for 30 min. Then the aqueous (upper) layer 
was carefully transferred to a clean 15 mL centrifuge tube. For the extraction with 
chloroform, the aqueous phase of each sample was transferred to a Phase Lock Gel tube 
(5 Prime, Gaithersburg, MD), and 2 mL of chloroform was added into the tube. Again, 
the samples were vortexed for 1 min, and centrifuged at 1500 × g and 4 Ԩ for 15 min. 
After extraction with phenol and chloroform, the aqueous phase (ca. 2 mL) was 
transferred to a clean 15 mL centrifuge tube and mixed with 10 mL pre-chilled ethanol (-
20 Ԩ ). DNA was precipitated at -20 Ԩ  for overnight, and then recovered by 
centrifugation (1500 × g at 4 Ԩ for 15 min). Next, the DNA pellet in each tube was 
dissolved in 200 µL deionized water and transferred to a 1.5 mL centrifuge tube. In each 
tube, 1 mL of pre-chilled ethanol (-20 Ԩ) was added. By inverting the tube for several 
times, the DNA solution was mixed with ethanol completely. Then, DNA was 
precipitated at -20 Ԩ for 1 h. After recovered the DNA pellet through centrifugation 
(10000 × g at 4 Ԩ for 15 min), the sample in each tube was washed with 1 mL pre-cooled 
70% ethanol (4 Ԩ) for once, and centrifuged at 10000 × g and 4 Ԩ for 5 min. The 1.5 mL 
centrifuge tubes containing DNA were left uncapped in a fume hood for 1 h. After drying, 
the DNA pellets were reconstituted with 5 mM BisTris buffer (pH 7.0) to a concentration 
of 1 mg/mL (based on UV absorption at 260 nm). Finally, all samples were incubated in a 
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boiling water bath for 15 min to remove the remaining protease K activity. The DNA 
samples were stored at 4 Ԩ before analysis. 
 
3.2.11. MX-AP concentration normalization 
 For the real samples, the concentrations of MX-AP calculated from the calibration 
equation were normalized according to the amount of dNs released after digestion: 
 After enzyme digestion and IS addition, yet prior to the sample extraction, 1 µL 
of the digestion product was taken out from each real sample and the double blank 
calibrator. Each of 1 µL the digestion product was than diluted with 1999 µL of 
deionized water. Next, the diluted digestion samples were injected into the LC-MS/MS 
system following the methods described in the legend of figure 2.2 in section 2.3.4. The 
percentile of a specific dN in a real sample was determined with equation 2.2. 
 Each sample, including the positive control, was injected and analyzed for 3 times, 
and the mean dN% values were obtained by taking the average of the dN% obtained from 
each analysis. The normalized concentration of MX-AP in each real sample was then 
calculated by equation 3.1: 
ሾܯܺ െ ܣܲሿ௡௢௥௠. ൌ ሾܯܺ െ ܣܲሿ௖௔௟./ሾሺ݀ܣ%൅ ݀ܥ%൅ ݀ܩ%൅ ݀ܶ%ሻ/4ሿ 
 (3.1) 
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Here [MX-AP]cal. means the calculated concentration of MX-AP obtained from the 
calibration equation; while [MX-AP]norm. indicates the normalized MX-AP concentration. 
Both concentrations were in the unit of adducts/106 bases. 
 
3.3. Results and discussions 
 
3.3.1. Characterization of MX-dR and the IS with mass spectrometry 
  
 Since MX-AP is bound to DNA strand, to realize the quantification, a tetra-
enzyme system was utilized to release MX-AP as MX-dR (figure 3.2). By carrying out 
this enzymatic digestion, the quantification of MX-AP bound to DNA was converted to 
the quantification of the free small molecule, MX-dR. To achieve highly accurate and 
repeatable results, another small molecule, MX-R was synthesized as the IS. After 
reaction, the two post-reaction mixtures were diluted with 5 mM NH4Fc for 100 times, 
respectively, and infused into the mass spectrometer by a syringe pump at a flow rate of 5 
µL/min. As both MX-dR and the IS are more easily to form protonated species through 
ESI, ESI+ mode was utilized. As shown in figure 3.3, MX-dR and the IS produced 
molecular ions at m/z 164 {[MX-dR+H]+} and m/z 180 {[MX-R+H]+}, respectively. To 
achieve higher specificity in the quantification, the molecular ions were further 
dissociated with CID. From the resulted fragmentation pattern, two predominant 
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fragments were observed at m/z 117 for MX-dR and m/z 102 for the IS, respectively. 
Therefore, the mass transition pairs m/z 164>117 for MX-dR and m/z 180>102 for the IS 
were utilized in the quantification work with MRM mode. 
 
  
86 
 
 
 
 
 
 
 
Figure 3.2, Enzymatic release of MX-AP from the DNA backbone as MX-dR. 
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Figure 3.3, Mass spectra of MX-dR and MX-R: (A) full scan and (B) fragmentation mass 
spectra of MX-dR; and (C) full scan and (D) fragmentation mass spectra of MX-R.
A B
C D
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3.3.2. Digested DNA sample extraction 
 
 As the quantification was carried out toward the MX-dR in the enzyme digested 
DNA samples, several major interferences were expected: buffer salts (i.e., 4.69 mM 
BisTris, 145 µM NaCl, and 14.1 µM ZnCl2), proteins (i.e., protein impurities existing in 
the DNA samples and enzymes utilized in the digestion), and the dNs (with a total 
concentration of around 3 mM). To avoid signal suppression and ion source 
contamination caused by these interferences, the analyte must be effectively separated 
from these interferences through on-line and/or off-line procedures. 
 Two off-line extraction methods were tried in order to remove the matrix 
interferences:  
 A LLE method with a mixture of ethyl acetate and isopropanol (95:5, v/v) was 
tried. This method was effective in removing NaCl and ZnCl2. It was also able to remove 
over 90% BisTris. However, it failed to eliminate the dNs effectively.  
 An SPE method with a cation exchange cartridge, the Oasis® MCX cartridge, was 
utilized under the intention of retaining all the dNs on the cartridge, yet collecting MX-
dR from the cartridge pass-trough. To retain dA, dC, and dG, moderate acidic pH (i.e., 
pH 4) had to be utilized in sample loading. Under the same pH, however, dT was 
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predominantly negatively charged, and could not be retained on the cartridge. Besides, 
extra steps were still needed to separate the analyte from the buffer salts.  
 As a result, the samples were simply processed by one-step acetonitrile 
precipitation to remove the proteins. Removal of the buffer salts and the dNs was left as a 
task in the LC method development. 
 
3.3.3. LC separation of the analyte from the matrix interferences 
 
 Several columns (i.e., an YMC ODS-AQ® column, an Xterra MSC18® column, 
and a HypercarbTM column) were tried to obtain the separation between MX-dR and the 
other interference compounds.  
 The YMC ODS-AQ® column was tried due to its capability of retaining highly 
polar compounds, and its compatibility with highly aqueous mobile phases. However, 
even when the percentage of the organic component (i.e., methanol) was dropped below 
2%, no significant retention was observed for MX-dR.  
 As MX-AP adduct can also be converted to MX-deoxyribose 5’-phosphate (MX-
dRp) in the enzymatic releasing of MX-AP through eliminating ALP from the enzyme 
cocktail, ion-pairing chromatography with TEA was considered. In this test, the Xterra 
MSC18® column was utilized. By adjust the pH and the organic percentage of the mobile 
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phase, MX-dRp could be retained on the column for up to 3 column volumes without 
causing significant tailing. However, all the 2’-deoxyribonucleotide monophosphates 
(dNMPs) released after enzyme cutting could not be separated from the analyte 
effectively.  
 In the work of Antonio et al., several sugar and sugar phosphates were separated 
on a porous graphitic carbon (PGC) column, the HypercarbTM column [22]. Because the 
graphite surface possesses a large amount of delocalized π-electrons, it is easy to induce 
electronic interaction with the analytes carrying polarizable or polarized groups [23]. And 
thus, the columns can provide strong retention to highly polar compounds. Another 
advantage of the PGC columns lies in their pH stability: they are stable throughout the 
pH range. 
 As the structure of MX-dR is similar to those of the sugars, separation between 
the analyte and the matrix interferences was tried on this column. Isocratic elusion with a 
mixture of NH4Fc and organic solvents (i.e., methanol, acetonitrile, isopropanol, 
methanol/acetonitrile, or methanol/isopropanol) was able to retain MX-dR for at least 2 
column volumes and achieve single symmetrical peak at the same time. Some of the 
conditions were also able to separate the analyte effectively from all the dNs and the 
inorganic salts. However, the separation between BisTris and MX-dR was always not 
enough due to the column’s slightly retention to BisTris. Better separation between MX-
dR and BisTris can be achieved through utilizing lower percentage of weaker organic 
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solvents, such as methanol, but the peak of MX-dR started to split. Besides, the retention 
times of the dNs were increased significantly (over 60 min for dA and dG). Based on 
these reasons, a gradient elusion with the conditions described in section 3.2.3 was finally 
adopted. With this LC method, MX-dR was able to be retained on the column for 2.8 min, 
while all the dNs were eluted out after 3.2 min (figure 3.4). The BisTris was eluted out at 
0.6 min. By applying the same LC condition, the IS was eluted out at 2.7 min. 
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Figure 3.4. Representative MRM chromatograms of MX-dR, MX-R (IS), and other 
matrix interferences. (A) BisTris (m/z 210 > 106), (B) MX-dR (m/z 164 > 117), (C) MX-
R (m/z 180 > 102), (D) dC (m/z 228 > 112), (E) dT (m/z 243 > 127), (F) dA (m/z 252 > 
136), and (G) dG (m/z 268 > 152).  
A 
B 
C 
D 
E 
F 
G 
93 
 
3.3.4. MX-AP DNA standard preparation 
 
 Since the quantification of MX-AP was realized through quantification of MX-dR 
released after enzyme digestion, DNA spiked with synthesized MX-dR would not be 
reliable in accurate quantification due to its invalidity in reflecting the digestion 
efficiency. Neither would the MX-AP DNA synthesized according to the protocol 
described in section 2.2.2 be reliable standards due to the uncertain amount of MX-AP 
sites it carries from batch to batch. Based on these considerations, a single strand DNA 
11-mer with one MX-AP adduct located in the middle [i.e., 5’-GCCGT-(MX-AP)-
AGGTA, the MX-oligo] was synthesized by modifying an existing protocol for AP-oligo 
synthesis [24]. Spiking the MX-oligo into blank CT-DNA resulted MX-AP DNA 
calibrators carrying all the necessary information required by the accurate quantification.  
 To monitor the synthesis process of MX-oligo, the starting material and product 
of each step of reaction were analyzed with the LC-MS method described in section 3.2.3 
(figure 3.5). As the remaining reactant was less than 1% of the original amount after each 
step of reaction, both steps were considered as complete. The U-mid-oligo was converted 
to equal amount of MX-oligo.  
 To avoid high quantification background caused by the reaction between the 
excessive MX in the synthesis product and the AP sites generated through spontaneous 
hydrolysis during the enzyme digestion, the MX-oligo was purified on an Oasis® HLB 
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SPE cartridge with a protocol adjusted from a published method [20]. By comparing the 
peak area of MX-oligo from the reaction product before and after purification, the 
recovery was determined as 94.2±1.6%. 
 As UDG is unable to remove uracil from the end of a DNA strand, UDG digestion 
on the U-end-oligo is not effective in producing AP-oligo (figure 3.5). Further reaction 
with MX was not able to generate MX-oligo efficiently as well. Thus, the U-end-oligo 
was processed parallel with the U-mid-oligo as a negative control of the studies. In 
another word, the U-mid-oligo is able to reflect any background caused by excessive MX 
remaining in the purified oligomer products, or the background caused by MX-AP 
adducts formed from the reaction between MX and the AP sites generated spontaneously 
during the oligomer synthesis. 
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Figure 3.5, MX-oligo synthesis. Solid lines: the chromatograms obtained from the 
experiments with U-mid-oligo as the starting material; dash lines: the chromatograms 
obtained from the experiments with U-end-oligo as the starting material. 
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3.3.5. Method performance 
 
 To evaluate the performance of the developed methods in quantitative studies, a 
calibration curve was established with a linear calibration range of 0.358- 22.7 MX-AP 
adducts/106 bases. The curve was weighted by the reciprocal of MX-AP concentration, 
1/x. The calibration equation has been shown in table 3.1, and the linearity, represented 
by correlation coefficient R2, was 0.999 ± 0.000. The accuracy and inter-assay precision 
of each point on the calibration curve ranged from 93.6-115% and 0.73-4.53%, 
respectively (table 3.1).  
 The accuracy, intra-assay precision, and inter-assay precision of the analysis were 
determined through the quintuplicate calibrators at three concentration levels (low, 
medium, and high). All data were summarized in table 3.2. The accuracy ranged from 
86.7- 98.2%; while the intra- and inter- assay precision varied from 1.02-5.25% and 3.14-
3.78%, respectively. 
 Here the accuracy was calculated by the relative deviation between a calculated 
concentration and the nominal concentration; while the precision was calculated by 
percent standard deviation. 
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Table 3.1, Calibration equation of MX-AP. 
Actual [MX-AP], 
adducts/106 bases 
Measured [MX-AP], 
adducts/106 bases 
Accuracy 
(%) 
Inter-assay 
Precision (%) 
0.358 0.409 114 4.53 
0.715 0.664 92.9 3.32 
1.43 1.37 95.8 0.730 
2.85 2.73 95.8 2.78 
5.70 5.58 97.9 2.84 
11.4 11.2 98.3 2.36 
22.7 23.1 102 1.30 
Calibration equation: Y = (0.26 ± 0.01) X + (0.024 ± 0.005), R2 = 0.999 ( ± 0.000) 
Each datum point was based on three separate measurements toward the same set 
of samples. 
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Table 3.2, Accuracy, intra- and inter-assay precision. 
 Low  Medium  High  
Accuracy (%) n=5 86.7 96.5 98.2 
Intra-assay Precision 
(%) n=5 
5.25 1.02 3.97 
Inter-assay Precision 
(%) n=3 
3.78 3.14 3.60 
The concentrations of MX-AP in the calibrators of low, medium and high 
concentrations were 0.358, 2.85, and 22.7 adducts/106 bases respectively. 
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3.3.6. Analysis of TMZ plus MX treated T98G cells 
 
 In the cellular DNA analysis in this section and section 3.3.7, the MX-AP 
concentration of every real sample was normalized with the method described in section 
2.12. The reason of carrying out this normalization procedure lies in its advantages in 
more accurate quantification.  
 T98G cells treated with TMZ plus MX with different dosages and time spans 
were analyzed with the developed methods. A dose-effect profile (figure 3.6 A) and a 
time-effect profile (figure 3.6 B) were obtained afterward. 
 From the dose-effect profile, a clear relationship between the dosage of TMZ plus 
MX and the concentration of MX-AP can be observed. For each dosage level of TMZ, 
the concentration of MX-AP was elevated with the increase of the MX dosage. 
Meanwhile, when the dosage of TMZ was increased, the profile of response was lifted 
systematically. These results are consistent with our hypothesis: higher concentration of 
MX blocks more AP sites; while higher concentration of TMZ generates more AP sites 
systematically. 
 From the time-effect profile, when the treatment time increased from 6 h to longer, 
the concentration of MX-AP decreased slightly at the beginning, and then reaches a 
relatively steady state after 24 h treatment. 
100 
 
3.3.7. Analysis DNA samples from TMZ plus MX treated patient 
 
 The DNA samples from the patient with solid tumor enrolling in the phase I 
clinical trial of TMZ plus MX drug combination were analyzed. The time-response 
profile has been illustrated in figure 3.6 C. Determined from the profile, the concentration 
of MX-AP quickly reaches to the maximum after 4 h treatment, and then decreased 
gradually below 0.500 MX-AP adducts/106 bases after 24 h. The quick response of the 
patient to the treatment was consistent with our in vitro result. The clearance rate of MX-
AP adducts, however, was much higher in the patient comparing to the cultured cells. 
The reason for the difference is still under investigation. 
 In fact, DNA samples from 4 patient enrolled in the phase I clinical studies were 
analyzed with our method, and only this one showed detectable signals for MX-AP. The 
PK profile of the patient indicated a significantly lower blood concentration of free MX. 
This may indicate extremely high MX incorporation into the patient’s DNA. However, 
during the drug effect analysis, the amounts of MX-AP detected from the real samples 
were much lower comparing to the expectation. 
 Under physiological conditions, DNA bases can be dissociated from the DNA 
strand through spontaneous hydrolysis at rate of 2 bases/106 bases in every 24 h. Under 
the treatment of TMZ, although the amount of AP site generated after treatment has not 
been evaluated, it should be much higher than the AP sites generated by spontaneous 
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hydrolysis. Assume that addition of MX will lead to 1 MX-AP adduct/106 bases after 24 
h treatment; at the same time, the white blood cell count in of the patient is 5×106 
cells/mL blood. As the blood drawn from each time point was around 5 mL and the 
extracted DNA samples were typically dissolved in 15 L of BisTris buffer before 
digestion, a calculation on the total amount of MX-AP adduct in the patient DNA 
samples can be roughly estimated as the following: 
ሾܯܺ െ ܣܲሿ,݉݋݈݁ ܮ⁄
ൌ 5݉ܮ  ൈ ሺ5 ൈ 10଺ ݈݈ܿ݁ ݉ܮ⁄ ሻ ൈ ሺ6 ൈ 10ଽ  ܾܽݏ݁ݏ ݈݈ܿ݁⁄ ሻ ൈ ሺ1
ൈ 10ି଺  ܯܺ െ ܣܲ ܾܽݏ݁ሻ ൊ ሺ6.02 ൈ 10ଶଷ  ܯܺ െ ܣܲ ݉݋݈݁⁄ ሻ ൊ ሺ1.5 ൈ 10ିହ ܮሻ ൌ 16.6 ݊ܯ⁄   
Since the total concentration of the dNs in a digested DNA sample is around 3.2 mM, if 
convert the detection limit of MX-AP from standards to mole concentration: 
ሾܯܺ െ ܣܲሿ,݉݋݈݁ ܮ ൌ ሺ0.358 ൈ 10ି଺  ܯܺ െ ܣܲ ܾܽݏ݁ሻ  ൈ  3.2 ݉ܯ⁄⁄  ൌ 1.15 ݊ܯ 
 Based on the calculation, the MX-AP signal should be detectable in the patient 
DNA. However, due to the patients enrolled in the clinical trial were with solid tumor, the 
white blood cell count in these patient may be much lower than healthy donors. 
Meanwhile, as the cellular DNA was extracted in a relatively inefficient way, the 
recovery of the DNA may well below 100%. Last but not the least, the DNA extracted 
from the real samples can be easily contaminated with histon, SDS, and protease K. All 
three kinds of impurities may greatly inhibit the releasing efficiency of the enzyme 
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cocktail on the MX-AP adducts. In another word, before applying the developed method 
into the analysis of patient DNA samples, further optimizations must be carried out. The 
optimization can be done in two aspects. First, the DNA extraction and purification 
method can be further optimized. DNA extraction kit can be utilized for higher recovery 
and purity, as well as more reproducible results from sample to sample. Second, the 
enzyme digestion conditions can be further optimized. If necessary, different enzymatic 
system can be experimented. 
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A.              B. 
          
 
C. 
   
 
Figure 3.6, MX drug effect studies. (A) The dose-effect profile obtained from TMZ plus 
MX treated T98G cells: (■) 1.50 mM TMZ; (▲) 1.13 mM TMZ; (●) 0.750 mM TMZ. (B) 
The time-effect profile obtained from TMZ (0.750 mM) plus MX (25 mM) treated T98G 
cells. (C) The time-effect profile obtained from the clinical patient. 
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3.4. Conclusion 
 
 A tetra-enzyme cocktail containing DNase I, NP1, PDE I and ALP has been 
utilized for the quantitative releasing of MX-AP from the DNA backbone as MX-dR. A 
protein precipitation procedure was utilized in the sample preparation to remove protein 
interferences in the sample matrix. LC separation was realized on a HypercarbTM column 
for further separation of MX-dR and the IS from all the other interferences existing in the 
sample matrix. The MX-AP calibrators were prepared by spiking DNA 11-mers with one 
MX-AP site on each 11-mer into blank CT-DNA. A calibration curve ranged from 0.358-
22.7 MX-AP adducts/106 bases were established, and the accuracy and precision were 
evaluated through a set of quality control calibrators. The feasibility of the method was 
tested by drug effect studies both in vitro (i.e., with the TMZ plus MX treated T98G cells) 
and in vivo (i.e., with the lymphocytes of the clinical patient treated with TMZ plus MX 
in a phase I clinical trial). The method we developed provided direct information on drug 
effect of MX, and thus will assist in providing dosimetric guidance in future clinical trials. 
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CHAPTER IV 
 
 
DRUG EFFECT ANALYSIS OF FLUDARABINE (F-ARA-A) BY MEASURING 
THE DRUG INCORPORATION IN DNA WITH LC-MS/MS 
 
 
4.1.  Introduction 
 
 Fludarabine (9-β-D-arabino-furanosyl-2-fluoradenine or F-ara-A) is an adenosine 
analogue mainly utilized in the treatment of hematological malignencies, such as non-
Hodgkin’s lymphoma, B-cell chronic lymphocytic leukemia (CLL) and acute myeloid 
leukemia (AML) [1-3]. The monophosphorylated F-ara-A (9-β-D-arabino-furanosyl-2-
fluoradenine monophosphate, or F-ara-AMP) is the major form of the drug utilized in 
clinical purposes due to its improved solubility, and thus bioavailability in aqueous 
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environment [4]. The clinical application of F-ara-AMP has been approved by FDA, and 
the drug is now commercially available under the brand name of Fludara® (used for 
intravenous injection) or Oforta® (used for oral administration).  
 A brief functioning mechanism of F-ara-AMP after administration can be 
summarized as the following: first, the drug is dephosphorylated by serum phosphatase to 
F-ara-A shortly after being administrated intravenously; then, the dephosphorylated drug 
can be transported into the cells through nucleoside-specific membrane transport carrier 
(NT); after uptake, F-ara-A is first re-phosphorylated by deoxycytidine kinase to F-ara-
AMP and gets activated; next, F-ara-AMP is further phosphorylated, under the successive 
actions of nucleoside monophosphate- and diphosphate-kinases, to F-ara-ADP and then 
F-ara-ATP; finally, the triphosphorylated form of the drug can be incorporated into the 
DNA strand, halting DNA strand elongation through inhibiting multi enzymes involved 
in DNA synthesis; meanwhile, both the di- and tri-phosphorylated forms of the drug can 
inhibit ribonucleotide reductase (RR), causing deoxyribonucleotide poor imbalance and 
affecting DNA repair and synthesis [5,6]. 
 As an FDA approved chemotherapy agent, the pharmacology properties of F-ara-
A have been studied intensively during the past years. However, the drug effect of F-ara-
A has never been quantified on a molecular level. Besides, some details about the drug’s 
functioning mechanisms are still not fully understood. To be more specific, although the 
drug has been generally accepted as a chain terminator due to its inhibition on enzymes 
involved in DNA synthesis, argument on F-ara-A’s incorporation into the middle of the 
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DNA strands has also been raised. Quantifying F-ara-A incorporated in cellular DNA is 
not only meaningful in providing drug effect data on the molecular level, but may also be 
essential in drug mechanism elucidation. Once the amount of the free 3’-end of DNA is 
quantified, by comparing the data with the quantity of the total incorporated F-ara-A, the 
number of F-ara-A incorporated in the middle of the strand can be determined. 
 In this work, the incorporated drug was first released by the tera-enzyme system 
described in Chapter II from the DNA backbone as free F-ara-A. Then, an LC-MS/MS 
method was developed in order to analyze the released F-ara-A from the digestion matrix. 
An in vitro drug effect study was carried out afterward on HL60 cells. Cellular DNA 
extracted from HL60 cells treated with different dosage of F-ara-AMP was analyzed, and 
a semi-quantitative dose-effect profile was established with the unvalidated method.  
 
4.2. Material and methods 
 
4.2.1. Chemicals and solutions 
  
 Formic acid, acetonitrile, BisTris, deoxyribonuclease I from bovine pancreas, 
nuclease P1from Penicillium citrinum, bovine alkaline phosphatase, and Tris EDTA 
buffer were obtained from Sigma-Aldrich (St. Louis, MO). NaCl, ZnCl2, PBS, water 
saturated phenol, and chloroform were purchased from Fisher Scientific (Fair Lawn, NJ). 
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The 10% SDS were from Bio-Rad Laboratories (Hercules, CA). RPMI 1640 medium and 
L-glutamine were from Mediatech (Manassas, VA). RNase and protease K were from 
Invitrogen (Carlsbad, CA). Methanol was purchased from Pharmco-AAPER (Brookfield, 
CT). Snake venom Phosphodiesterase I was obtained from Worthington Biochemical 
Corporation (Lakewood, NJ). Fetal bovine serum was purchased from Hyclone 
Laboratories (Logan, UT). Fludarabine 5’-monophosphate (F-ara-AMP) was from 
Ochem (Des Plaines, IL). Deionized water was prepared by the Barnstead NANOpure® 
water purification system (Thermo Scientific, Waltham, MA, USA). 
 
4.2.2. Preparation of F-ara-A 
 
 F-ara-AMP stock solution (25 mg/mL in 1×PBS) was diluted with 5 mM BisTris 
(pH 7.0) to 3.2 mM. 1 mL of this diluted solution was mixed with 0.5 µL of ALP (12.5 
units) at 37 Ԩ  for 6 h. The reaction was stopped by addition of equal volume of 
acetonitrile. The reaction product was kept at 4 Ԩ till use. 
 
4.2.3. LC-MS/MS instrumentation 
 
 The instrument system included a Shimadzu HPLC system (Kyoto, Japan) 
composed of a solvent reservoir, a degasser (DGU-20A3), a binary pump (LC-20AD), a 
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flow controller (CBM-20A), and an autosampler (SIL-20ACHT), together with an AB 
SCIEX 5500 QTRAP® 5500 mass spectrometer (Foster City, CA) controlled by Analyst 
software (version 1.5.1). 
 For the LC-MS/MS of F-ara-A, a Waters (Milford, MA) YMC-AQ® column 
(2.0mm×50mm, 5 µm) was utilized. An isocratic elution with a mobile phase containing 
0.1% formic acid, 14.5% methanol, and 85.4% water (v/v/v) was utilized at ambient 
temperature (23 Ԩ ) at 0.2 m/min. The column eluent was diverted to the mass 
spectrometer after 2.5 min. The ESI-MS was operated under positive-electrospray-
ionization (ESI+) mode. The source-dependent parameters were as follows: CUR, 40; IS, 
5000; TEM, 300; G1, 40; G2, 40. The compound-dependent parameters were as follows: 
DP, 50; EP, 5. Detection of the F-ara-A was achieved on MRM with the mass transition 
of 286 > 154 m/z. The related MRM conditions were set as follows: CAD, medium; CE, 
30.0; CXP, 13.0; Dewell Time, 100 ms. 
 
4.2.4. Cell culture and treatment 
 
 HL60 (a human AML cell line) cells obtained from ATCC (Rockville, MD, USA) 
were cultured in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum 
and 2 mM of L-glutamine at 37 Ԩ in a humidified 5% CO2 incubator. 
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 For each 5 × 106 cells, the dosages of F-ara-AMP added into the culture media 
were 0.0, 5.0, 10, 20, or 40 µM. Cells were treated for 24 h at 37 Ԩ in a humidified 5% 
CO2 incubator. The treatment was stopped by removal of culture media through 
centrifugation at 350 × g at 4 Ԩ for 10 min, and the cells were washed three times with 5 
mL PBS (1×, pH 7.4). For each wash step, the cells were resuspended in PBS, and then 
centrifuged down at 350 × g at 4 Ԩ for 10 min. After centrifugation, the cell pellets 
collected were stored in -20 Ԩ till DNA extraction. 
 
4.2.5. Cellular DNA extraction 
 
 For each 15 mL centrifuge tube containing the HL60 cell pellet, 2 mL of TE 
buffer (containing 10 mM Tris and 1 mM EDTA, pH 8.0) was added. A short vortex was 
performed to ensure homogenous suspension. Next, 0.24 mL of 10% SDS solution was 
added and mixed with the cell suspension gently by inverting the centrifuge tubes slowly 
for several times. After complete mixing, 20 µL of RNase (20 mg/mL dissolved in 
deionized water) was added and was incubated with the sample at 37 Ԩ for 1 h. Then, 25 
µL of protease K (20 mg/mL dissolved in deionized water) was added and was incubated 
with the sample at 37 Ԩ for another 1 h. Then, the samples were extracted twice with 
phenol followed by two times extraction with chloroform. For the extraction with phenol, 
2 mL of water saturated phenol was added into each tube and vortexed with the sample 
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for 1 min. The samples were then centrifuged at 1500 × g and 4 Ԩ for 30 min. Then the 
aqueous (upper) layer was carefully transferred to a clean 15 mL centrifuge tube. For the 
extraction with chloroform, the aqueous phase of each sample was transferred to a Phase 
Lock Gel tube (5 Prime, Gaithersburg, MD), and 2 mL of chloroform was added into the 
tube. Again, the samples were vortexed for 1 min, and centrifuged at 1500 × g and 4 Ԩ 
for 15 min. After extraction with phenol and chloroform, the aqueous phase (ca. 2 mL) 
was transferred to a clean 15 mL centrifuge tube and mixed with 10 mL pre-chilled 
ethanol (-20 Ԩ). DNA was precipitated at -20 Ԩ for overnight, and then recovered by 
centrifugation (1500 × g at 4 Ԩ for 15 min). Next, the DNA pellet in each tube was 
dissolved in 200 µL deionized water and transferred to a 1.5 mL centrifuge tube. In each 
tube, 1 mL of pre-chilled ethanol (-20 Ԩ) was added. By inverting the tube for several 
times, the DNA solution was mixed with ethanol completely. Then, DNA was 
precipitated at -20 Ԩ for 1 h. After recovered the DNA pellet through centrifugation 
(10000 × g at 4 Ԩ for 15 min), the sample in each tube was washed with 1 mL pre-cooled 
70% ethanol (4 Ԩ) for once, and centrifuged at 10000 × g and 4 Ԩ for 5 min. The 1.5 mL 
centrifuge tubes containing DNA were left uncapped in a fume hood for 1 h. After drying, 
the DNA pellets were reconstituted with 5 mM BisTris buffer (pH 7.0) to a concentration 
of 0.5 mg/mL (based on UV absorption at 260 nm). Finally, all samples were incubated 
in a boiling water bath for 15 min to remove the remaining protease K activity. The DNA 
samples were stored at 4 Ԩ before analysis. 
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4.2.6. Enzymatic hydrolysis of DNA 
 
 The enzyme working solutions were prepared as those described in section 2.2.3. 
An enzyme cocktail was prepared by mixing 10 µL DNase I, 15 µL NP1, 40 µL PDE I, 
and 0.5 µL of ALP together. For each 40 µL of DNA sample, 2.6 µL of the enzyme 
cocktail was added and mixed well with the DNA sample. The incubation was then kept 
at 37 Ԩ for 17 h. 
 
4.3. Results 
 
4.3.1. MS characterization of F-ara-A 
 
 The F-ara-A obtained from ALP digested F-ara-AMP (section 4.2.2) was diluted 
with the mobile phase containing 0.1% formic acid, 14.5% methanol, and 85.4% water 
(v/v/v), and then infused into the mass spectrometer by a syringe pump at a flow rate of 5 
µL/min. As F-ara-A tends to be protonized under the pH of the mobile phase, ESI+ mode 
was utilized. As shown in figure 4.1, F-ara-A produced molecular ions at m/z 286 {[F-
ara-A+H]+}. To achieve higher specificity in the quantification, the molecular ions were 
further dissociated with CID. From the resulted fragmentation pattern, a predominant 
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fragment was observed at m/z 154. Thus the mass transition 286 > 154 has been utilized 
in the compound monitoring. 
 
4.3.2. LC method development 
 
 As it has occurred in the analysis of MX-dR, after enzyme digestion, large 
amount of dNs were released. Together with the interferences caused by the buffer salts 
existing in the digestion system, it is necessary to develop a method, so that the analyte, 
F-ara-A, can be separated from the matrix interferences. With the method we developed, 
we were able to retain F-ara-A on the column for 2.9 min (figure 4.2 B). All the buffer 
salts were not retained to the column under the LC conditions we developed, and were 
eluted out before 1.0 min. With the same condition, BisTris, dC, dA, dG, and dT were 
eluted out before 2.5 min (figure 4.2 A). 
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Figure 4.1, Mass spectra of F-ara-A. (A) Full scan spectrum; (B) fragmentation spectrum 
of F-ara-A after CID.  
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Figure 4.2, Representative MRM chromatograms of F-ara-A (B) and other matrix 
interferences (A). 
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4.3.3. Drug effect analysis of F-ara-A on HL60 cells 
 
 In the HL60 cellular DNA analysis, the peak area of every sample was normalized 
with equation 4.1. Here the dN% of the sample with the highest peak areas for the dNs 
was assigned as 100%. The dN% of the other samples were then determined with the 
method described in section 2.3.4.  
ܣ௡௢௥௠. ൌ ܣ௠௘௔௦./ሾሺ݀ܣ%൅ ݀ܥ%൅ ݀ܩ%൅ ݀ܶ%ሻ/4ሿ 
  (4.1) 
In this equation, Anorm. indicates the normalized peak area of F-ara-A; while Ameas. 
indicates the actual peak area obtained from experiments. 
 After data analysis, a dose-effect profile of F-ara-AMP has been illustrated in 
figure 4.3. From the profile, a clear relationship between the dosage of F-ara-AMP and 
the incorporated drug can be observed. The drug incorporation first increase with the 
treatment dosage, and then reached to a relatively stable level after the dosage of the drug 
exceeds 10 µM. 
 
  
120 
 
 
 
 
 
 
 
Figure 4.3, A dose-effect profile of F-ara-AMP on HL60 cells. The Y axis represents the 
peak area of F-ara-A released from the cellular DNA (normalized according to the 
amounts of dNs released from the samples). 
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4.4. Conclusion 
 
 A tetra-enzyme cocktail containing DNase I, NP1, PDE I and ALP was utilized in 
the releasing of incorporated F-ara-A from the DNA backbone as free small molecules. A 
protein precipitation procedure was utilized in the sample preparation to remove protein 
interferences in the sample matrix. LC separation was realized on an YMC-AQ® column 
for further separation of F-ara-A from all the other interferences existing in the sample 
matrix. The method has been applied to an in vitro drug effect study involving analysis of 
F-ara-A incorporation after the HL60 cells were treated with F-ara-AMP. The developed 
method, although still a semi-quantitative one, has provided direct information on the 
drug effect evaluation. With further validation, the method can become a quantitative one, 
and assist in providing dosimetric guidance in clinical trials and practice. 
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CHAPTER V 
 
 
DETERMINATION OF 2-FLUOROADENINE REMOVED FROM 
FLUDARABINE (F-ARA-A) INCORPORATED IN DNA WITH LC-MS/MS 
 
 
5.1. Introduction 
 
 2-Fluoroadenine (F-Ade, figure 3-1A) has long been known as a toxic metabolite 
of fludarabine phosphate (9-β-D-arabino-furanosyl-2-fluoradenine monophosphate or F-
ara-A, figure 3-1B) [1], which is used as therapeutic agent for treatments of 
hematological malignancies such as CLL, AML, and non-Hodgkins lymphomas [2, 3]. 
Metabolic studies of F-ara-A in animals found that F-Ade was present in plasma, urine, 
and cerebrospinal fluid [4-6]. As F-Ade is a potent cytotoxic compound yet lacks of 
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therapeutic benefit [7], investigations of biological origin of F-Ade were attempted [8-10]. 
After failing to identify the enzyme responsible for generation of F-Ade in mammalian 
cells [8, 9], it was suggested that F-Ade might be released by bacterial purine nucleoside 
phosphorylase because the bacteria were systemically available by the enterohepatic 
circulation [10].  
 Our recent study reveals that uracil-DNA glycosylase (UDG) is most likely 
accountable for the releasing of F-Ade [11]. Since it has been well accepted that F-ara-A 
exerts its therapeutic effect through the incorporation of its triphosphorylated metabolite, 
F-ara-ATP, into elongating DNA strand [12], it is hypothesized that the F-Ade moiety of 
the F-ara-A incorporated DNA is recognized by UDG as an abnormal base, which 
triggers DNA base excision repair (BER) pathways [11, 13]. To prove this mechanism, a 
series of experiments were carried out [11], yet the most direct proof would be the 
detection of F-Ade from the UDG digested DNA samples where F-ara-A was 
incorporated by either chemical synthesis or dosing cells with F-ara-A. 
 There were two methods reported for analysis of metabolites of F-ara-A in 
biological matrices [14, 15]. In the method by Struck et al, 3H-labeled fludarabine 
monophosphate was used and the amount of F-Ade was measured by the radioactivity in 
the corresponding HPLC fraction [14]; whereas in the method by Kemena et al, F-Ade 
was first derivatized with chloroacetaldehyde to form a fluorescent product which was 
then detected by HPLC with fluorescent detection [15]. Both methods involved laborious 
sample preparations and neither had been validated for F-Ade quantification.  
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 In this paper, we report a simple LC-MS/MS method for the direct determination 
of F-Ade from F-ara-A incorporated DNA 40-mer and from cells treated with F-ara-A.  
In this method, 2-Chloroadenine (Cl-Ade) was chosen as the IS (figure 5.1 C). A solid 
phase extraction (SPE) protocol was adopted for sample preparation, and a reversed-
phase liquid chromatographic method with tandem mass spectrometric detection (LC-
MS/MS) was developed for quantitative determination of F-Ade.  The method was 
validated following the US FDA guidance for bioanalytical method [16]. The method has 
been used for determination of F-Ade in DNA samples from UDG digested synthetic 
DNA 40-mer with F-ara-A incorporated in  position 19 of the sense strand, and cell lysate 
of F-ara-A treated human promyelocytic leukemia cell line HL60, as well as cell lysates 
of F-ara-A treated lymphocytes of chronic lymphcytic leukemia patients and healthy 
donors. The data obtained not only confirm the feasibility of the analytical method, but 
also support the hypothesis of UDG-initiated base excision repair of F-ara-A incorporated 
DNA. This method is useful for quantifying F-Ade in cell lysate and for studying tumor 
resistance of fludarabine phosphate by BER pathways. 
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Figure 5.1, The chemical structures of 2-fluoroadenine (A), fludarabine phosphate (B), 
and the IS, 2-chloroadenine (C).      
  
A 
B 
Fludarabine phosphate (F-ara-AMP) 
MW = 365 
2-Chloroadenine (Cl-Ade, IS) 
MW = 169 
2-Floroadenine (F-Ade) 
MW = 153 
C 
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5.2. Material and methods 
 
5.2.1. Chemicals and solutions 
 
 Sterile lyophilized fludarabine phosphate (for intravenous use) was obtained from 
Berlex Laboratories (Richmond, CA, USA). F-Ade, dithiothreitol (DTT), bovine serum 
albumin, glycerol, formic acid, and HPLC-grade methanol were from Sigma-Aldrich (St. 
Louis, MO, USA). Cl-Ade was from Waterstone Technology (Carmel, IN, USA). EDTA 
disodium salt and tris (hydroxymethyl) aminomethane were from Bio-Rad (Hercules, CA, 
USA). Sodium chloride, potassium chloride, sodium phosphate (dibasic), and phosphate 
buffer saline (PBS, 1 ×, pH 7.4) were from Fisher Scientific (Fair Lawn, NJ, USA). 
Hydrochloric acid was from Pharmco (Brookfield, CT, USA). Sodium phosphate 
(monobasic) was from J.T. Baker Chemical (Phillipsburg, NJ, USA). 5’-hexachloro-
fluorescein phosphoramidite (HEX) labeled DNA 17-mer (i.e., 5’-[HEX] GTA AAA 
CGA CGG CCA GT-3’), DNA 21-mer (i.e., 5’-ATT CGA GCT CGG TAC CCG GGG-
3’), and DNA 40-mer (i.e., 5’-C CCC GGG TAC CGA GCT CGA ATT CAC TGG CCG 
TCG TTT TAC-3’) were from Operon Biotechnologies (Huntsville, AL, USA). 
Deoxyguanosine triphosphate (dGTP) was from Roche Applied Science (Indianapolis, IN, 
USA). F-ara-ATP was from Sierra Bioresearch (Tucson, AZ, USA). DNA polymerase 
was from Travigen (Gaithersburg, MD, USA). T4 DNA ligase was from Invitrogen 
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(Carlband, CA, USA). RPMI 1640 medium and fetal bovine serum were from HyClone 
(Logan, UT, USA). L-glutamine was from Cellgro (Manassas, VA, USA). Uracil-DNA 
glycosylase (UDG, 5 U/µL) in a buffer containing 10 mM Tris-HCl, 50 mM KCl, 1 mM 
DTT, 0.1 mM EDTA, and 50% glycerol at pH 7.0, and 10 × UDG buffer (200 mM Tris-
HCl, 10 mM EDTA, 10 mM DTT, pH 8.0) were from New England BioLabs (Ipswich, 
MA, USA). Fludarabine phosphate stock solution was prepared by dissolving the 
lyophilized solid cake in RPMI 1640 medium to a concentration of 25 mM. Working 
solutions of fludarabine phosphate (10.0, 40.0 and 50.0 μM) were prepared freshly by 
serial dilution of the stock solution with RPMI 1640 medium. Deionized water was 
prepared by the Barnstead NANOpure® water purification system (Thermo Scientific, 
Waltham, MA, USA). 
 
5.2.2. LC-MS/MS instrumentation 
 
 The LC-MS/MS system included an Agilent 1100 HPLC system (Agilent, Santa 
Clara, CA, USA) and a Micromass Quattro II triple quadrupole tandem mass 
spectrometer (Micromass, Wythenshawe, Manchester, UK), which was controlled by 
Micromass MassLynx software (version 3.3). The system consisted of a solvent reservoir, 
a degasser, a binary pump, an autosampler, an inert in-line filter (0.5 µm pore) (Upchurch 
Scientific, Oak Harbor, WA, USA), a Waters YMC-ODS AQ® column (2.0×50 mm, 5 
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µm particle size with 120 Ǻ pore size), a two-position 6-port switching valve (Alltech, 
Deerfield, IL, USA), and an electrospray ionization tandem mass spectrometer (ESI-
MS/MS).  
 The LC separation was carried out by isocratic elution with a mobile phase 
containing 20% methanol, 0.1% formic acid and 79.9% deionized water (v/v/v) at a flow 
rate of 0.15 mL/min and a room temperature of 23 Ԩ. For each analysis, 20-µL sample 
was injected to the system. By controlling the switching valve, eluate within the time 
window of 2.5-5 min was diverted to the ESI-MS/MS detector. 
 The ESI-MS/MS was operated under positive-electrospray-ionization (ESI+) 
mode. The ionization conditions were tuned by infusion of a mixture of F-Ade (10.0 
µg/mL) and IS (10.0 µg/mL) in the mobile phase at a flow rate of 3 µL/min with a 
syringe pump (Harvard Apparatus, South Natick, MA, USA). The optimized conditions 
were as follows: drying gas, 300 L/h; nebulizer gas, 15 L/h; capillary voltage, 3.5 kV; 
HV lens, 0.5 kV; cone voltage, 35 V; skimmer voltage, 1.5 V; RF lens, 0.2 V; ion source 
temperature, 90 Ԩ; ion energy, -0.2 V.  Analyte quantification was carried out by the 
multiple-reaction-monitoring (MRM) mode with mass transitions of m/z 154 > 134 for F-
Ade and m/z 170 > 134 for the IS. The optimized parameters of MRM were as follows: 
argon collision gas, 2.0-2.5 µbar; collision energy, 18 eV for F-Ade and 23 eV for the IS; 
dwell time, 0.4 sec; inter-scan delay, 0.05 sec; low- and high-mass resolution, 15 for both 
quadrupoles 1 and 3; and multiplier voltage, 650 V. 
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5.2.3. Synthesis of F-ara-A incorporated DNA 40-mer 
 
 DNA 40-mer with an F-ara-A incorporated at position 19 of the sense strand was 
synthesized using the procedure described by Yang et al. [17] with modifications as 
follows: (a) three single-stranded DNA oligomers {i.e., 5’-[HEX] GTA AAA CGA CGG 
CCA GT-3’ (17-mer), 5’-ATT CGA GCT CGG TAC CCG GGG-3’ (21-mer), and 5’-C 
CCC GGG TAC CGA GCT CGA ATT CAC TGG CCG TCG TTT TAC-3’ (40-mer)} at 
100 pmol each annealed together in a 100-µL buffer solution (containing 10 mM Tris-
HCl, 50 mM KCl, and 1 mm EDTA; pH 7.6) at 95 Ԩ for 5 min, followed by a cooling 
down period at room temperature for 1 h. This annealing step produced a double-stranded 
DNA oligomer with fluorescent labels on both ends, and a gap of two nucleotides at the 
18th and the 19th positions on the sense strand 5’-[HEX] GTA AAA CGA CGG CCA 
GT_ _AT TCG AGC TCG GTA CCC GGG G-3’ which complemented the anti-sense 
strand 3’-CAT TTT GCT GCC GGT CAC TTA AGC TCG AGC CAT GGG CCC C-5’; 
(b) 20 µL of the resulted DNA oligomer was incubated at 37 Ԩ for 1 hr with 2.5 nmol 
dGTP (500 µM, 5 µL), 2.5 nmol of F-ara-ATP (500 µM, 5 µL), 10 U of DNA 
polymerase 5 U/µL, 2 µL), 5 µL of 10 × polymerization buffer (containing 0.500 M Tris-
Cl at pH 8.8, 0.100 M MgCl2, 1.00 M KCl, 10.0 mM DTT, and 10.0% glycerol), and 13 
µL of water.  This reaction step extended the sense strand of the 17-mer with dGMP on 
the 18th position and F-ara-A on the 19th position; (c) the extended oligomer was then 
precipitated from the reaction buffer using ice-cold solution containing 25 µL of 7.5 M 
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ammonium acetate and 250 µL of ethanol and kept at -80 Ԩ for 1 h, then, recovered by 
centrifugation at 16100 × g and 4 Ԩ for 10 minutes.  The resulted pellet was washed with 
100 µL of 70% ice-cold ethanol twice, and dried at room temperature for 20 min; (d) the 
recovered extended oligomer was further incubated with 25 U of T4 DNA ligase in a 50 
µL reaction buffer consisting 50 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 1 mM ATP, 1 
mM DTT at 14 Ԩ for 18 h.  This ligation step resulted in an intact double-stranded DNA 
40-mer with an F-ara-A incorporated at the 19th position of the sense strand (i.e., sense 
strand 5’- [HEX] GTA AAA CGA CGG CCA GTG FAT TCG AGC TCG GTA CCC 
GGG G-3’, and anti-sense strand 3’-CAT TTT GCT GCC GGT CAC TTA AGC TCG 
AGC CAT GGG CCC C-5’); (e) the synthesized DNA 40-mer was electrophoresed 
through a polyacrylamide (19%)-urea (7 M) gels and visualized by using a Typhoon 9200 
fluorescent Imager (Amersham BioScience, Piscarawat, NJ, USA).  After electrophoresis, 
the band of the 40-mer was cut out and purified with Qiaex II Gel Extraction Kit (Qiagen, 
Valencia, CA, USA) following the instruction provided by the manufacturer; (f) the 
purified DNA 40-mer was suspended in 20 µL buffer containing 10 mM Tris-HCl, 50 
mM NaCl, and 1 mM EDTA at pH 8.0 to give an approximate concentration of 1 µM; (g) 
repeated (a) to (f) to give 500 µL of F-ara-A incorporated DNA 40-mer solution. 
 
5.2.4. Removal of F-Ade from F-ara-A incorporated DNA 40-mer by UDG 
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 In this part of the experiment, 500 µL of F-ara-A incorporated DNA 40-mer 
solution (ca. 1 µM) was mixed with 60 µL of 10 × UDG buffer and 40 µL (or 200 U) of 
UDG. The excision of F-Ade from the DNA 40-mer by UDG took place at 37 Ԩ 
overnight (12 h). After reaction the reaction mixture was heated at 95 Ԩ for 5 min to 
deactivate UDG; then, centrifuged at 16100 × g for 5 min. The supernate was stored at -
20 Ԩ before the LC-MS/MS analysis. 
 
5.2.5. Cell isolation and culture 
 
 Peripheral blood samples were collected into heparinized Vacutainer® tubes from 
CLL patients and healthy donors who had signed written informed consent at the 
University Hospital Case Medical Center (Cleveland, OH, USA). The CLL patients were 
mixed-sex with median age of fifty-eight, and had absolute lymphocytes counts of typical 
CLL patients (11-365 × 103 counts/mL). At the time of blood drawing, they were not on 
therapy. In this work, heparinized blood was fractioned by Ficoll-Paque method [18]. 
Briefly, 10-mL heparinized blood was layered on the top of 12-mL Ficoll-Paque Plus 
reagent (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) in a 50-mL sterile 
polypropylene centrifuge tube (RNase/DNase free); then the tube was centrifuged at 
room temperature and 300 × g for 30 min. Cells at the interface were collected, washed 
twice with PBS  (1×, pH 7.4) solution, and resuspended at a density of 1 × 106 cell 
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counts/mL in a pre-warmed culture medium [i.e., RPMI 1640 medium supplemented with 
10 % (v/v) fetal bovine serum and 2 mM L-glutamine].   
 The isolated lymphocytes from CLL patients, and human promyelocytic leukemia 
HL60 cells obtained from American Type Culture Collection (Rockville, MD, USA) 
were cultured in the culture medium at 37 Ԩ in a humidified 5% CO2 incubator. 
 
5.2.6. Cell treatment 
 
 The human promyelocytic leukemia HL60 cells (5 × 106 each) were treated with 
40 µM of fludarabine phosphate for 0 (pre-dosing), 3, 6, and 24 hrs. The lymphocytic 
cells (5 × 106 each) collected from CLL patients were treated with 10 and 50 µM of 
fludarabine phosphate for 0 (pre-dosing), 6 and 24 hrs. At the indicated time points, cells 
were harvested by centrifugation at 4 Ԩ and 300 × g for 10 min. Cell pellets were washed 
twice with 1 mL each of PBS (1×, pH 7.4). The cell pellets collected were resuspended in 
deionized water in a concentration of 107 cells/mL and lysated by a Branson Sonifier 450 
(VWR Scientific, Batavia, IL, USA) with 2 sonication cycles at 15 impulses per cycle. 
The duty cycle of the sonicator was set at 30 and output control was set at 3. After 
sonication, the cell lysate was immersed in boiling water bath for 5 min; then, centrifuged 
at 16100 × g for 5 min.  The supernate was stored at -20 Ԩ before the LC-MS/MS 
analysis. 
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5.2.7. Preparation of F-Ade calibrators and QCs 
 
 F-Ade stock solution (1.00 mg/mL) and Cl-Ade (IS) stock solution (1.00 mg/mL) 
were prepared individually by dissolving proper amount of solid compound in known 
volume of 1.0 M and 10 M HCl, respectively. F-Ade standard solutions (10.0, 16.5, 20.0, 
40.0, 44.4, 49.4, 80.0, 148, 160, 320, 400, 444, 640, 1.28 × 103, 1.33 × 103, 3.60 × 103, 
and 4.00 × 103 ng/mL) and the IS solution (100 and 200 ng/mL) were prepared by serial 
dilution of their corresponding stock solutions with 0.1 M phosphate buffer at pH 8.0. 
 F-Ade calibrators (1.67, 3.33, 6.67, 13.3, 26.7, 53.3, 107, and 213 ng/mL) in UDG 
digestion matrix for the measurement of F-Ade from the F-ara-A incorporated DNA 40-
mer were prepared individually by mixing 50-µL buffer containing 100 mM Tris-HCl, 
500 mM NaCl, and 10 mM EDTA at pH 8.0; 60 µL of 10× UDG buffer; 40 µL of UDG 
mimic solution containing 10 mM Tris-HCl, 50 mM KCl, 1 mM DTT, 0.1 mM EDTA, 
0.2 mg/mL BSA, and 50% glycerol at pH 7.0; 100 µL of F-Ade standard solution (at 6× 
of the corresponding calibrator concentration) and 350 µL of deionized water.    
 F-Ade calibrators (0.825, 2.47, 7.40, 22.2, 66.5, and 200 ng/106 cells) and F-Ade 
QCs (2.22, 20.0, and 180 ng/106 cells) in cell lysate for the measurements of F-Ade from 
cells after F-ara-A treatment were prepared individually by mixing 100-µL HL60 cell 
lysate of the untreated cell control (107 cells/mL), and 50-µL F-Ade standard solution 
(for calibrators at 16.5, 49.4, 148, 444, 1.33 × 103, and 4.00 × 103 ng/mL, respectively; 
for QCs at 44.4, 400, and 3.60 × 103 ng/mL, respectively). 
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5.2.8. SPE of cell lysates and UDG-digested DNA 
 
 Oasis® HLB cartridges (3 cc, 60 mg, Waters, Milford, MA, USA) were used for 
analyte extraction. Prior to sample extraction, the cartridges were equilibrated with 3.0 
mL of methanol and 3.0 mL of 10 mM phosphate buffer (pH 8.0), sequentially. For the F-
Ade calibrators in UDG reaction buffer and the supernate of UDG digested F-ara-A 
incorporated DNA 40-mer, 600 µL of each calibrator or supernate sample was mixed 
with 100 µL of IS solution (100 ng/mL) and 700 µL of 10 mM phosphate buffer (pH 8.0) 
before loading to the cartridge. For the F-Ade calibrators in cell lysate and cell samples 
after F-ara-A treatment, 150 µL of each calibrator or cell sample was mixed with 50 µL 
of IS solution (200 ng/mL) and 1000 µL of 10 mM phosphate buffer (pH 8.0) before 
loading to the cartridge. After loading samples, the cartridges were washed with 4.0 mL 
of deionized water; then, the analytes were eluted with 2.0 mL of 10% formic acid in 
methanol (v/v). The eluates were then evaporated to dryness at 60 Ԩ for 60 min in a 
TurboVap® LV Evaporator (Zymark, Hopkinton, MA, USA) under a pressurized stream 
of nitrogen gas (25 psi). Each residual was reconstituted in 100 µL of deionized water 
before the LC-MS/MS analyses. 
 
5.2.9. Construction of calibration curves 
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 The calibration curve of F-Ade in UDG digestion matrix was established using a 
blank (i.e., matrix without F-Ade and IS), a zero (i.e., matrix with IS at 16.7 ng/mL) and 
eight non-zero calibrators (F-Ade at1.67, 3.33, 6.67, 13.3, 26.7, 53.3, 107 and 213 ng/mL; 
IS at 16.7 ng/mL). The calibration curve of F-Ade in cell lysate was established using a 
blank, one zero and six non-zero calibrators (F-Ade at 0.825, 2.47, 7.40, 22.2, 66.5 and 
200 ng/106 cells; IS at 10.0 ng/106 cells). Peak-area ratios of F-Ade (m/z 154 > 134) to 
the IS (m/z 170 > 134) were plotted against F-Ade concentrations for linear regression 
equations with weighting factor of 1/x and passing zero. 
 
5.2.10. Matrix effect and recovery 
 
 For the matrix effect study, aliquots of 500 µL UDG digestion matrix or 100 µL 
HL60 cell lysate were first extracted with the established SPE protocol; then, F-Ade and 
IS standard solutions were spiked in the extracted matrix to make standard solutions 
containing F-Ade at 1.67, 16.7, 167 ng/mL and IS at 16.7 ng/mL in the extracted UDG 
digestion matrix; and F-Ade at 2.22, 20.0 and 180 ng/106 cells and IS at 10.0 ng/106 cells 
in the extracted HL60 cell lysate. The peak area ratios of F-Ade to IS in these spike-after-
extraction (SAE) standards (A/A’)matrix were compared with those of the corresponding 
standard solutions in 0.1 M phosphate buffer at pH 8.0 (A/A’)buffer. The matrix effect 
137 
 
(either suppression or enhancement) on analytical signal of F-Ade was calculated by the 
IS normalized matrix factor (MFIS) (equation 5.1): 
ܯܨூௌ ൌ ሺܣ/ܣ′ሻ௠௔௧௥௜௫ሺܣ/ܣ′ሻ௦௢௟௩௘௡௧ 
     (5.1) 
Here, unless otherwise specified, A represents the peak area of the analyte; while A’ 
indicates the peak area of the IS. (A/A’) indicates the peak area ratio of the analyte over 
the IS. Thus, (A/A’)matrix indicates the peak area ratio in the post-extraction matrix; while 
(A/A’)solvent indicates that in the pure solvent [19]. 
 For the recovery study, standard solutions containing F-Ade at 1.67, 16.7 and 167 
ng/mL and IS at 16.7 ng/mL in the UDG digestion matrix; F-Ade at 2.22, 20.0 and 180 
ng/106 cells and IS at 10.0 ng//106 cells in HL60 cell lysate were prepared, and analyzed. 
The peak area ratios of F-Ade to IS in sample matrix (A/A’)extraction were compared with 
those of the corresponding SAE standards (A/A’)matrix  for the calculation of IS 
normalized recovery RCIS (equation 5.2). 
ܴܥூௌ ൌ ሺܣ ܣ′⁄ ሻ௘௫௧௥௔௖௧௜௢௡ሺܣ/ܣ′ሻ௠௔௧௥௜௫ ൈ 100% 
   (5.2) 
Here (A/A’)extraction represent the peak area ratio in extracted plasma samples. 
 
5.2.11. Stability 
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 The stability of F-Ade in HL60 cell lysate was evaluated at two different 
concentrations (2.22 and 180 ng/106 cells). These stability controls were prepared in the 
similar way of the QCs except the IS was added right before the solid phase extraction. 
All experiments were run in triplicate and the results were compared with freshly 
prepared stability controls. 
 In the short-term stability study, the stability controls were kept at the room 
temperature (23 Ԩ) for 4 h prior to analysis. For the freeze and thaw stability study, the 
stability controls were undergone 3 freeze-and-thaw cycles; and in each cycle, the 
stability controls were frozen at −20 Ԩ for at least 24 h and thawed at room temperature 
unassisted. For the long-term stability study, the stability controls were stored at -20 Ԩ 
for 30 days prior to analysis. 
 
5.3. Results 
 
5.3.1. Synthesis of F-ara-A incorporated DNA 40-mer 
 
 Use the anti-sense strand 3’-CAT TTT GCT GCC GGT CAC TTA AGC TCG 
AGC CAT GGG CCC C-5’ as template, the extension of the green fluorescent labeled 
17-mer oligonucleotide, 5’-[HEX] GTA AAA CGA CGG CCA GT-3’ to the 19-mer 
oligonucleotide with F-ara-A at position 19 of the sense strand 5’-[HEX] GTA AAA 
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CGA CGG CCA GTG F-3’, and the ligation of the 19-mer with the 21-mer 5’-ATT CGA 
GCT CGG TAC CCG GGG-3’ to produce the sense strand of 40-mer 5’-[HEX] GTA 
AAA CGA CGG CCA GTG FAT TCG AGC TCG GTA CCC GGG G-3’ can be 
illustrated by figure 5.2 A, and visualized in figure 5.2 B and C. The F-ara-A 
incorporated double-stranded DNA 40-mer has a mismatch base pair (F-ara-A:T) at 
position 19, which can be repaired by UDG enzyme to give off F-Ade as a free base and 
a double-stranded oligonucleotide 40-mer containing an arabinose abasic site (ara-AP) at 
its 19th position. 
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A 
  
B             C 
Figure 5.2, Synthesis of F-ara-A incorporated DNA 40-mer. Schematic illustration of 
incorporation of F-ara-A in DNA oligomers (A); confirmation of F-ara-A incorporated 
DNA 19-mer (Lane 7) (B) and DNA 40-mer (Lane 7) (C).  
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5.3.2. LC-MS/MS method for the measurement of F-Ade 
 
 F-Ade and Cl-Ade (IS) are basic compounds which can be protonated in acidic 
solution and detected by positive electrospray ionization tandem mass spectrometer.  As 
shown in figure 5.3 A and C, F-Ade and the IS produced molecular ions [F-Ade + H]+ at 
m/z 154 and [IS+H]+ at m/z 170, respectively. These molecular ions could further 
undergo collision induced dissociation (CID) by argon gas and produce product ion 
spectra (figures 5.3 B and D). The predominant product ions of F-Ade and IS are both at 
m/z 134 which may due to the loss of HF from F-Ade and HCl from Cl-Ade. Therefore, 
mass transition pairs of m/z 154 > 134 for F-Ade and m/z 170 > 134 for IS were chosen 
for quantification by multiple-reaction-monitoring (MRM) mode.  
 The representative chromatograms for separation of F-Ade and IS in UDG 
digestion matrix and HL-60 cell lysate were shown in figure 5.4. Baseline resolution of 
F-Ade and IS were achieved using Waters YMC-ODS AQ® column (2.0 × 50 mm, 5 µm) 
with a mobile phase containing 20% methanol, 0.1% formic acid and 79.9% deionized 
water (v/v/v) at a flow rate of 0.15 mL/min. The retention times of F-Ade and the IS were 
3.0 an 4.0 min, respectively. 
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Figure 5.3, The mass spectra of F-Ade and Cl-Ade (IS). 
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Figure 5.4, Representative MRM chromatograms of F-Ade and IS.  Column I (in UDG 
digestion matrix): (A) Blank 1 (no F-Ade), (B) Blank 2 (no IS), (C) F-Ade at 1.67 ng/mL 
(LLOQ, S/N = 25.6), (D) F-Ade at 26.7 ng/mL, and (E) IS at 16.7 ng/mL; and Column II 
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(in HL60 cell lysate): (F) Blank 1 (no F-Ade), (G) Blank 2 (no IS), (H) IS at 0.825 ng/106 
cells (LLOQ, S/N = 14.7), (I) F-Ade at 22.2 ng/106 cells, and (J) IS at 10.0 ng/106 cells.
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5.3.3. Analytical method validation 
 
 Matrix effect and recovery  
 Table 5.1 summarized the data from the matrix effect and recovery studies. As 
shown in the table, over the concentration range studies, the IS normalized matrix factors 
(MFIS) were 0.977-1.00 in the UDG digestion matrix and 0.878-0.921 in the HL60 cell 
lysate, whereas the IS normalized recovery (RIS) were 90-101% in the UDG digestion 
matrix, and 84-104% in the HL60 cell lysate. 
 
 Calibration equations and lower limit of quantification (LLOQ) 
 The internal calibration curves of F-Ade were established in both UDG digestion 
matrix (1.67-213 ng/mL) and HL60 cell lysate (0.823-200 ng/106 cells) and the data were 
summarized in table 5.2. With the weighing factor of 1/X, the linear calibration equations 
were derived as Y1 = 0.075 ( ± 0.002) X1, R12 = 0.999 ( ± 0.001) in the UDG digestion 
matrix, and Y2 = 0.079 ( ± 0.001) X2, R22 = 0.999 ( ± 0.000) in the HL60 cell lysate. The 
LLOQs of the calibration curves defined by the lowest F-Ade calibrators were 1.67 
ng/mL in UDG digestion matrix and 0.823 ng/106 cells in HL60 cell lysate. 
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Table 5.1, Recovery and matrix effect data. 
Matrix Concentration level (ng/mL) 
Recovery ± S.D. 
(%) MFI.S. ± S.D. 
Enzyme Digestion 
Matrix 
1.67 89.5 ± 2.6 1.00 ± 0.05 
16.7 95.3 ± 2.1 0.989 ± 0.041 
167 101 ± 0 0.977 ± 0.028 
Matrix Concentration level (ng/106 cells) 
Recovery ± S.D. 
(%) MFI.S. ± S.D. 
HL60 Cell Lysate 
2.22 84.3 ± 6.8 0.912 ± 0.026 
20.0 101 ± 3 0.878 ± 0.033 
180 104 ± 3 0.921 ± 0.006 
Three measurements were performed for each datum point. S.D. here and in table 
2 and 4 represents standard deviation. 
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Table 5.2, Calibration equations of F-Ade in enzyme digestion matrix and HL60 cell 
lysate. 
Biological 
matrices 
[F-Ade]actual 
ng/mL 
[F-Ade]measured 
ng/mL S.D. 
Accuracy 
(%) 
Precision 
(%) 
Enzyme 
digestion 
matrix 
1.67 1.76 0.08 5.39 4.55 
3.33 3.38 0.07 1.40 1.97 
6.67 7.2 0.1 7.45 1.62 
13.3 14.3 0.4 7.63 2.71 
26.7 28 2 3.37 7.03 
53.3 54 2 1.79 4.14 
107 108 3 0.984 2.57 
213 209 2 -2.14 0.857 
Biological 
matrices 
[F-Ade]actual 
ng/106 cells 
[F-Ade]measured 
ng/106 cells S.D. 
Accuracy 
(%) 
Precision 
(%) 
HL60 cell 
lysate 
0.823 0.84 0.09 1.82 10.6 
2.47 2.47 0.07 -0.202 2.74 
7.41 7.7 0.1 4.04 1.58 
22.2 23.7 0.5 6.97 2.27 
66.7 69.9 0.8 4.73 1.12 
200 195 0 -2.50 0.140 
Calibration equations: Enzyme digestion matrix, Y = 0.075 ( ± 0.002) X, R2 = 
0.999 ( ± 0.001) 
HL60 cell lysate, Y = 0.079 ( ± 0.001) X, R2 = 0.999 ( ± 0.000) 
Each datum point was based on three separate measurements toward the same set 
of samples. 
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 Accuracy and precision 
 The accuracy and precision for the quantification of F-Ade in HL60 cell lysate 
were further evaluated with QC samples at three-concentration levels (2.22, 20.0, and 180 
ng/106 cells). At each concentration level, five replicates of QC samples were prepared 
and each was analyzed by triplicate measurements. The results are summarized in table 
5.3. The accuracy was determined by the percent deviation of the measured concentration 
from the nominal concentration, which was ≤  ±14%. The intra- and inter-assay 
precisions determined as by the percent peak area ratios of F-Ade to the IS were ≤ ±9% 
and ±7%, respectively. 
 
 Stability 
 The stabilities of F-Ade in HL60 cell lysate were tested at two concentration 
levels (2.22 and 180 ng/106 cells) with triplicate measurements, and the results expressed 
as recovery were summarized in table 5.4. As seen in the table, there was no significant 
loss of F-Ade observed under the tested conditions with recovery ranged from 86% to 
104%. Therefore, F-Ade stock solutions and cell lysate samples were kept at −20 Ԩ for 
this work, and the analyses of F-Ade samples were done within a 4 h timeframe. 
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Table 5.3, Accuracy, intra- and inter-assay precision of F-Ade in HL60 cell lysate. 
 LQC MQC HQC 
Accuracy (%) n=5 -14.3 -1.47 2.45 
Intra-assay Precision (%) n=5 8.58 1.89 0.97 
Inter-assay Precision (%) n=3 7.12 2.88 2.64 
The concentrations of F-Ade in the LQC, MQC and HQC were 2.22, 20.0, 180 
ng/106 cells respectively in the HL60 cell lysate. The concentration of the I.S. was 
10.0 ng/106 cells. 
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Table 5.4, Stability of F-Ade in HL60 cell lysate under various test conditions. 
Storage Conditions [F-Ade] added ng/106 cells Recovery ± S.D. (%) 
Room Temperature, 4 hr 
2.22 99 ± 1 
180 99 ± 1 
Freeze-thaw, 3 cycles, -20 Ԩ 
2.22 104 ± 7 
180 102 ± 6 
Long-term, 30 days, -20 Ԩ 
2.22 91 ± 1 
180 86 ± 1 
Each datum point was based on triplicate measurements. 
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5.3.4. Determination of F-Ade in F-ara-A incorporated DNA 40-mer and cells treated 
with F-ara-A 
 
 The validated LC-MS/MS method was applied to the determination of F-Ade in 
UDG digested F-ara-A incorporated DNA 40-mer, or cells (i.e., human promyelocytic 
leukemia HL60, lymphocytes of CLL patients) treated with F-ara-A at various dosages 
and durations. As shown in table 5.5, UDG digested F-ara-A incorporated DNA 40-mer 
gave a concentration of F-Ade at 28.5 ng/mL; HL60 cells treated with 40 µM F-ara-A at 
3, 6 and 24 h gave concentrations of F-Ade at 0.363, 0.622, and 1.22 ng/106 cells; 
lymphocytic cells of CCL patients treated with 10 µM, or 50 µM F-ara-A at 6 and 24 h 
gave concentrations of F-Ade at 0.165 and 0.333 ng/106 cells, or 0.861 and 1.73 ng/106 
cells. Since the actual concentrations of F-Ade in several cell samples treated with F-ara-
A were below the LLOQ of the LC-MS/MS method, these samples were enriched 9 times 
together with the concentration QCs (0.247, 2.22, and 20.0 ng/106 cells) by solid phase 
extraction prior to their analyses by LC-MS/MS (table 5.5). 
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Table 5.5, F-Ade concentrations measured from QCs, UDG digested F-ara-A 
incorporated DNA 40-mer, HL60 cells, and lymphocytic cells of CLL patients. 
Samples 
[F-Ade]measured
ng/106 cells 
Concentration
Factor 
[F-Ade]actual 
ng/106 cells 
Accuracy 
(%) 
QC1 
(0.247 ng/106 cells, 
n = 5) 
2.21 9 0.246 99.6 
QC2 
(2.22 ng/106 cells, 
n = 5) 
21.5 9 2.39 108 
QC3 
(20.0 ng/106 cells, 
n = 5) 
154 9 17.1 85.4 
UDG digested 
F-ara-A incorporated 
DNA 40-mer 
28.5 
(ng/mL) 
1 28.5 
(ng/mL) 
N/A 
HL60 
untreated 
0.00 1 0.00 N/A 
HL60 
treated with F-ara-A 
(40 M, 3 h) 
3.27 9 0.363 N/A 
HL60 
treated with F-ara-A 
(40 M, 6 h) 
5.60 9 0.622 N/A 
HL60 
treated with F-ara-A 
(40 M, 24 h) 
1.22 1 1.22 N/A 
CLL lymphocytes 
untreated 
0.00 1 0.00 N/A 
CLL lymphocytes 
treated with F-ara-A 
(10 M, 6 h), n = 3 
1.49 9 0.165 N/A 
CLL lymphocytes 
treated with F-ara-A 
(10 M, 24 h), n = 3 
3.00 9 0.333 N/A 
CLL lymphocytes 
treated with F-ara-A 
(50 M, 6 h), n = 3 
0.861 1 0.861 N/A 
CLL lymphocytes 
treated with F-ara-A 
(50 M, 24 h), n = 3 
1.73 1 1.73 N/A 
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5.4. Discussion 
 
5.4.1. F-ara-A incorporated DNA is a target for BER pathways 
 
 F-ara-A is a chemotherapy agent that is widely used in the treatment of 
hematological malignancies. The primary action of F-ara-A is its incorporation into DNA 
during replication. The incorporated F-ara-A is a poor substrate for DNA replication 
enzymes (i.e., DNA polymerase alpha, ribonucleotide reductase and DNA primase), thus 
inhibiting further DNA synthesis [12, 20, 21]. F-ara-A produces higher response rates in 
CLL patients comparing to some alkylating agents (e.g., chlorambucil) alsong, and thus it 
is highly effective in CLL treatments [22]. However, the therapeutic effect of F-ara-A is 
often transient, and most patients experience relapse of the disease.  In our previous 
studies [11], we hypothesized that F-ara-A resistance by patients may due to the 
recognition of F-ara-A nucleotide by DNA glycosylases as abnormal nucleobase and 
trigger the DNA BER pathways. Co-administration of F-ara-A and methoxyamine (MX, 
an investigational chemotherapeutic agent that blocks BER through forming stable 
adducts with abasic sites generated during BER) enhanced the fludarabine induced 
apoptotic cell death in HL60 and Jurkat cells. In an in vivo study with nude mice carrying 
HL60 and U937 xenografts, co-administration of F-ara-A with MX also significantly 
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reduced the tumor sizes and resulted growth delay to the tumors comparing to the 
treatments with F-ara-A along [11]. 
 
5.4.2. UDG is a DNA glycosylase having activity on F-ara-A:T mismatches 
 
 In addition to its incorporation in DNA and the inhibition on DNA replication 
enzymes, fludarabine-induced inhibition of ribonucleotide reductase results in the 
depletion and imbalance of deoxynucleotide pools that are required for DNA repair and 
synthesis. This imbalance may subsequently favor the incorporation of F-ara-A itself, and 
other mismatched nucleotides such as uridine, into the newly synthesized DNA strand. 
These mismatched DNA base pairs would activate BER [11]. 
 Actually, another experiment involving UDG digestion to the F-ara-A 
incorporated DNA has already strongly supported our hypothesis with indirect evidence 
[11]. In this experiment, DNA 40-mer with F-ara-A incorporated at the 19th position was 
digested with UDG followed by apurinic/apyrimidinic endonuclease (APE). According to 
the basic mechanisms of BER, removal of F-Ade by UDG will generate an apurinic (AP) 
site on the DNA strand and this AP site can be recognized by APE. Then, the APE will 
cleave at the 5’ end of the AP site and introduce a strand break on the DNA strand [23]. 
Based on this mechanism, we should expect a DNA fragment with 18 bases after 
digesting the F-ara-A incorporated DNA 40-mer with UDG plus APE. In our experiments, 
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after electrophoresis on a denature gel, a single strand DNA 18-mer was observed from 
the digestion product and thus proved the actions of both enzymes. This result can well 
support our hypothesis, however, recovery of F-Ade from the UDG digested F-ara-A 
incorporated 40-mer DNA directly confirmed the releasing activity of UDG on the F-Ade. 
By quantifying the F-Ade moiety released by UDG, we are even able to analyze the 
repair speed and efficiency quantitatively.  
 As an effective therapeutic agent for hematological malignances, fludarabine and 
its metabolites are under intensive investigation. Our hypothesis of UDG-initiated BER 
of F-ara-A incorporated DNA, once fully proved, will not only illustrate a possible source 
of this toxic metabolite, but also discover a new drug resistance mechanism and thus 
provide a new target for drug effect enhancement. 
 
5.4.3. LC-MS/MS method provides unequivocal identification and quantification of F-
Ade 
 
 LC-MS/MS excels in F-Ade identification and quantification because of the direct 
and accurate results it is able to provide. As this technique identifies F-Ade by its 
molecular weight (through the m/z ratio) and structure (through the fragmentation 
pattern), the specificity of the detection is higher than most of the indirect identification 
methods. The validated method, on the other hand, enables the quantification to be more 
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reproducible, and thus allows the results from different experiments to be more 
comparable. 
 
5.4.4. F-Ade concentrations in cells treated with F-ara-A correlate with dose and time 
 
 When we applied our method to the analysis of HL60 cells treated with 
fludarabine for different time spans. From the data obtained we were able to see a clear 
relationship between treatment time and the concentration of F-Ade in the cell lysate: 
with the increase of the treatment time, the concentration of F-Ade also increased. 
Although this phenomenon is not adequate to prove that the releasing of F-Ade is caused 
by UDG, it at least provided a possible origin of F-Ade other than bacterial enzymes. As 
the cells were cultured in a sterilized environment, lysed immediately after harvest and 
stored on ice or dry ice before analysis, there is little chance for the samples to get 
contaminated by bacterial enzymes.   
 Moreover, in another set of experiments carried out by Bulgar et al. [11], a colon 
cancer cell line DLD1 with UDG+/+ and UDG-/- were treated with 10 or 50 µM of 
fludarabine for 24 h.  F-Ade concentrations in the treated cell samples were evaluated 
with the method described in this paper. Although without fully validating our method in 
DLD1 cell lysate, the semi-quantitative results still clearly indicated that at both 
treatment doses, UDG+/+ cells released significant higher (p< 0.05) amount of F-Ade 
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comparing to UDG-/- cells. This may indicate that the F-Ade detected from HL60 lysate is, 
at least partially, released by UDG. 
 By applying our method to the F-Ade quantification from CLL patient and 
healthy donor cells treated with fludarabine, we again observed a clear relationship 
between F-Ade concentration and treatment time/dose. Besides, data summarized in table 
5 indicated that when treated with higher dose (i.e., 50 µM) for longer time (i.e., 24 h), 
CLL patient lymphocytic cells showed averagely higher F-Ade signals than the 
lymphocytic cells obtained from the healthy donors. This result is consistent with the 
results obtained from another set of experiments performed by Bulgar et al., indicating 
higher UDG activity in CLL patient cells than the healthy donor cells [11]. 
 
5.4.5. Identification of an unknown substance existing in the same MRM channel with 
F-Ade, yet with different retention time 
 
 During the process of analyzing cell samples, we observed that in some samples, 
the signal obtained from MRM channel m/z 154>134 shifted around 0.7 min in retention 
time comparing to the chromatography peaks detected from cell lysates spiked with F-
Ade standard solutions. Although differed from the standard peak significantly in 
retention time, the shifted peak, however, was positively related to fludarabine treatment 
dose and time. To further identify the shifted peak, MS2 function on the mass 
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spectrometer was utilized to give a full scan of the fragmentation pattern of the shifted 
peak after CID (figure 5.5 B). A fragmentation scan under exactly the same conditions 
was carried out to the F-Ade standard spiked in blank cell lysate (figure 5.5 A). Highly 
similar spectra were obtained for both peaks in spite of the differences in retention time. 
The results indicated that the species coming out in the shifted peak may share a high 
similarity with F-Ade structural wise and most likely to be an isomer of F-Ade with the 
fluorine transferred to another position. Further investigation is still under going for 
better understanding of the identity of this shifted peak. 
 
5.5. Conclusion 
 
 An LC-MS/MS method for quantitative determination of F-Ade in DNA enzyme 
digest matrix and cell lysates has been developed and validated.  This method employed 
an internal standard (i.e., Cl-Ade) for calibration, a SPE protocol (i.e., Oasis® HLB 
cartridge, 3cc) for sample preparation, a reverse-phase LC column (i.e., YMC-ODS AQ®, 
2.0 x 50 mm) for analyte separation, and a tandem mass spectrometer for analyte 
quantification.  The feasibility of the method for the quantification of F-Ade in UDG 
digested F-ara-A incorporated DNA 40-mer solution, and cells (i.e., HL60 cells, 
lymphocytic cells of CCL patients and healthy donors) treated with F-ara-A has been 
established.  This method provided supporting evidence that UDG is a major DNA 
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glycosylase for repairing F-ara-A:T mispair.  It may be useful not only for the 
quantitative measurement of action of fludarabine phosphate, but also for the assessment 
of efficiency of DNA base excision repair. 
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Figure 5.5, Identification of the shifted peak. (A) Chromatogram and fragmentation 
spectrum of F-Ade (retention time 3.0 min) from cell lysate spiked with F-Ade; (B) 
chromatogram and fragmentation spectrum of the unknown species (retention time 3.7 
min) from a F-ara-AMP treated cell sample. 
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CHAPTER VI 
 
 
QUANTITATIVE DETERMINATION OF 6BT WITH LC-MS/MS, A 
PHARMACOKINETIC STUDY IN MICE, AND AN IN VITRO DRUG 
MECHANISM STUDY 
 
 
6.1. Introduction 
 
 6BT is an adenosine analogue (figure 1.1 C) that has been originally used in the 
property studies of adenosine aminohydrolase [1]. In the later 1990s, 6BT was discovered 
to be potentially useful in the treatment of toxoplasmosis [2,3] caused by Toxoplasma 
gondii, an intracellular parasite that infects humans and many other warm-blooded 
animals, due to its specific entry into the parasite [4,5]. Recently, 6BT was identified 
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through a small molecule library screen as a promising differentiation-inducing agent for 
leukemic cells as less toxic and more efficacious treatment for acute myeloid leukemia 
(AML) [6]. 
 According to statistics data reported by American Society of Clinical Oncology in 
2008, AML is the most common form of acute leukemia in the United States. It is most 
often observed in elderly population over age 65 [7,8]. The general accepted molecular 
pathogenesis of AML is a combination of differentiation arrest together with the 
uncontrolled proliferation of the myeloblasts [9]. The standard chemotherapy agents 
represented by adriamycin and cytarabine work through introducing high cytotoxicity and 
nonselectively killing of highly proliferative cells [8]. In spite of the fact that up to 75% 
of the patients can achieve complete remission (CR), the prognosis of the patients 
remains poor. The average 5-year survival rate of the patients after treatments is as low as 
21% [7]. Unlike the traditional chemotherapeutics, the treatment of acute promyelocytic 
leukemia, a rare subtype of AML that only share around 5% of the total AML cases, 
utilizes a differentiation-inducing agent, all-trans retinoic acid (ATRA). With the 
treatment that induces the terminal differentiation of the myeloblasts, the 5-year disease 
free survival rate of the patients can reach to 74% [10]. Due to its high therapeutic 
specificity, ATRA can be effectively used in combination with low dose 
chemotherapeutic agents without introducing extra toxicity significantly [11]. This 
differentiation approach is especially meaningful for elderly patients, to whom the 
traditional chemotherapeutics are often too toxic to tolerate. However, ATRA is only 
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useful for acute promyelocytic leukemia patients. To search for efficacious 
differentiation-inducing agents for the treatment of other AML subtypes, a cell-based 
compound-library screen has been carried out by Wald et al. [6]. In their research, 6BT 
has been identified as a promising differentiation-inducing agent that not only displays 
high differentiation-inducing activity to myeloid leukemia cell lines (i.e., HL-60 and 
OCI-AML3), but also to the primary cells of AML patients. More interestingly, 6BT 
induces cell death to a subset of AML cell lines (i.e., HNT34 and MV4-11) as well. 
However, 6BT shows very low toxicity to non-malignant cells, such as fibroblasts, 
normal bone marrow, and endothelial cells. In mouse xenograft studies, 6BT significantly 
inhibited the xenograft tumor (HL-60 and/or MV4-11) growth and formation. A 129% 
increase of CD11b (a mature myeloid marker) in comparison to the untreated ones has 
been shown by flow cytometric analysis of the dissected tumors in 6BT treated tumors 
[6]. 
 The preclinical studies of 6BT for the treatment of AML and toxoplasmosis 
demonstrated its high potential of being an investigational new drug, and thus further 
therapeutic development has been warranted. To insure the validity of the future 
pharmacological and toxicological studies, quantitative analytical methods for 6BT will 
be needed. Measurement of 6BT from biological samples will also provide useful 
information in drug metabolism and functioning mechanisms. Nevertheless, a recent 
search by SciFinder® Scholar revealed that there is no analytical method available to date 
for quantification of 6BT in biological matrices. Only a qualitative LC–UV method for 
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6BT and its analogues was reported by Rais et al. [12], which was not validated for 
quantitative measurement of 6BT and did not have the sensitivity and specificity required 
for pharmacokinetic study of 6BT. 
 Given the above considerations, we have developed a novel LC–MS/MS method 
for the direct analysis of 6BT in both mouse and human plasma, as well as in several 
types of whole cell lysates. The IS was selected as 2-amino-6-benzylthioinosine (2A6BT). 
Sample preparation was realized by a liquid–liquid extraction procedure, and LC was 
realized on an YMC ODS-AQ® column with a mobile phase consists 0.1% formic acid, 
45% acetonitrile and 54.9% deionized water (v/v/v). A QqQ mass spectrometer with an 
ESI source was employed in the analyte detection. The method developed has been 
validated in both mouse and human plasma according to the FDA guidance, and has 
become a quantitative method [13]. Semi-quantitative analysis of 6BT from different cell 
lines treated with the drug also confirmed the enhanced entry of the drug into leukemia 
cell lines. The quantitative and semi-quantitative assessment of 6BT fills the gap of 
lacking analytical method for the pharmacokinetic studies. 
 
6.2. Material and methods 
 
6.2.1. Chemicals and solutions 
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 6BT and the IS, 2A6BT, were kindly provided by the Developmental 
Therapeutics Program of the National Cancer Institute (Bethesda, MD, USA). Deionized 
water was collected from the Barnstead NANOpure® water purification system (Thermo 
Scientific, Waltham, MA, USA).Formic acid was purchased from Acros (Morris Plains, 
NJ, USA). Dimethylsulfoxide (DMSO), HPLC-grade acetonitrile and ethyl acetate were 
obtained from Sigma–Aldrich (St. Louis, MO, USA). Pooled blank mouse plasma was 
from Equitech-Bio (Kerrville, TX, USA). Isoflurane was obtained from Baxter 
Healthcare Corporation (Deerfield, IL, USA). Pooled blank human plasma was from 
Haemtech, Inc. (Essex Junction, VT, USA). 
 6BT and IS stock solutions were prepared according to the following procedure: 
first, the compounds were weighted out by an analytical balance and dissolved separately 
into acetonitrile to a concentration of 1.00 mg/mL; then, for 6BT, the stock solution was 
transferred into 1.5-mL microcentrifuge tubes as 100 µL per aliquot, and the IS, 25.0 µL 
per aliquot; afterward, the microcentrifuge tubes containing either 100 µg/tube of 6BT or 
25.0 µg/tube of the IS stock solution were dried on a DNA120 SpeedVac® 
(ThermoSavant, Hollbrook, NY, USA) vacuum evaporator at 25 Ԩ for 10 min; finally, 
the dried stocks were kept at −20 Ԩ until use.  
 Each time before use, 1.00 mLof deioinized water was added in to each 
microcentrifuge tube to make the working solution of 6BT and IS at 100 and 25.0 µg/mL, 
respectively. The 6BT and the IS working solutions were freshly prepared daily right 
before the analysis.  
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 The mobile phase of LC was prepared by mixing 0.1% formic acid, 45.0% 
acetonitrile and 54.9% deionized water (v/v/v) together. 
 
6.2.2. LC-MS/MS instrumentation 
 
 The LC–MS/MS system was composed by an Agilent (Santa Clara, CA, USA) 
1100 HPLC and a Micromass (Manchester, UK) Quattro II triple quadrupole mass 
spectrometer. The HPLC unit included of two binary pumps, a degasser, an autosampler, 
an inline filter (0.5 µm pore) (Upchurch Scientific, Oak Harbor,WA,USA), a Waters 
(Milford, MA, USA) YMC-AQ® column (2.0 mm×50 mm, 5mparticle size with 120Å 
pore size), a two-position 6-port switching valve (Alltech, Deerfield, IL, USA), and a 
post-column splitter (Valco, Houston, TX, USA). Micromass MassLynx software 
(version 3.3) was utilized for the LC–MS/MS system operation, data acquisition and 
processing. For each LC-MS/MS analysis, the injection volume of the sample onto the 
column was 20 µL. Isocratic elution was utilized in the chromatographic separation. The 
flow rate was set as 100 µL/min. The post-column switching valve was programmed so 
that only the column eluate after 2.0 min was diverted to the mass spectrometer for 
analysis. A post-column splitter splits the total column flow at a ratio of 1:3, so that only 
1/3 of the flow entered into the mass analyzer. Positive electrospray- ionization (ESI+) 
mode was adopted when operating the mass spectrometer. The mass spectrometer was 
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tuned by direct infusion of a solution containing 10.0 µg/mL 6BT and IS 10.0 µg/mL IS 
dissolved in the mobile phase. The flow rate of infusion was set at 3 µL/min with a 
syringe pump (Harvard Apparatus, South Natick, MA, USA). After signal optimization, a 
set of ionization condition parameters were obtained: drying gas 300 L/h, nebulizer 15 
L/h, capillary voltage 3.5 kV, HV lens 0.5 kV, cone voltage 25 V, skimmer 1.5 V, RF 
lens 0.2 V, ion source temperature 40 Ԩ, ion energy 0.3 V. Multiple-reaction-monitoring 
(MRM) was utilized for analyte monitoring and quantification. The MRM parameters 
were set as: argon collision gas 2.0–2.5bar, collision energy 17 eV, dwell time 0.4 s, 
inter-scan delay 0.05 s, lowand high-mass resolution 15 (for both quadrupoles 1 and 3), 
and multiplier 650. 
 
6.2.3. Standard solutions, plasma calibrators and controls, and mouse plasma samples 
 
 6BT standard solutions at the concentration of 6.00, 18.0, 20.0, 60.0, 180, 200, 
600, 1.80×103, 2.00×103, and 3.20×103 ng/mL were prepared by serial dilution of 100 
µg/mL 6BT working solution. The standard solution of the IS was diluted from the 25 
µg/mL working solution to 100 ng/mL.  
 The calibrators (3.00, 10.0, 30.0, 100, 300, and 1.00×103 ng/mL) of 6BT in mouse 
and human plasma were obtained individually by mixing 100 µL of pooled blank plasma, 
together with 50.0 µL of 6BT standard solution (at twice of the concentration of the 
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related calibrator) and 50.0 µL of IS standard solution at 100 ng/mL. The controls of 6BT 
in mouse plasma (3.00, 9.00, 90.0, 900, and 1.60×103 ng/mL) and human plasma (3.00, 
90.0 and 900 ng/mL) were prepared individually according to the same way as the 
calibrators.  
 Mouse plasma samples obtained from the preliminary pharmacokinetic study 
were prepared by mixing 100 µL of plasma from 6BT administered mice with 50.0 µL of 
deionized water and 50.0 µL of 100 ng/mL IS standard solution. 
 
6.2.4. LLE of 6BT 
 
 Plasma calibrators, controls and animal samples were extracted with an LLE 
protocol: 1mL of ethyl acetate was mixed with the plasma sample in a 1.5mL 
microcentrifuge tube. Then, a short vortex for 1 min followed by a centrifugation at 
13000×g for 10 min were applied to the samples. Next, 85% of the organic (upper) layer 
(ca. 850 µL) was transferred into a clean 1.5-mL microcentrifuge tube and dried by 
vacuum evaporation on the DNA 120 SpeedVac® at 25 Ԩ for 30 min. The sample residue 
was finally reconstituted with 85 µL of deionized water. 
 
6.2.5. Matrix effect and recovery studies 
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 In the matrix effect study, of 100 µL pooled blank plasma mixed with 100 µL of 
water was extracted with the protocol described in Section 6.2.4. Afterward, a mixture of 
6BT and the IS standard solutions were spiked into the post-extract matrix. The resulted 
samples possessed 6BT of 9.00, 90.0 and 900 ng/mL, and the IS of 50.0 ng/mL. The peak 
area ratios of 6BT to IS in these spike-after-extraction (SAE) standards were compared 
with those of the corresponding authentic pure standards. 
 To obtain the recovery data, 6BT plasma calibrators (9.00, 90.0 and 900 ng/mL, 
with the IS at 50.0 ng/mL) were analyzed. IS normalized recovery of 6BT was calculated 
after comparing the peak area ratios of 6BT to IS in the plasma calibrators with those of 
the corresponding SAE standards. The absolute recovery of the IS was obtained by 
comparing the peak areas of the IS in the plasma calibrators with those of the 
corresponding SAE standards. 
 
6.2.6. Stability studies 
 
 Mouse and human plasma test controls (9.00 and 900 ng/mL) were prepared as 
described in Section 6.2.3 except the IS standard was added prior to the LLE. All 
experiments were run in triplicate and the results were compared with freshly prepared 
plasma controls. For the freeze and thaw stability study, the test controls were undergone 
three freeze and thaw cycles. In each cycle, the test controls were frozen for at least 24 h 
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at −20 Ԩ and thawed at room temperature without help. The short-term temperature 
stability study was carried out by leaving the test controls at the room temperature (23 Ԩ) 
for 4–24 h. For the long-term stability, the test controls were stored at −20 Ԩ for 30 days 
prior to analysis. 
 
6.2.7. Preliminary PK study of 6BT in mice 
 
 This preliminary PK study is also a feasibility test of the developed methods. 
Male C57BL/6 mice from Charles River Laboratories International (Spencerville, OH, 
USA) were utilized in the preliminary PK study. The mice were housed randomly in a 
group of five. The average body weight of the mice at the time of administration was 24 g. 
6BT was dissolved in 10% DMSO–PBS (1×) solution at a concentration of 0.2 mg/mL. 
Mice were administered through intraperitoneal injection at a single bolus of 1mg/kg. 
After the mice were under anesthesia with isoflurane, blood samples were collected 
through cardiac puncture using heparinized needle and syringe at 5, 13, 22, 35, 45, 58, 
121 and 237 min post-6BT injection. For each mouse, an average of 0.4 mL of blood 
sample was collected. The whole blood was placed on ice immediately after collection 
and centrifuged at 8000 × g for 15 min within 1 h. The plasma samples harvested from 
the whole blood samples were stored at −20 Ԩ before analysis. Predose plasma samples 
were obtained from mouse injected with 10% DMSO–PBS (1×) along. PK analysis was 
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modeled with WinNonLin® nonlinear estimation program (Version 5.2) (Pharsight Corp., 
Mountain View, CA, USA). PK model 5 (1 compartment 1st order, K10 = K01, 1st order 
elimination) was finally adopted. 
 
6.3. Results and discussions 
 
6.3.1. Method development 
 
 Mass spectrometric detection of 6BT and the IS 
 In this work, “auto-tune” function of the MassLunx was utilized for the 
instrument response optimization. Due to their chemical properties, 6BT and the IS can 
form protonated species more easily than the deprotonated species through electrospray 
ionization. Thus, the positive electrospray ionization mode was utilized for the 
identification and quantification of 6BT and the IS. Figure 6.1 A and B demonstrates the 
predominant molecular ions of 6BT and the IS at m/z 375 for [6BT+H]+ and m/z 390 
[IS+H]+, respectively. With collision-induced-dissociation (CID) introduced by argon gas 
in the second quadrupole, these two molecular ions were further dissociated into product 
ions illustrated in figure 6.1 C and D, respectively. The major product ion of the 
protonated 6BT and the IS were shown at m/z 243 and m/z 258, respectively. As a result, 
the mass transition pairs m/z 375 > 243 for 6BT and m/z 390 > 258 for the IS were 
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adopted in the compound quantification with the multiple-reaction-monitoring (MRM) 
mode. To understand the fragmentation mechanisms in CID, the m/z difference of the 
compound before and after CID were compared. Summarized with the structural 
information of the compounds, the proposed fragmentation mechanism is shown in figure 
6.2. 
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Figure 6.1, The mass spectra of 6BT and the internal standard. 
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Figure 6.2, The proposed major fragments of 6BT and the IS.  
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 LC separation of 6BT 
 According to a SciFinder® search, at the intended the mobile phase pH, pH 3.0, 
the logD values of 6BT and 2A6BT are 1.45 and 0.94, respectively. Thus, both 
compounds can be considered as more hydrophobic than hyerophilic. Based on this 
reason, two C-18 based reverse phase columns, a Phenomenex Gemini® column 
(2.0mm×50mm, 5 µm particle size with 110Å pore size) and a YMC ODS-AQ® column 
(2.0mm×50mm, 5 µm particle size with 120Å pore size) have been tried for optimized 
LC separation. Both columns successfully retained 6BT and the IS on the column for 
over 2 column volumes and were able to provide base line separation between 6BT and 
the IS. However, the YMC ODS-AQ® column was able to provide better peak shape 
comparing to the Phenomenex Gemini® column. Meanwhile, since 6BT and the IS are 
basic compounds, 0.1% of formic acid was added into the mobile phase in order to 
facilitate the protonation of the analytes, and thus enhance the sensitivity of MS detection. 
The increased hydrophilicity of the analyte after the addition of the formic acid also 
reduced the retention times of the analyte and the IS, and lead to shorter retention time 
and faster LC analysis.  
 In this work, to optimize the separation efficiency, the percentage of acetonitrile 
in the mobile phase was adjusted. Although a complete baseline resolution between 6BT 
and the IS can be achieved with a mobile phase consists of 35.0% acetonitrile, 0.1% 
formic acid and 64.9% deionized water (v/v/v), the total LC time was as long as 7 min at 
a flow rate of 0.1 mL/min. To shorten the total run time so that time can be significantly 
180 
 
saved in the future method application stage, the percentage of acetonitrile has been 
increased to 45%. This kind of adjustment resulted partial separation between 6BT and 
the IS with retention time of 3.9 and 3.5 min, respectively (figure 6.3). Nevertheless, it 
was able to reduce the total LC time to 5 min. To shorten the total running time to 5.0 
min (nearly 30%) at the same flow rate. Since the two compounds were still retained on 
the column long enough and can be completely separated from the sample matrix, the 
detection sensitivity was not significantly affected. Besides, as both compounds were 
quantified by MRM in different MS transition, no interferences between the two 
compounds would take place. Therefore, the mobile phase gave shorter LC time was 
adopted. 
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Figure 6.3, Representative MRM chromatograms of analytes in human plasma. (A) 
double-blank plasma (no 6BT detected); (B) 3 ng/mL 6BT in plasma (at LLOQ with a 
S/N of 18.3); (C) 100 ng/mL 6BT in plasma; (D) double-blank plasma (no IS detected); 
and (E) 50 ng/mL IS in plasma.  
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6.3.2. Method validation 
 
 The performance of the method developed was validated according to the FDA 
guidance for industry bioanalytical method validation [13]. 
 
 Matrix effect and recovery studies 
 In the studies of matrix effect and recovery, triplicate measurements were 
performed at each concentration level of three different concentration levels (i.e., low, 
medium, and high). The matrix effect was normalized by the signal of the IS (MFIS), and 
thus was calculated with equation 5.1. As table 6.1 illustrated, the MFIS in mouse and 
human plasma matrices varied between 1.10–1.13 and 0.97–1.04, respectively. 
Meanwhile, the values of MFIS were quite consistent over the concentration range with a 
deviation of −0.03 to +0.13 from its ideal value of 1.00 (i.e., no matrix effect) and 
reproducible with standard deviation (SD) ≤0.06. 
 To reduce the variation caused by instrument, the recovery was also studies as the 
IS normalized form (RIS). It was calculated with equation 5.2. The summarized recovery 
data can be viewed in table 6.1. The values ranged from 82 to 87% for mouse plasma, 
and 90 to 98% for human plasma. The absolute recoveries (RC’) of the IS from both 
kinds of plasma samples were also calculated (equation 6.1): 
ܴܥ′ ൌ ܣ′௘௫௧௥௔௖௧௜௢௡ܣ′௠௔௧௥௜௫ ൈ 100% 
    (6.1) 
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Here A’extraction means the peak area of the IS in the extracted plasma sample; while 
A’matrix means the peak area of the IS in the post-extraction matrix. The values of RC’ 
ranged from 59 to 66% in mouse plasma, and from 60 to 64% in human plasma. In spite 
of the low recovery of IS from both kinds of plasma samples, the results were 
reproducible and consistent within the calibration range. 
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Table 6.1, Matrix effect and recovery. 
Plasma matrices 
[6BT] 
(ng/mL) 
Recovery ± SD 
(%) 
MFIS ± SD 
Mouse 
9.00 82 ± 2 1.13 ± 0.06 
90.0 83 ± 1 1.10 ± 0.05 
900 87 ± 1 1.11 ± 0.04 
Human 
9.00 98 ± 5 0.97 ± 0.02 
90.0 90 ± 6 1.04 ± 0.02 
900 96 ± 7 1.04 ± 0.04 
Each datum point was based on triplicate measurements. 
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 Calibration curve, accuracy, and precision of the method 
 The calibration curve of 6BT in both mouse and human plasma were established 
with six non-zero plasma calibrators. For each set of calibrator, one double-blank (with 
neither 6BT nor IS) plasma sample and one zero (with IS only) plasma sample were also 
included, The concentrations of 6BT for the non-zero calibrators were 3.00, 10.0, 30.0, 
100, 300 and 1.00×103 ng/mL. The linear calibration curves ranged from 3.00 to 
1.00×103 ng/mL were established by plotting A/A’ in mouse and human plasma versus 
the concentrations of 6BT. The weighting factor for both calibration curves were utilized 
as 1/x (the reciprocal of 6BT concentration). Both calibration equations were given in 
table 6.2. When it came to the determination of the lower limits of quantification (LLOQ), 
the plasma calibrator with the lowest concentration, yet still fit in the calibration curve 
with acceptable accuracy and precision were defined as the LLOQ. The concentrations of 
the calibrators were back-calculated according to the calibration equation with the 
information of the A/A’. The accuracy and precision were calculated as they have been 
described in chapter I. For the analysis of mouse plasma samples, the accuracy and 
precision ranged from 0.2 to 5% and from 1 to 4%, respectively. For the human plasma 
samples, both accuracy and precision ranged from 1 to 7% (table 6.2). All values fell 
within the acceptable criteria (i.e., ≤±15% at all concentrations except at LLOQ where 
≤±20%) suggested by the FDA guidance. 
 The precision of the method was evaluated in two aspects: the intra-and inter-
assay precisions.  As described in Chapter I, to determine the precisions, five replicates of 
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plasma control samples at low-, mid- and high-concentration levels (LQC, MQC and 
HQC) were prepared and analyzed. Since the LQC of mouse plasma were then same with 
the LLOQ for human plasma control samples, no extra LQC or LLOQ samples were 
prepared and analyzed. Meanwhile, as one sampling point in the preliminary 
pharmacokinetic study in mouse exceeded the upper limit of quantification (ULOQ), a set 
of dilution quality control samples (DQC) for mouse plasma were also evaluated. The 
intra- and inter-assay precision data were summarized in table 6.3.  
 The accuracies of the above studies were between −13 to 5% (table 6.3). They, 
again, fell well within the acceptable criteria suggested by the FDA guidance. 
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Table 6.2, Calibration equations of 6BT in mouse and human plasma. 
Plasma 
Matrices 
Actual 
[6BT] 
ng/mL 
Measured 
[6BT] 
ng/mL 
SD Accuracy 
(%) 
Precision 
(%) 
Mouse 3.00 2.84 0.04 5 1 
10.0 9.8 0.2 2 2 
30.0 30.3 0.9 -1 3 
100 101 4 -1 4 
300 301 9 -0.3 3 
1.00 × 103 1.00 × 103 0.01 × 103 0.2 1 
Human 3.00 2.78 0.09 7 3 
10.0 9.8 0.3 2 3 
30.0 29.3 0.7 2 3 
100 102 1 -1 1 
300 3.1 × 102 0.2 × 102 -4 7 
1.00 × 103 9.9 × 102 0.2 × 102 1 2 
Calibration Equations:  Mouse plasma y = (0.020 ± 0.002) x + (-0.007 ± 0.002), 
R2 = 1.00 ± 0.00 
Human plasma y = (0.017 ± 0.002) x + (-0.003 ± 0.001), R2 = 0.999 ± 0.002 
Each measured concentration was based on three measurements carried out on 
three different days and the S.D. values showed in the table indicated the standard 
deviation of each triplicate measurement. The calibration equations were based on 
three separate measurements carried out on three different days. 
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Table 6.3, Accuracy, intra- and inter-assay precisions of 6BT in human and mouse 
plasma.  
Plasma matrices LQC MQC HQC 
Mouse 
Accuracy (%), n = 5 4 -3 3 
Intra-assay precision (%), n = 5 6 4 4 
Inter-assay precision (%), n = 3 5 5 3 
Human 
Accuracy (%) n = 5 -13 -0.6 4 
Intra-assay precision (%), n = 5 3 4 2 
Inter-assay precision (%), n = 3 11 2 1 
The concentrations of 6BT in the LQC, MQC and HQC of mouse plasma were 
9.00, 90.0 and 900 ng/mL, respectively.  For the human plasma, they were 3.00, 
90.0 and 900 ng/mL, respectively.  The concentration of the I.S. was 50.0 ng/mL. 
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 Stability studies 
 Two concentration levels, 9.00 and 900 ng/mL, were utilized in the stability tests. 
Triplicate measurements were performed in each concentration level. The stability results 
were summarized in table 6.4. As indicated by the table, no significant loss of 6BT 
(recovery ranged from 97 to 108%) was observed in human plasma under the tested 
storage conditions. Indicated by the data, again, 6BT also remain stable in mouse plasma 
samples when stored at room temperature for up to 4 h and after three freeze-and-thaw 
cycles (recovery ranged between 88 and 106%. Long-term storage of mouse plasma 
samples spiked with 6BT at -20 Ԩ also showed adequate recoveries after storage. Based 
on these experimental facts, 6BT stock solutions and the plasma samples were kept at 
−20 Ԩ for freshness, and the analysis of mouse plasma samples was done within 4 h 
timeframe. 
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Table 6.4, Stability data of 6BT under various test conditions. 
Storage Conditions Plasma Matrices 
[6BT] added 
ng/mL 
Recovery ± S.D. 
(%) 
Room Temperature, 4 hr Mouse 9.00 88 ± 5 
900 94 ± 2 
Human 9.00 102 ± 7 
900 102 ± 2 
Room Temperature, 8 hr Mouse 9.00 68 ± 7 
900 87 ± 3 
Human 9.00 102 ± 8 
900 99 ± 1 
Room Temperature, 24 hr Mouse 9.00 19 ± 2 
900 30 ± 2 
Human 9.00 100 ± 4 
900 97 ± 1 
Freeze-thaw,  
(3 cycles, -20 oC) 
Mouse 9.00 (1.1 ± 0.1)×102 
900 98 ± 8 
Human 9.00 100 ± 4 
900 103 ± 4 
Long-term,  
(30 days, -20 oC) 
Human 9.00 108 ± 8 
900 108 ± 3 
Each datum point was based on triplicate measurements. 
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6.3.3. Method application in a preliminary PK study in mice 
 
 A preliminary PK study of 6BT in mice was carried out with the validated LC–
MS/MS method. The mouse plasma samples together with eight calibrators (i.e., one 
double-blank, one zero and six nonzero) and three sets of quality control samples at low-, 
mid- and high-concentrations (i.e., 9, 90, 900 ng/mL) were extracted after the addition of 
the IS. The PK sample with the concentration exceeding the ULOQ (i.e., 1.00×103 ng/mL) 
were re-analyzed along with the DQC (1.60×103 ng/mL) after 1:1 dilution with blank 
pooled mouse plasma. 
 Figure 6.4 included representative mass chromatograms of mouse plasma samples 
obtained from the PK analysis. From the chromatograms, no sign of interference from 
endogenous compound in mouse plasma was observed in the pre-administered sample. 
The plasma concentrations of 6BT were plotted against the sampling times. The 
preliminary PK profile after single bolus injection was illustrated in figure 6.5. With the 
analysis by the WinNonLin® software, the profile fitted the best in a nonlinear one-
compartment first-order pharmacokinetic model (percent relative standard deviations of 
12–15%). The PK parameters were calculated accordingly as: Tmax, 18.9 min; Cmax 1086 
ng/mL; T1/2 13.1 min; and AUC, 5.57×104 min ng/mL.  
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Figure 6.4, Representative MRM chromatograms of mouse plasma samples. (A) predosed 
mouse plasma with IS, (B) the plasma sample collected 5 min after intraperitoneal 
injection with IS, and (C) the plasma sample collected 13 min after intraperitoneal 
injection with IS. 
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Figure 6.5, Plasma concentration-time profile of 6BT. Mice: C57BL/6, male; 
administration: intraperitoneal injection; dosage: 1 mg 6BT/kg mouse.  
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6.3.4. Enhanced 6BT uptake in leukemia cell lines 
 
 Two human AML cell lines (i.e., OCI-AML3 and Nomo-1), normal human bone 
marrow cells, one human embryonic kidney cell line (i.e., 293), a human prostatic 
carcinoma cell line (i.e., LNCap), and a human ovarian cancer cell line (i.e., SK-OV-3) 
were treated with 10 µM 6BT. After harvest, the cells were washed with PBS for 3 times 
first, and then the cell lysates were obtained by sonication. The concentration of the cell 
lysate samples were normalized according to their protein concentrations (determined by 
UV280). To be more specific, when the cell lysate with the lowest protein concentration 
was determined, other cell lysates with higher protein concentrations were diluted with 
deionized water accordingly till all the samples reach to the same protein concentration 
level. Then, 200 µL of each sample was taken and extracted with 1.00 mL ethyl acetate. 
After centrifugation, 900 µL (90%) of the organic phase was recovered for each sample. 
After the samples were dried with vacuum evaporation, 162 µL deionized water and 18 
µL of 500 ng/mL IS solution was added to each sample, making the final volume of each 
sample as 180 µL and the concentration of the IS in each sample as 50 ng/mL.  
 After analyzing the cell lysates with the developed LC-MS/MS method, the peak 
area ratios of 6BT and the IS (A/A’) in each sample was obtained. The relative uptake of 
6BT by the cells was determined through comparing the A/A’ ratio of 6BT in a specific 
cell sample with the sample possessing the highest A/A’ ratio (assigned as 1.00 for the 
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relative uptake). The relative uptakes of 6BT in other samples were then determined by 
equation 6.2: 
ܴ݈݁ܽݐ݅ݒ݁ ܷ݌ݐܽ݇݁ ൌ ሺܣ ܣ′⁄ ሻሺܣ ܣ′⁄ ሻ௠௔௫ 
    (6.2) 
Here, (A/A’)max indicates the maximum peak area ratio obtained from the samples. 
 From table 6.5, a significant enhanced uptake of 6BT can be observed from the 
two AML cell lines, OCI-AML3 and Nomo-1. While the normal human bone marrow 
cells, the embryonic kidney cell, and the two cell lines coming from other cancer types 
indicated much lower drug uptake. The result explained, at least from one aspect, the 
mechanism of the selective cytotoxicity of 6BT to leukemia cells. This enhanced entry 
may due to elevated expression of certain membrane transporter. However, detailed 
mechanism is still under investigation. 
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Table 6.5, 6BT uptake in different cell lines. 
Cell 
Lines 
Treatment 
Status A6BT A31730 A6BT/A31730 
Relative 
Uptake 
OCI 
Untreated 31 1.09×103 0.0284 0.000792 
Treated 5.03×104 1.68×103 29.9 0.835 
Nomo 
Untreated 29 1.30×103 0.0224 0.000624 
Treated 7.31×104 2.04×103 35.9 1.00 
Normal 
Untreated 131 1.43×103 0.0918 0.00256 
Treated 5.29×103 1.25×103 4.25 0.118 
293 
Untreated 31 1.99×103 0.0156 0.000435 
Treated 6.22×103 1.55×103 4.01 0.112 
LNCap 
Untreated 11 1.35×103 0.00812 0.000227 
Treated 1.50×104 2.04×103 7.34 0.205 
SK-
OV-3 
Untreated 14 2.01×103 0.00697 0.000194 
Treated 81 1.53×103 0.0528 0.00147 
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6.3.5. On-line SPE extraction of 6BT with a boronic acid cartridge 
 
 Besides the LLE combined with LC-MS/MS method developed above, an on-line 
SPE combined with MS/MS analysis method was also developed for 6BT. The on-line 
SPE method was based on the specific reversible interaction between the cis-hydroxyl 
groups of 6BT and boronic acid. Under basic conditions, phenylboronic acid is able to 
condense the cis-hydroxyl moieties of sugar in aqueous solution and form stable cyclic 
ester (figure 6.6). In this work, an SPE cartridge (2.0 × 20 mm) was packed in our lab 
with silica based NuGELTM Phenyl Boronic Acid (particle size 50 µm, Biotech Support 
Group, Monmouth JCT, NJ) as the packing material. As binding between 6BT and the 
phenylboronic group takes place most efficiently under basic pH, a mobile phase 
containing 5 mM of NH4HCO3 buffer at pH 8.4 was utilized as the loading buffer. The 
analyte was eluted out from the cartridges with 45% acetonitrile plus 54.9% water with 
0.1% formic acid, the mobile phase utilized in the LC-MS/MS method. The flow rate was 
set as 0.1 mL/min, and the MS/MS parameters were the same as those described in 
section 6.2.2. The instrumentation of the on-line extraction was set up as it has been 
illustrated in figure 1.4. 
 Two minutes after the injection of 6BT standard solution (100 ng/mL), the 
switcher was switched from the loading position to the elution position. At 4.5 min after 
injection, the switcher was switched back to the loading position, and the cartridge was 
re-equilibrated for next injection. From figure 6.7, a sharp and symmetrical 
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chromatography peak of 6BT can be observed at 2.3 min. The result indicated the 
effective extraction of 6BT with this self-packed cartridge. As the process is simple and 
time saving in sample preparation, it has great potential to provide fast and low cost 
methods in future 6BT analysis from biological samples. 
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Figure 6.6, Reaction between the phenyl boronic acid and a molecule carrying cis-
hydroxyl groups. 
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Figure 6.7, Representative MRM chromatogram for the on-line SPE of 6BT. 
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6.4. Conclusions 
 
 Based on all the experimental data obtained, a quantitative LC–MS/MS method 
for the assessment of 6BT in mouse and human plasma has been developed. Briefly 
speaking, the analytes in plasma were extracted by ethyl acetate, separated by Waters 
YMC ODS-AQ® column, and then analyzed through the tandem mass spectrometry. 
Method validation has been performed in mouse and human plasma by referring to the 
FDA guidance. The linear range of the method is from 3.00 to 1.00×103 ng/mL in both 
mouse and human plasma. The method was also successfully applied to a preliminary PK 
study of 6BT in mice. Due to its high accuracy, precision, and sensitivity, it will facilitate 
the therapeutic development of not only 6BT but its analogues in human. Meanwhile, 
semi-quantitative analysis of 6BT from cells treated with 6BT confirmed the enhanced 
uptake of 6BT by leukemia cell lines, and provided insight in drug functioning 
mechanism elucidation. 
 
6.5. References 
 
1. B.M. Chassy, R.J. Suhadolnik, J Biol Chem. 242 (1967) 3655. 
 
202 
 
2. M.H. Iltzsch, S.S. Uber, K.O. Tankersley, M.H. el Kouni, Biochem. Pharmacol. 
49 (1995) 1501. 
 
 
3. M.H. el Kouni, V. Guarcello, O.N. Al Safarjalani, F.N. Naguib, Antimicrob. 
Agents. Chemother. 43 (1999) 2437. 
 
4. J.P. Dubey, C.P. Beattie. Toxoplasmosis of animals and man, CRC Press, Boca 
Raton, FL, 1988, p. 1. 
 
5. P.D. Walzer, R.M. Genta (Eds.), Parasitic infections in the compromised host, 
Marcel Dekker, New York, NY, 1989, p. 179. 
 
6. D.N. Wald, H.M. Vermaat, S. Zang, A. Lavik, Z. Kang, G. Peleg, S.L. Gerson, 
K.D. Bunting, M.L. Agarwal, B.L. Roth, W. Tse, Cancer Res. 68 (2008) 4369. 
 
7. American Society of Clinical Oncology, Leukemia - Acute Myeloid: overview, 
available at http://www.cancer.net/patient/Cancer+Types/Leukemia+-
+Acute+Myeloid+-+AML. 
 
8. E. Estey, H. Döhner, Lancet. 368 (2006) 1894. 
203 
 
9. B. Steffen, C. Müller-Tidow, J. Schwäble, W.E. Berdel, H. Serve, Crit Rev Oncol 
Hematol. 56 (2005) 195. 
 
10. Z.Y. Wang, Z. Chen, Blood. 111(2008):2505.  
 
11. M.S. Tallmann, Ann Hematol. 83 (2004) S81. 
 
12. R.H. Rais, O.N. Al Safarjalani, V. Yadav, V. Guarcello, M. Kirk, C.K. Chu, F.N. 
Naguib, M.H. el Kouni, Biochem. Pharmacol. 69(2005) 1409. 
 
13. U.S. Food and Drug Administration (FDA) & Center for Drug Evaluation and 
Research (CDER), Guidance for Industry: Bioanalytical Method Validation, 
available at http://www.fda.gov/cder/guidance/4252fnl.htm, 2001. 
 
14. E.R. Badman, Z. Liang, S. Bansal, J. Gibbons, Applied Biosystems Users 
Meeting, ASMS, Denver, CO, June 1, 2008. 
 
